EP3662054B1 - A three-dimensional hydrogel scaffold for cell culturing and a method for the production thereof - Google Patents
A three-dimensional hydrogel scaffold for cell culturing and a method for the production thereof Download PDFInfo
- Publication number
- EP3662054B1 EP3662054B1 EP18730009.0A EP18730009A EP3662054B1 EP 3662054 B1 EP3662054 B1 EP 3662054B1 EP 18730009 A EP18730009 A EP 18730009A EP 3662054 B1 EP3662054 B1 EP 3662054B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- water
- solid mixture
- scaffold
- cell
- scaffolds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000017 hydrogel Substances 0.000 title claims description 116
- 238000000034 method Methods 0.000 title claims description 97
- 238000012258 culturing Methods 0.000 title claims description 25
- 238000004519 manufacturing process Methods 0.000 title description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 68
- 239000002953 phosphate buffered saline Substances 0.000 claims description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 64
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 45
- 230000001143 conditioned effect Effects 0.000 claims description 40
- 238000002386 leaching Methods 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 37
- 229920002125 Sokalan® Polymers 0.000 claims description 35
- 230000003750 conditioning effect Effects 0.000 claims description 34
- 239000000843 powder Substances 0.000 claims description 31
- 239000008247 solid mixture Substances 0.000 claims description 29
- 230000001954 sterilising effect Effects 0.000 claims description 29
- 238000004659 sterilization and disinfection Methods 0.000 claims description 29
- -1 poly(acrylic) Polymers 0.000 claims description 27
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 26
- 229920000642 polymer Polymers 0.000 claims description 26
- 239000011780 sodium chloride Substances 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 19
- 238000004108 freeze drying Methods 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 14
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 13
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 12
- 239000008367 deionised water Substances 0.000 claims description 11
- 229910021641 deionized water Inorganic materials 0.000 claims description 11
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 11
- 239000012736 aqueous medium Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 8
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 8
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 7
- 239000001506 calcium phosphate Substances 0.000 claims description 7
- 229950005134 polycarbophil Drugs 0.000 claims description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 235000010216 calcium carbonate Nutrition 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 6
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 5
- 238000000151 deposition Methods 0.000 claims description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 5
- 239000001103 potassium chloride Substances 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 5
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 4
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 4
- 235000012538 ammonium bicarbonate Nutrition 0.000 claims description 4
- 239000001099 ammonium carbonate Substances 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 230000001089 mineralizing effect Effects 0.000 claims description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 4
- 239000011736 potassium bicarbonate Substances 0.000 claims description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 4
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims description 4
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 4
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 4
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 4
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 4
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 4
- 235000010265 sodium sulphite Nutrition 0.000 claims description 4
- 239000007832 Na2SO4 Substances 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 3
- 239000006143 cell culture medium Substances 0.000 claims description 3
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000391 magnesium silicate Substances 0.000 claims description 3
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 3
- 235000019792 magnesium silicate Nutrition 0.000 claims description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 3
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 3
- 229910052882 wollastonite Inorganic materials 0.000 claims description 3
- 239000010456 wollastonite Substances 0.000 claims description 3
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 claims description 2
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 2
- 239000007836 KH2PO4 Substances 0.000 claims description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 238000007907 direct compression Methods 0.000 claims description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 235000011056 potassium acetate Nutrition 0.000 claims description 2
- 235000011151 potassium sulphates Nutrition 0.000 claims description 2
- 235000011152 sodium sulphate Nutrition 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical group 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 144
- 210000001519 tissue Anatomy 0.000 description 35
- 238000007669 thermal treatment Methods 0.000 description 32
- 238000004113 cell culture Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- 239000000499 gel Substances 0.000 description 23
- 239000011159 matrix material Substances 0.000 description 23
- 239000011148 porous material Substances 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 210000004072 lung Anatomy 0.000 description 19
- 210000000981 epithelium Anatomy 0.000 description 17
- 238000002156 mixing Methods 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 238000005406 washing Methods 0.000 description 16
- 229920000936 Agarose Polymers 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 14
- 239000004584 polyacrylic acid Substances 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000009792 diffusion process Methods 0.000 description 13
- 239000007789 gas Substances 0.000 description 13
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 13
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 12
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 12
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 12
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- 201000005296 lung carcinoma Diseases 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 12
- 238000001878 scanning electron micrograph Methods 0.000 description 12
- 238000012604 3D cell culture Methods 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000035899 viability Effects 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 230000033558 biomineral tissue development Effects 0.000 description 10
- 210000004748 cultured cell Anatomy 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 229910001415 sodium ion Inorganic materials 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 9
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 9
- 230000000975 bioactive effect Effects 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 230000009401 metastasis Effects 0.000 description 9
- 229960004329 metformin hydrochloride Drugs 0.000 description 9
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 9
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 9
- 238000010899 nucleation Methods 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000006399 behavior Effects 0.000 description 8
- 238000005520 cutting process Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 239000011812 mixed powder Substances 0.000 description 8
- 210000001672 ovary Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 238000007873 sieving Methods 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 244000309469 Human enteric coronavirus Species 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000002329 infrared spectrum Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 238000002834 transmittance Methods 0.000 description 7
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 238000003501 co-culture Methods 0.000 description 6
- 239000011247 coating layer Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- SDCJMBBHNJPYGW-UHFFFAOYSA-L disodium;hydrogen carbonate;chloride Chemical compound [Na+].[Na+].Cl.[O-]C([O-])=O SDCJMBBHNJPYGW-UHFFFAOYSA-L 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 238000000386 microscopy Methods 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 5
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 5
- 208000004860 Blast Crisis Diseases 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 206010029260 Neuroblastoma Diseases 0.000 description 5
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 5
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 5
- 208000000389 T-cell leukemia Diseases 0.000 description 5
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 201000008275 breast carcinoma Diseases 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- 239000010935 stainless steel Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102400001368 Epidermal growth factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 4
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 208000005017 glioblastoma Diseases 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 4
- 229910000363 nickel(II) sulfate Inorganic materials 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000002151 Pleural effusion Diseases 0.000 description 3
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 201000010989 colorectal carcinoma Diseases 0.000 description 3
- 238000012669 compression test Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000006911 nucleation Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 210000002220 organoid Anatomy 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000004161 plant tissue culture Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 201000001514 prostate carcinoma Diseases 0.000 description 3
- 239000012890 simulated body fluid Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 238000012605 2D cell culture Methods 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 241000289422 Didelphis virginiana Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 241000289573 Potorous tridactylus Species 0.000 description 2
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229910052586 apatite Inorganic materials 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003592 biomimetic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000008873 bone osteosarcoma Diseases 0.000 description 2
- 208000024055 brain glioblastoma Diseases 0.000 description 2
- 201000011609 brain glioblastoma multiforme Diseases 0.000 description 2
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 2
- 201000010983 breast ductal carcinoma Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 208000030381 cutaneous melanoma Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001739 density measurement Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940012466 egg shell membrane Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000004362 fungal culture Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 239000002114 nanocomposite Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical class [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 201000003708 skin melanoma Diseases 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000012414 sterilization procedure Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 239000002351 wastewater Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- MXNRLFUSFKVQSK-UHFFFAOYSA-N 2-Amino-6-(trimethylazaniumyl)hexanoate Chemical compound C[N+](C)(C)CCCCC(N)C([O-])=O MXNRLFUSFKVQSK-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical group [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 238000010146 3D printing Methods 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- LLLVZDVNHNWSDS-UHFFFAOYSA-N 4-methylidene-3,5-dioxabicyclo[5.2.2]undeca-1(9),7,10-triene-2,6-dione Chemical compound C1(C2=CC=C(C(=O)OC(=C)O1)C=C2)=O LLLVZDVNHNWSDS-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- RNIHAPSVIGPAFF-UHFFFAOYSA-N Acrylamide-acrylic acid resin Chemical compound NC(=O)C=C.OC(=O)C=C RNIHAPSVIGPAFF-UHFFFAOYSA-N 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000862448 Chlorocebus Species 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 108010013698 HLA-B17 antigen Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101000775498 Homo sapiens Adenylate cyclase type 10 Proteins 0.000 description 1
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 description 1
- 101001057159 Homo sapiens Melanoma-associated antigen C3 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 102100027248 Melanoma-associated antigen C3 Human genes 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 101100058191 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) bcp-1 gene Proteins 0.000 description 1
- 241000080590 Niso Species 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 101150036892 VP40 gene Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 229940086737 allyl sucrose Drugs 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- MXZRMHIULZDAKC-UHFFFAOYSA-L ammonium magnesium phosphate Chemical compound [NH4+].[Mg+2].[O-]P([O-])([O-])=O MXZRMHIULZDAKC-UHFFFAOYSA-L 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229920001448 anionic polyelectrolyte Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000010261 calcium sulphite Nutrition 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 229940082484 carbomer-934 Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000032341 cell morphogenesis Effects 0.000 description 1
- 239000012094 cell viability reagent Substances 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000007156 chain growth polymerization reaction Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- OSVXSBDYLRYLIG-UHFFFAOYSA-N chlorine dioxide Inorganic materials O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000001033 granulometry Methods 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000003014 ion exchange membrane Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000000593 microemulsion method Methods 0.000 description 1
- 239000012229 microporous material Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical group Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 238000001579 optical reflectometry Methods 0.000 description 1
- 238000013488 ordinary least square regression Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 239000012783 reinforcing fiber Substances 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 102200082402 rs751610198 Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- 238000000807 solvent casting Methods 0.000 description 1
- 238000004729 solvothermal method Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007155 step growth polymerization reaction Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002145 thermally induced phase separation Methods 0.000 description 1
- 201000002743 tongue squamous cell carcinoma Diseases 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2300/00—Characterised by the use of unspecified polymers
- C08J2300/14—Water soluble or water swellable polymers, e.g. aqueous gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
- C08J2333/02—Homopolymers or copolymers of acids; Metal or ammonium salts thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/78—Cellulose
Definitions
- This invention relates to the fields of material technology for cell culturing and tissue engineering.
- the present invention relates to a method for the production of an unerodible, transparent and sterilizable hydrogel scaffold for a three-dimensional cell culture which can be used to culture a variety of different cells and tissues in vitro for prolonged periods of time.
- Cell culture is the process by which cells are grown under controlled conditions, generally outside their natural environment.
- the term “cell culture” refers to the culturing of cells derived from multi-cellular eukaryotes, especially animal cells, but the culturing can be extended to other growing cells, such as plant tissue culture, fungal and microbiological culture.
- Cells can be grown either in suspension or as adherent cultures. Some cells naturally live in suspension, without being attached to a surface, such as blood cellular components. There are also cell lines that have been modified to be able to survive in suspension, so they can be grown to a higher density than adherent conditions would allow.
- Adherent cells require a surface, such as tissue culture plastics or microcarriers, which may be coated with extracellular matrix components (such as collagen, laminine, polylysine) to improve adhesion properties and provide other signals needed for growth and differentiation.
- Plating density (number of cells per volume of culture medium) plays a critical role for culturing some cell types: cells generally continue to divide in culture until the available area or volume is filled.
- a "three-dimensional cell culture” or also named “3D cell culture” allows cells in vitro to grow in all directions, similar to in vivo condition.
- Three-dimensional cell cultures have greater stability and longer lifespans than cell cultures in 2D. Also, 3D aggregates can be cultured for longer, also more than two weeks, as compared to almost one week with 2D monolayer culture due to cell confluence. Therefore, they might be more appropriate for long-term studies and surviving cells and for demonstrating long-term effects of the drug. Thanks to the 3D environment, the cells are allowed to grow undisturbed compared to the 2D models, where regular dissociation by animal origin (porcine) trypsin, or more recent animal-free recombinant cell-dissociation enzymes, is necessary in order to provide them with sufficient nutrients for normal cell growth.
- animal origin porcine
- 3D cell culture allows generating 3D aggregates in a non-turbulent environment, with minimal shear force and continually suspended "freefall” culture, it allows the generation of 3D tissue-like aggregates which display physiologically relevant phenotypes, such as lower proliferation rate, hypoxic regions and vasculature.
- the 3D cell culture systems let understand the complex cellular physiological mechanisms, and are therefore widely applied in differentiation studies, pharmaceutical assays, tumor models and cancer biology research [4], gene and protein expression studies, besides being applied in tissue engineering, in bioreactor and in vitro modeling of human organs.
- the cells can grow as spheroids, or 3D cell colonies.
- 3D spheroids more closely resemble in vivo tissue in terms of cellular communication and the development of extracellular matrixes. These matrixes help the cells move within their spheroid similarly to the way cells would move in living tissue.
- the spheroids are thus improved models for cell migration, differentiation, survival, and growth and gene/ protein expression[6].
- stem cells or progenitor cells By culturing stem cells or progenitor cells in a 3D culture, it is possible to assist to organoid formation.
- Organoid is a miniaturized and simplified version of an organ produced in vitro in three dimensions that shows realistic micro-anatomy. They are derived from one or a few cells from a tissue, embryonic stem cells or induced pluripotent stem cells, which can self-organize in three-dimensional culture owing to their self-renewal and differentiation capacities. Organoids have also been created using adult stem cells extracted from the target organ, and cultured in 3D media [7, 8].
- Hydrogels can be used to influence mesenchymal stem cell differentiation towards hard (bone) or soft tissue (neural-like, adipose) cell phenotypes in the absence of differentiation media, immobilized matrix proteins or bioactive motifs.
- the 3D nature of the gels offers a major opportunity to develop more realistic in vitro models for cancer research.
- Transwell or collagen overlay assays are standard methods used to measure macrophage and tumor cell co-migration.
- Hydrogels can be suitable to create a reliable, more in vivo-like culture system that opens up to new possibilities in cancer research, from mimicking ECM environment to designing multi-cellular, tumor-like systems, to developing culture systems that favor tumor stem cells.
- monocyte-derived cells as macrophages
- scaffold techniques There are a number of commercially available culturing tools for 3D cell culture, which can be classified in two types: scaffold techniques and scaffold-free techniques.
- Scaffold-free techniques employ another approach independent from the use of scaffolds.
- the scaffolds currently used may be classified in solid structures and hydrogel matrixes.
- 3D cell culture scaffolds The main requirements for 3D cell culture scaffolds are: high compatibility with most cell lines, suitable mechanical strength, optical transparency, high porosity and interconnectivity, sterilizability, manageability, hydrophilicity, easy diffusion of substances to be tested and gas, easy dissection into thin layers, absence of interference with conventional assays for cell growth evaluation, easy production and low cost [9-12].
- the optimal 3D scaffold combining the most appropriate characteristics has not been developed yet.
- Solid scaffolds are normally made of either inorganic (calcium phosphate) or organic polymeric materials (polystyrene). Their main shortcomings are: they are not transparent (therefore limiting cell observation during culture growth), difficult to sterilize, not suitable to hold cells; moreover, cell detachment and recovery to perform viability tests or to move the culture to another support are labor intensive and allow only a partial recovery of the cells.
- This type of scaffolds may be applied in immunohistochemistry, electronic microscopy, fluorescence microscopy, confocal microscopy, cytofluorimetry, biochemical assays, protein and nucleic acid production and extraction, analysis of molecules synthesized by various cell lines.
- Hydrogels are three-dimensional, cross-linked polymeric networks which can swell in water forming soft elastic materials, and retain a significant fraction of water in their structure without dissolving.
- hydrogels can be employed for tissue engineering, since their structures are soft, easily hydrated and several hydrogels can be tuned to resemble specific tissues. These features support very well the transport/exchange of nutrients, and water-soluble factors, as removal of catabolites.
- the hydrogels are commonly quite transparent allowing to a sufficient extent the possibility of microscopy observation, during culture time, to check the healthy state of cells.
- hydrogels have to be maintained in a hydrated state, therefore they could possibly suffer from long term stability issues in vitro and some densely crosslinked gels can hinder cellular migration.
- the scaffolds based on polymeric hydrogels are more similar to the extracellular matrix (ECM) of living tissues and porous scaffolds based on hydrophilic polymer networks can mimic in vivo tissue architecture, therefore being more favorable for organotypic cell proliferation [13]. Yet, their weaknesses can be: inadequate mechanic strength or weak rheological consistency, difficult cell attachment, complex and expensive preparation costs.
- Porous materials are classified into several kinds by their size. According to IUPAC notation [14], microporous materials have pore diameters of less than 2 nm and macroporous materials have pore diameters of greater than 50 nm; the mesoporous category thus lies in the middle.
- Hydrogels are the most promising option for cell culture and have proven useful in a range of cell culture applications, revealing fundamental phenomena regulating cell behavior and providing tools for the expansion and directed differentiation of various cell types in ways not possible with conventional 2D cultures.
- 3D hydrogel mammary epithelial cell assemble into multicellular spherical structures resembling healthy acini; pluripotency markers of embryonic stem cells can be controlled over mechanic properties or chemical modifications; in peptide hydrogel cells show improved resistance to chemotherapeutics, neurons with genetic mutations related to Alzheimer's disease show the formation of the lesions typical of this pathology, as the amyloid plaques and the neurofibrillary tangles [15], [16].
- Three-dimensional scaffolds can be prepared by different techniques, such as gas-forming foam, three-dimensional printing, thermally-induced phase separation, electrospinning, freeze-drying, solvent casting, compression moulding, immersion precipitation, particulate leaching, supercritical CO 2 technique, free-radical polymerization or copolymerization, double network polymerization, templating fabrication.
- hydrogels can encapsulate seeded cells after their fabrication or the viable cells can be encapsulated with the hydrogel precursor that generates the hydrogels by chain-growth or step-growth polymerization. It is important to use nontoxic initiators (it has been reported that free radicals in the photo-polymerization process can damage the cells) and cross linkers for a rapid gel formation to prevent cell settling during the encapsulation process [15].
- the porogenic template is a diverse and versatile route for the preparation of porous materials that has been applied over a wide range of length scales. Water is cheap and a number of porous scaffolds for tissue engineering and biological applications have been prepared by freeze-drying, in which ice was used as a porogenic template [17].
- freeze-drying techniques encounter difficulty in precisely tuning pore size since the hydrogel architectures formed using this method are extremely sensitive to the kinetics of the thermal quenching process; other drawbacks are the low structural stability and generally weak mechanical properties of the surface, because the matrix may collapse at the scaffold-air interface due to the interfacial tension caused by solvent elimination [18].
- Scaffolds should have high porosity and interconnected porous structure to provide adequate space for the cell seeding, growth and proliferation, in fact, an appropriate micro-architecture of the scaffolds can influence directly the behavior of the cultured cells.
- Most scaffolds can be weak at high porosities (more than 90%) and they can collapse during preparation and in this case it is mandatory to find ways to strengthen them, for example through reinforcing fibers or solid supports. This can be detrimental to other useful properties like transparency, cytocompatibility or sterilizability.
- the capacity of the scaffolds to retain water is another essential parameter of the polymeric network for the permeation of nutrients and waste from the cells.
- hydrogels three different types of water can exist, depending on the interactions: free water, water linked through hydrogen bonds and water more strongly linked through polar interactions as with carboxylate group [23].
- Water within the hydrogel is mainly stored in pores and channels of the scaffolds and only in part is absorbed in the hydrogel wall. Generally, the elasticity of the hydrogel correlates with the swelling behavior of the hydrogels increasing with the amount of water absorbed.
- Natural biomaterials suitable for 3D cell culture in vitro include collagen (Purecol, Fibricol, Flexcell or collagen-containing mixtures such as Matrigel ® ), alginate, agarose, and fibrin.
- collagen Purecol, Fibricol, Flexcell or collagen-containing mixtures such as Matrigel ®
- these hydrogels are known to exhibit fast release of loaded growth factors and degrade very quickly, often not allowing adequate time for cell attachment and growth.
- Synthetic materials although non-toxic, could be non-suitable for culturing cells: in fact, neuronal cell are known to die in PEG-like hydrogels within 1 day of culture and do not exhibit greater viability or proliferation as compared to monolayer controls [24]; polyacrylamide is suitable for 2D cell culture only [15].
- Hybrid materials like hyaluronic acid can influence the cellular experiments because of their numerous cellular interactions, while polypeptides have prohibitive cost for large-scale culture systems and often they are not stable for a long period.
- PAA Poly(acrylic acid)
- Hydrogel networks formed from PAA have the ability to absorb many times their weight in water and are the basis of a class of materials called super-absorbents. These polymers are used in many applications, including filters, ion exchange resins, and membranes for hemodialysis, ultrafiltration, and controlled release devices.
- Poly(acrylic acid) has a carboxylic acid functionality (or carboxyl group or -COOH), providing a useful substrate for subsequent surface modifications and bio-conjugations [25] to ameliorate the control of cultured cell behaviors: for example, collagen has been immobilized on PAA. which remarkably improved the attachment and proliferation of human dermal fibroblasts and myoblasts [26].
- Non cross-linked acrylic polymers [27] have also been disclosed as non-living material enveloped by stromal cells and connective tissue proteins to form a three-dimensional structure having interstitial spaces bridged by the stromal cells.
- a patent [28] discloses a polycarbophil conjugate with EGF (Epidermal growth factor) or bFGF (Basic fibroblast growth factor) as attachment and growth promoting agents for growing corneal endothelial cells, for artificial corneal transplants, but not as scaffold and not as thermally-treated polymer.
- EGF Epidermal growth factor
- bFGF Basic fibroblast growth factor
- Sheetz discloses a non-porous scaffold for cell growth comprising a portion of substrate and fiber stretched over the substrate portion, wherein the substrate comprises a growth medium and a cross-linked polymer.
- the substrate comprises a growth medium and a cross-linked polymer.
- polyacrylic acid is only mentioned; but the procedure does not involve thermal treatment or leaching steps in the presence of porigen substances.
- Liu et al. [30] disclose a three dimensional solid construct which can be coated with a polyacrylic acid.
- Shin et al. [31] disclose a complex support for regenerating bone-cartilage, where a polyacrylic acid can be present in the bone regeneration layer.
- Zussman et al. [32] disclose a fiber-reinforced hydrogel containing acrylic polymers usable as scaffolds for cell culture.
- Scaffolds used as cell culture or bioreactors must be sterilized to exclude or reduce bacterial contamination, and this aspect represents a critical issue for most part of the scaffold.
- Rarely polymer scaffolds can be sterilized by thermal processes or ionizing radiation (gamma and beta-rays) which can be cause of damage to the polymeric skeleton of the scaffolds, or by a chemical process which can contaminate the cells with toxic residues or react with the polymers used in the scaffold.
- ionizing radiation gamma and beta-rays
- the largely employed ultraviolet irradiation is only an aid in the reduction of contamination only on the exposed surface because of its negligible penetration.
- Chemical disinfection ethylene oxide, ethanol
- Polymeric hydrogel can rarely resist to terminal sterilization by classical thermal methods, such as moist heat sterilization. For this reason the large majority of 3D scaffolds must be produced by expensive aseptic procedures [15].
- Sponges are porous structures whose properties are determined by interconnectivity, pore size, and porosity, which impact cell penetration and migration, matrix deposition and distribution, and nutrient and waste exchange.
- a hydrogel is a network of polymer chains that are hydrophilic, swollen polymer matrixes with a cross-linked structure and which retain a large amount of water. Sponges are defined by morphology, while hydrogels are defined by hydrophobicity. According to some authors, hydrogels are made of hydrophilic materials with water contact angles less than 60°, while sponges are porous structures made of materials with a water contact angle of 80° or above.
- Macroporous hydrogel sponges can be used as scaffolds for 3D culturing cells, tissue engineering and in the bioreactor technology [33],[30]. Also filling hydrogels into sponges have been reported to be a very efficient tool for 3D culture in scaffold [34].
- WO 2016/168196 A1 discloses water-insoluble but water-swellable and deformable crosslinked PEGylated microgel particles of proteins and protein-based macromolecules tha are pseudoplastic and flow in aqueous medium under shear. These microgel particles function as a matrix to support cell growth, viability and proliferation.
- US 2007/0098799 discloses mineralized hydrogels obtained by combining a first mixture including a calcium derivative, a second mixture including a phosphate derivative and a hydrogel to form a calcium phosphate dispersion containing the hydrogel.
- the hydrogel in the calcium phosphate dispersion is crosslinked to form a mineralized hydrogel, in which calcium phosphate minerals are substantially dispersed within the hydrogel.
- the objective technical problem underlying the present invention is to provide a method for the production of a three-dimensional scaffold suitable for culturing cells for a long time, which, while being unerodable in aqueous mediums, has a high optical transparency allowing a microscopic observation of cell growth and morphology, and also has high molecular diffusion to permit the use in situ of agent for cell viability evaluation test or for standard immunostaining protocols and suitable mechanical properties to be easily handled. It should also be resistant to the energy sterilization process or to chemical agents.
- the thermal treatment carried out on the compact units obtained from the above-mentioned solid mixture generates a robust 3D matrix which can be submitted to the leaching treatment with deionized water to become highly porous.
- the at least one water-soluble salt and the at least one gas-forming agent can be used as powder with a size controlled by milling and sieving procedures.
- the present method does not use any organic solvent or cross-linking agent, and produces a scaffold with the above-mentioned properties suitable for culturing different kinds of the cells even for a long time (longer than 2D), allowing a good permeation of gases, nutrients and waste from the cells.
- the three-dimensional scaffold obtained with the method according to the present invention involves several advantages.
- the gas-forming agent improves the structure and increases the interconnectivity and porosity of the three-dimensional scaffold, thus guaranteeing and promoting cell and small molecules movement through the three-dimensional structure.
- the water-soluble salt improves micro-porosity and interconnectivity of the above-mentioned scaffold.
- the scaffold obtained with the method of the invention can be used in conventional cell culture vessels, such as cell culture dishes, cell culture plates, cell culture flasks, micro-well plates, cell culture bags, bioreactors and microfluidic devices.
- conventional cell culture vessels such as cell culture dishes, cell culture plates, cell culture flasks, micro-well plates, cell culture bags, bioreactors and microfluidic devices.
- said scaffold permits the use in situ of agents for cell viability evaluation test or for standard immune-staining protocols.
- the scaffold with cultured cells may be employed in a variety of applications ranging from cytotoxical and pharmacological screening, assaying the biological activity of compounds in vitro, studying the growth, proliferation, and function of cells, and the production of biologically active molecules, as biological model of tissues, for growing tissue and for in vivo implantation o transplantation of tissue (bone, bone marrow, liver, mucosal epithelium, pancreas, brain, lung, vascular, hearth, gut, intestinal, membranous, retina, eyes, cartilaginous etc).
- tissue bone, bone marrow, liver, mucosal epithelium, pancreas, brain, lung, vascular, hearth, gut, intestinal, membranous, retina, eyes, cartilaginous etc.
- the scaffold obtained with the method of the present invention may be used to grow other kinds of cells, such as plant tissue culture, mycological and microbiological culture (of microbes).
- the 3D scaffold according to the invention can be used for culturing and studying microbiota that normally inhabits the skin, mouth, nose, digestive tract, and vagina.
- the scaffold obtained with the method of the present invention resists to the high temperature and pressure of the sterilization treatment by moist-heat autoclave, maintaining the mechanical and morphological properties and the suitability for culturing cells.
- the present invention relates to a method for the preparation of a three-dimensional hydrogel scaffold for cell culturing, which comprises the steps of:
- the scaffold obtained by this method can be used to culture different cellular types in mixed co-culture models or segregated co-culture systems.
- the 3D scaffolds obtained by the method of the present invention are useful for culturing cells derived from multi-cellular eukaryotes, especially animal cells or genetically-modified cells or other types of cell culture such as plant tissue culture, fungal culture, and microbiological culture.
- the scaffold When conditioned in an aqueous medium, the scaffold appears to be a highly transparent sponge, through which it is possible to observe and study the cell cultures growing in the pores of the structure.
- initial composition or “first uniform solid mixture” as used herein mean a mixture comprising a polymeric component, namely a cross-linked poly(acrylic) acid powder, which is hydrophilic but not soluble in water, and a fraction including a thermostable water-soluble salt and a gas-forming agent.
- said cross-linked poly(acrylic) acid may be a polymer of acrylic acid cross-linked with either allyl sucrose or allyl ethers of pentaerythritol like Carbomers (as defined by British Pharmacopeia (BP), European pharmacopoeia Ph. Eur., or US Pharmacopeia (USP) or Handbook of Pharmaceutical Excipients sixth edition, 2009 (UK ISBN 978 0 85369 792 3 ) and their salts, which is identified by CAS registry number [9003-01-4 ].
- Alternative CAS registry numbers have been used for Carbomer 934 ([9007-16-3]), 940 ([9007-17-4]) and 941 ([9062-04-08]).
- the CAS registry number [9007-20-9 ] has also been used for Carbomer.
- cross-linked poly(acrylic) acids may also be polymers of acrylic acid cross-linked with divinyl glycol like Polycarbophil [ CAS number 9003-97-8 ] or Noveon AA-1 and its salts.
- the cross-linked polymers of acrylic acid can be used in an amount between 20-80% (w/w) of the initial mixture used to produce the compacted unit.
- the cross-linked polymers of acrylic acid are used in an amount between or 22-60% or 30-50% (w/w) of the initial mixture.
- thermostable water-soluble salt is preferably selected from the group comprising: sodium chloride (NaCl), potassium chloride (KCl), potassium sulfate (K 2 SO 4 ), sodium sulfate (Na 2 SO 4 ), potassium dihydrogen phosphate (KH 2 PO 4 ), disodium hydrogen phosphate (Na 2 HPO 4 ), magnesium sulfate (MgSO 4 ), aluminum chloride (AlCl 3 ), magnesium chloride (MgCl 2 ), potassium acetate (KC 2 H 3 O 2 ) or a mixture thereof. More preferably, the thermostable water-soluble salt is sodium chloride or potassium chloride.
- said salts may be used in combination with non-ionic water soluble molecules (such as, for example, carbohydrates or polymers), provided that they are stable to the subsequent thermal treatment.
- non-ionic water soluble molecules such as, for example, carbohydrates or polymers
- thermostable water-soluble salt can be used in an amount between 0.5-79.5 % (w/w) of the initial composition preferably 10-50% (w/w), even more preferably 20-40% (w/w).
- the gas forming agent may be thermolabile.
- thermolabile gas-forming agent is able to generate gas upon the heating of said thermal treatment (up to temperature of about or less than 160°C) according to the method of the present invention.
- the thermolabile gas-forming agent may be sodium hydrogen carbonate or another thermolabile compound which is able to generate gas, such as, for example, potassium hydrogen carbonate, sodium glycine carbonate, ammonium hydrogen carbonate, sodium bisulfite or sodium metabisulfite.
- the gas-forming agent improves the structure and increases the porosity and interconnectivity, such as sodium hydrogen carbonate or any thermolabile or thermostable gas-forming agent.
- the gas-forming agent may be a thermostable compound, such as calcium carbonate or sulfites, in particular sodium sulfite.
- a thermostable compound such as calcium carbonate or sulfites, in particular sodium sulfite.
- the decomposition of such thermostable gas-forming agent occurs in an acidic solution, because it does not decompose during the thermal treatment of the method according to the present invention (as instead the above-mentioned thermolabile gas-forming agent does). Therefore, in this particular embodiment, the step of gas forming occurs after the thermal treatment step and during the leaching step in a suitable acidic aqueous medium before the conditioning step (pH 0.1-3).
- Sodium hydrogen carbonate or other gas-forming agent could be used in a percentage between 0.5-79.5% (w/w) of the initial composition, preferably 10-50% (w/w), even more preferably 20-40% (w/w).
- the 3D scaffolds obtained with the method of the present invention have a porosity higher than 85%, preferably higher than 95% and a pore size comprised between 0.1 nm and 600 ⁇ m, as shown in the Examples.
- the Young's modulus, also known as the elastic modulus, of 3D hydrogel sponge scaffolds conditioned in PBS ranges from 5 to 200 kPa (15-120 or 20-110), while yield strength/weight of PBS-conditioned scaffolds ranges from 1 to 30 kPa/g or from 2 to 18 or 3 to 13 (see example 6).
- the apparent density of the lyophilized 3D scaffold obtained by freeze-drying from the hydrogel sponge conditioned in water ranges from (see example 4) 5 mg/ cm 3 to 50 mg/cm 3 , preferably 10 mg/ cm 3 to 45 mg/cm 3 , more preferably 12 mg/ cm 3 to 40 mg/ cm 3 , even more preferably 13 to 30 mg/ cm 3 , being the most preferred the range between 14 mg/ cm 3 and 25 mg/ cm 3 .
- the compacted units can be multilayer units produced by step by step compaction of different layers with different composition, each containing at least one cross-linked polyacrylic acid.
- the layers can have different or equal composition and contain the same or different cross-linked polyacrylic acid. Some layers, for example the external top or bottom layers, can contain only a cross-linked polyacrylic acid as barrier layers.
- the compacted multilayer units are submitted to the same preparative steps of thermal treatment, leaching, medium/solvent conditioning, optional vacuum chamber conditioning, optional lyophilization, and sterilization.
- the different layers can be used to culture different cellular types in mixed co-culture models or segregated co-culture systems [35] ( Figure 1A ).
- the compacted units can also be partially dry-coated, so that the compacted units are made only of lower and lateral coating without upper coating layer.
- the coating layers are applied by pressure in a tableting machine by centering a pre-compacted cylindrical core in a cylindrical die containing the powder bed of the coating mixture.
- the coating layers can have different or equal composition and contain the same or a different cross-linked polyacrylic acid. Both the coating layer and the core of the coated unit must contain at least a cross-linked polyacrylic acid.
- the coating layers can contain only a cross-linked polyacrilic acid as barrier layer.
- the partially coated units are submitted to the same preparative steps of thermal treatment, water leaching, medium/solvent conditioning, optional steps of vacuum chamber conditioning or lyophilization and sterilization ( Figure 1B ).
- the lyophilized scaffold obtained with the method of the present invention can also be partially film-coated by film forming agents like hydroxypropylcellulose (HPC), ethylcellulose (EC), hydroxyethylmethylcellulose (HEMC), hydroxypropylmethylcellulose (HPMC), methylcellulose (MC), polyvinylalcohol (PVA), polyvinylalcohol acetate phthalate, polymethacrylates (i.e. Eudragit)
- film forming agents like hydroxypropylcellulose (HPC), ethylcellulose (EC), hydroxyethylmethylcellulose (HEMC), hydroxypropylmethylcellulose (HPMC), methylcellulose (MC), polyvinylalcohol (PVA), polyvinylalcohol acetate phthalate, polymethacrylates (i.e. Eudragit)
- the at least one water-soluble salt for example sodium chloride
- the at least one gas-forming agent for example, sodium hydrogen carbonate
- the at least one water-soluble salt for example sodium chloride
- the at least one gas-forming agent for example, sodium hydrogen carbonate
- aqueous sodium chloride solution against a fluid bed of sodium hydrogen carbonate powder to obtain a macroaggregate with a controlled size, for example through sieving, between 50 to 500 ⁇ m.
- This macroaggregate after assaying its composition, can be used as template in the scaffold preparation to obtain a more regular porosity in the resulting hydrophilic sponge of 3D scaffold.
- the sodium chloride solution can contain up to 25% (w/w) of ethanol.
- aqueous solution containing the two above-mentioned components namely the at least one water-soluble salt and the at least one gas-forming agent, at the same concentration (from 5 to 15 %) it is possible to obtain a mixed macro-aggregated powder with controlled size, usable as scaffold template.
- the aqueous solution of the two components for spray drying can contain up to 25% (w/w) of ethanol.
- microspheres of a mixture of the at least one water-soluble salt and the at least one gas-forming agent with controlled sizes it is possible to obtain microspheres of a mixture of the at least one water-soluble salt and the at least one gas-forming agent with controlled sizes to use as porogenic template tableting with the other component (cross-linked polyacrylic acid).
- HBSS Hank's balanced salt solution
- MEM minimal essential medium
- DMEM Dulbecco's Modified Eagle Medium
- RPMI Roswell Park Memorial Institute medium
- fetal calf serum L-glutamine
- antibiotics e.g. Pen-Strep, gentamycine
- antifungals e.g. amphotericin B
- the hydrogel sponge or 3D scaffold can be filled with solution or gel (also obtainable in situ) based on artificial and natural biomaterials as hyaluronic acid, collagen (all types), Matrigel ® matrix (a gelatinous protein mixture secreted by Engelbreth-Holm-Swarm mouse sarcoma cells and marketed by Corning Life Sciences and BD Biosciences), alginate, gelatin, agarose, chitosan, chitosan-glycerophosphate, bioactive peptides, polyethylene glycol (PEG) modified with either hydrolysable units or bioactive peptides, hydrolyzed or partially hydrolyzed egg shell membrane, fibrin, polylysine, polypropylene imine hexadecylamine, polyethylene imine, glycoproteins, glycosaminoglycans, (e.g., heparan sulfate, chondroitin-4-sulfate, chondroitin
- the surface of the hydrogel sponge or 3D scaffold can be physically or chemically modified to immobilize substances useful for cell growth, e.g.: collagen, fibronectin, vitronectin, laminin, heparin, plasma, Arg-Gly-Asp (integrin-binding sequence -RGD-) or heparin binding sequence (-FHRRIKA-) peptides, hyaluronic acid, chitosan, chitosan-glycerophosphate, bioactive peptides, polyethylene glycol (PEG) modified with either hydrolysable units or bioactive peptides, fibrin, and glycoproteins, glycosaminoglycans.
- substances useful for cell growth e.g.: collagen, fibronectin, vitronectin, laminin, heparin, plasma, Arg-Gly-Asp (integrin-binding sequence -RGD-) or heparin binding sequence (-FHRRIKA-) peptides,
- the three-dimensional scaffold can be coated with osteogenic proteins such as bone morphogenic protein (BMP) and bone sialoprotein (BSP).
- BMP bone morphogenic protein
- BSP bone sialoprotein
- SIBLING small integrin-binding ligand N-linked glycoprotein
- BSP also mediates mineral deposition, binds type I collagen with high affinity, and binds ⁇ v ⁇ 3 and ⁇ v ⁇ 5 integrins which mediate cell signaling [37].
- the main mineral component of bone tissue is a nonstoichiometric carbonated multi-substituted apatite with calcium to phosphorus ratio (Ca:P) between 1.37 and 1.87
- Synthetic hydroxyapatite (Ca 10 (PO 4 ) 6 (OH) 2 ) is a popular bone replacement material because it has a similar crystal structure (Ca:P ratio fixed at 1.67) to native bone apatite. This resemblance can be exploited to 3D culture bone cells in the scaffolds.
- the scaffolds can be mineralized with other mineralizing components like tricalcium phosphate (Ca 3 (PO 4 ) 2 ), hydroxyapatite (Ca 5 (PO 4 ) 3 OH), carbonated hydroxyapatite, wollastonite, magnesium silicate, alumina and zirconia.
- Synthetic hydroxyapatite (HA) or the above-mentioned other mineralizing components can be added to the powder in the first uniform solid mixture in the range between 0.5-70 % or 10-40 % or 20-30% to obtain the compact units which will be submitted to subsequent thermal treatment.
- carboxylic acid group (COOH) negatively charged, as those present in the scaffold described in the present invention, are the most potent inducers group of mineralization [44]
- the mineralization may be carried out by hydro- and solvo-thermal methods [45 - 54], sol-gel method [55 - 58], or emulsion and microemulsion method [59-61].
- the scaffold may also be biomineralized.
- Biomineralization refers to the processes by which organisms form minerals; the control exerted by many organisms over mineral formation distinguishes these processes from abiotic mineralization.
- biomineralization is also used to refer to the process of mineralization of scaffolds influenced or favored by the presence of biologic materials, such as intestinal submucosa, collagen, body fluid or simulated body-fluid (SBF). In this case the process can be more precisely defined biomimetic nucleation/mineralization.
- biologic materials such as intestinal submucosa, collagen, body fluid or simulated body-fluid (SBF). In this case the process can be more precisely defined biomimetic nucleation/mineralization.
- SBF's as a rule contain the inorganic ion concentrations of human blood plasma and can be obtained by dissolving reagent grade salts (NaCl, NaHCO 3 , Na 2 SO 4 , KCl, K 2 HPO 4 ⁇ 3H 2 O, MgCl 2 ⁇ 6H 2 O, and CaCl 2 ⁇ 2H 2 O) in distilled water obtaining a final ionic concentration also more times (e.g. 2x) higher than physiological concentrations. Its pH is adjusted to 7.4 (37 °C) with suitable buffer solution; for example, 0.05 mol L-1) of tris(hydroxymethyl)aminomethane (Tris) and hydrochloric acid.
- Tris tris(hydroxymethyl)aminomethane
- the scaffold can be conditioned or soaked in SFB [62-64].
- the skeleton of the scaffold is made of cross-linked polyacrylic acid having free carboxyl groups (-COOH), which can be grafted or linked by covalent or strong and weak ionic bonds or electric bonds with molecules useful for culturing cells, like for example with: peptides (natural or synthetic, as Ac-CGGNGEPRGDTYRAY-NH 2 or Ac-CGGFHRRIKA-NH 2 ), proteins, poly(ethylene terephthalate, poly( ⁇ -caprolactone), carbohydrates (e.g.
- galactose and carbohydrate derivatives, and with hyaluronic acid, collagen (all types), Matrigel ® , alginate, gelatin, agarose, chitosan, chitosan-glycerophosphate, polyethylene glycol (PEG) with either hydrolysable units in bioactive peptides, bioactive peptides, hydrolyzed egg shell membrane, fibrin and growth factors including, but not limited to, bFGF (Basic fibroblast growth factor), EGF (Epidermal growth factor), VEGF (Endothelial growth factor).
- bFGF Basic fibroblast growth factor
- EGF Epidermatitisin
- VEGF Endothelial growth factor
- this scaffold can incorporate nanoparticles within the 3D hydrogel sponge network, either physically or covalently, to embrace various functionalities and properties.
- The-above mentioned nanoparticles may be silica, quantum dots, nanotubes, polymers, liposomes, micelles, or dendrimers. Moreover, they may contain different compounds such as, for example, graphene, gold, magnetic iron oxide, tricalcium phosphate (Ca 3 (PO 4 ) 2 ), hydroxyapatite (Ca 5 (PO 4 ) 3 OH), carbonated hydroxyapatite, wollastonite, magnesium silicate, alumina and zirconia.
- the scaffold it is possible to grow primary cells, from normal and tumor tissues, immortalized cell lines, embryonic and induced pluripotent stem cells (e.g., ESCs and iPSCs), and mesenchymal stem cells (e.g., MSCs), from fetal and several adult tissues (for example, adipose, bone marrow, skin, liver, kidney, neural tissues).
- ESCs and iPSCs embryonic and induced pluripotent stem cells
- MSCs mesenchymal stem cells
- Such cells include, but are not limited to, endothelial cells, pericytes, macrophages, monocytes, plasma cells, mast cells, adipocytes, hematopoietic tissue and reticular cells, fibroblasts, glial cells, Kupffer cells, vascular and bile duct endothelial cells.
- Fibroblasts may be derived from organs, such as skin, liver, pancreas, bone marrow, skin, liver, pancreas, kidney, adrenal and neurologic tissue, etc. to name but a few.
- Such cells include i.e. DU145 (prostate cancer), H295R (adrenocortical cancer), HeLa (cervical cancer), KBM-7 (chronic myelogenous leukemia), LNCaP (prostate cancer), MCF-7 (breast cancer), MDA-MB-468 (breast cancer), PC3 (prostate cancer), SaOS-2 (bone cancer), SH-SY5Y (neuroblastoma, cloned from a myeloma), T47D (breast cancer), THP-1 (acute myeloid leukemia), U87 (glioblastoma), National Cancer Institute's 60 cancer cell line panel (NCI60).
- DU145 prostate cancer
- H295R asdrenocortical cancer
- HeLa cervical cancer
- KBM-7 chronic myelogenous leukemia
- LNCaP prostate cancer
- MCF-7 breast cancer
- MDA-MB-468 breast cancer
- PC3 prostate cancer
- Table 1 list of cells which may be cultured on a 3D scaffold according to an aspect which is not part of the invention.
- Cell line Organism Origin tissue Morphology A172 Human Brain Glioblastoma A253 Human Submandibular duct Head and neck carcinoma A2780 Human Ovary Ovarian carcinoma A2780ADR Human Ovary Adriamycin-re sistant derivative of A2780 A2780cis Human Ovary Cisplatin-resistant derivative of A2780 A431 Human Skin epithelium Squamous cell carcinoma A549 Human Lung Lung carcinoma BCP-1 Human PBMC HIV+ primary effusion lymphoma BEAS-2B Human Lung Epithelial BOSC23 Human Kidney (embryonic) Epithelium BT-20 Human Breast epithelium Breast carcinoma BxPC3 Human Pancreatic adenocarcinoma Epithelial Caco-2 Human Colon Colorectal carcinoma Cal-27 Human Tongue Squamous cell carcinoma CML T1 Human CML acute phase T cell leuk
- the cells were seeded on top of the dried scaffold placed in a culture medium and the culture medium was adjusted within 15-30 minutes.
- the seeding stage could require a centrifugation step, immediately after overlayering the cells, for 2 to 10 min, not over 1000 g at temperature ranging from 4°C to 37°C to achieve a uniform cell distribution in the scaffold.
- the different cell cultures were incubated for a different time (up to 60 days) in humidified atmosphere of 5% CO 2 and 95% air at 37°C, with a variable medium change frequency depending on cell type, ranging from 1 to 4 days.
- some cellular lines can be cultured into the scaffold under different dynamic conditions by a proper mechanical stimulation which promotes an efficient progenitor cell expansion, or nutrients and catabolites exchange.
- the scaffold with the cells can be subjected to periodic manual compressive force in a suitable compressive apparatus or device.
- different enzymes can be used, including, but not limited to, trypsin, chymotrypsin, collagenase, elastase, and/or hyaluronidase, DNase, pronase, dispase etc.
- the cells can be recovered from the scaffold by the application of a mild centrifugation force.
- Scaffold mechanical disruption can also be accomplished by a number of methods including, but not limited to, the use of grinders, blenders, sieves, homogenizers, pressure cells or insonators.
- the presence or the number or the growth of cells inside the scaffold could be monitored by impedance based assay or by other electrical known measurement or method based on eco-Doppler effect or other acoustic methods.
- the three-dimensional scaffold is obtained by compression of the cross-linked polyacrilyc acid powder uniformly mixed with at least one water-soluble salt and at least one gas-forming agent.
- the resulting compact unit is submitted to a thermal treatment and the soluble fraction of the resulting matrix is leached therefrom by repeated washing with suitable amounts of deionized water up to complete swelling of the matrix and disappearance of the soluble fraction.
- water-soluble fraction of said unit means the fraction consisting of the at least one water-soluble gas-forming agent and the at least one water-soluble salt, prior to the thermal treatment of the method according to the present invention.
- water-soluble fraction of the thermally treated unit means the fraction consisting of the at least one water-soluble salt and the residue resulting from the decomposition of the at least one thermolabile gas-forming agent during the thermal treatment.
- the scaffold can be frozen and subjected to lyophilization. After conditioning in a suitable volume of water or an aqueous medium, the scaffolds are sterilized by moist heat in autoclave.
- the particles of the salts can be milled and sieved or only sieved or granulated, alone or together, to yield various particle sizes in the range from 50 to 500 ⁇ m.
- thermostable salt and the gas-forming agent can be used as powder aggregates in microbeads or microspheres of different size and shape, as pure components or in combination between them.
- cross-linked polyacrylic acid can be sieved to yield various particle sizes ranging from 50 to 500 ⁇ m.
- the powder of each component, before or after sieving, can be dried in oven at 100°C for 30 minutes and the dried powder is stored, before use, in a desiccator containing silica gel.
- the uniform mixed powder can be directly submitted to a direct compression procedure or can be granulated.
- Granulation can be performed in an apparatus for granulation commonly described (Handbook of chemical engineering), through the following preparative steps:
- the granulating fluid can be a saturated solution or brine of the salt used, like NaCl, which can be sprayed on the uniform mixed powder containing the remaining part of the salt used in the formulation.
- the granulation can involve only the uniform powder mixture of water soluble salts and the gas forming agents following the above-mentioned procedure and the granulate so obtained, after assaying the concentration of each component of the mixture and optionally sieving, is mixed with the polymeric fraction in a suitable ratio.
- the granulation involving only the water-soluble salts and the gas forming agent, can be performed in spray-dryer or in a fluid bed apparatus.
- the solution containing the components of the water-soluble fraction can contain up to 25% (w/w) of ethanol.
- the granulate so obtained after assaying the concentration of each component of the mixture and optionally sieving, is mixed with the polymeric fraction in a suitable ratio.
- polymeric fraction means at least one cross-linked polyacrylic acid according to the present invention.
- a solution containing the water-soluble salts of the water-soluble fraction e.g. sodium chloride
- a fluid bed of the gas-forming agent e.g. sodium hydrogen carbonate
- the solution containing the salt of the water-soluble fraction can contain up to 25% (w/w) of ethanol.
- the granulate so obtained, after assaying the concentration of each component of the mixture and optionally sieving, is mixed with the polymeric fraction in a suitable ratio.
- the powder or the granulate are compacted in a compact unit machine or using a hydraulic press.
- the shape of the compact unit depends on punch/die shape.
- the form of the compressed powder can be any regular three-dimensional geometric shape, and the weight of powder used can be any between 5 mg and 100 kg.
- the compression of the uniform powder can be conducted by working with a pressure per gram of powder between 2 kPa/g - 2500 GPa/g or 150 kPa/g - 25 GPa/g or 16 MPa/g -12 GPa/g.
- the machine may be a suitably modified model for carrying out multilayer or dry coating tableting.
- the treatment is carried out in a precise forced-air oven as the oven of a gas chromatograph and consists of heating to a predetermined treatment temperature and maintaining such temperature for a predetermined time.
- the treatment temperature ranges from 120 to 160°C (in particular 125-155°C) for a time in the range of 1-120 minutes, as a function of solid mixture weight, in particular 1-20 minutes.
- the heating rate of the compressed units can vary from 1°C/minute to 50°C/minute.
- the temperature program employed is as follows: 0.1 min at 25°C, then heating up to the treatment temperature with a gradient equal to 30°C/min and maintenance of such temperature for the established time, then forced or natural cooling of the compact units to room temperature.
- the cooling step after heating can occur naturally or in forced manner, for example controlling the cooling through the ventilation of dry air or inert gas (N 2 , Ar, He) at room temperature or dry air or inert gas cooled to a temperature lower than room temperature.
- dry air or inert gas N 2 , Ar, He
- a conditioning time at environmental conditions which can even last 24 hours, can be necessary.
- waiting time does not affect the quality of the production, but it is in any case preferable to wait a standard time of 5 minutes before the next steps.
- ⁇ w % w O ⁇ w / w O * 100 where w 0 is the initial weight of the compact unit and w is the weight of the same after heat treatment.
- the thermally treated compact unit is repeatedly washed in ultra-pure water up to full hydrogel matrix swelling and complete elimination of the water-soluble fraction, evaluated by detecting the water-soluble fraction components, as salt ions, in the washing water.
- the water-soluble fraction contains at least one water-soluble salt and the water-soluble residue of at least one thermolabile gas-forming agent.
- chloride ion selective electrode ISE
- ISE chloride ion selective electrode
- Standard and samples are mixed 50:1 with an ionic strength adjustment solution (ISA).
- Calibration is performed by analyzing a series of standards and plotting mV vs. chloride concentration on semi-log graph or by calibrating the ion meter directly in terms of chloride concentration.
- the presence of chloride is assayed also by formation of a precipitate with silver nitrate in the washing water acidified by adding diluted nitric acid. The absence of a visible precipitate or opalescence indicates the absence of chloride ions.
- the matrixes are washed with deionized water (leaching liquid) with a volume equal to 2.7 L per g of the compact unit and the washing is repeated replacing for 5-10 times the volume of leaching liquid with fresh water.
- leaching liquid deionized water
- the porous hydrogel sponge is kept in water under stirring for a variable time ranging from 15 to 120 min depending on the scaffold weight.
- the final point of leaching is determined after the complete matrix swelling when the hydrogel sponge reaches the maximum size and the residual salt ions are no more detectable in washing/leaching water.
- the presence of sodium ion is measured by sodium ion selective electrodes.
- the sodium ion in washing water can be determined potentiometrically using a sodium ion selective electrode (ISE) in conjunction with a double-junction reference electrode, or a chloride combination ISE, and a pH meter with an expanded millivolt scale or an ISE meter capable of being calibrated directly in terms of sodium concentration.
- ISE sodium ion selective electrode
- the scaffold is stored in a vacuum chamber to increase interconnectivity due to escape of the residual gas produced by the at least one gas-forming agent, which is still trapped in the matrix.
- the vacuum conditioning occurs in an evacuable chamber at residual pressure of 100 ⁇ 10 -3 mBar for 10 or 60 min depending on the weight of the conditioned hydrogel sponge.
- a further leaching step may be carried out in order to eliminate the water-soluble residue of the water-soluble fraction, after the escaping of the residual gas.
- the leached 3D scaffolds can be conditioned at different pH in different buffers.
- they can be conditioned at pH 7.4 in PBS or phosphate buffer saline solution, replacing completely the water or other liquid in the swollen hydrogel sponge obtained after the washing procedure, with this buffer solution.
- PBS or phosphate buffer saline solution
- the swollen hydrogel sponge is conditioned in a suitable volume of PBS (or other buffer), replacing the conditioning buffer with fresh buffer every hour until the hydrogel sponge is completely conditioned in the new solvent/buffer up to constant weight and/or dimensions.
- the matrixes are conditioned in 5 mL of PBS for gram of final weight of completely leached swollen scaffold or hydrogel sponge (i.e. 100 mL per 20 g) for at least 12-20 h, changing the conditioning solution every 1 hour for the initial 6 h and afterwards maintaining the scaffolds in a fresh PBS volume up to 12-20 h, or until maximum diameter contraction or volume contraction.
- the replacement of water in the water-swollen hydrogel with PBS solution or other conditioning medium can be obtained by reconstituting the freeze-dried hydrogel sponge or scaffold directly with PBS solution or other conditioning medium.
- Conditioning can be carried out also with other solutions or media used in cell culturing, e.g. DMEM or Dulbecco's Modified Eagle Medium, or EMEM (Eagle's Minimal Essential Medium), RPMI (Roswell Park Memorial Institute medium) or other medium used in the field.
- DMEM Dulbecco's Modified Eagle Medium
- EMEM Eagle's Minimal Essential Medium
- RPMI Roswell Park Memorial Institute medium
- the scaffold of the invention may be conditioned in water, a buffer solution or cell culturing media.
- porous swollen hydrogel sponge or 3D scaffold can be used as such or cut in a suitable irregular or regular shape: for example, it is possible to obtain a cylinder shape by a cylindrical cut mold or sharp edge tube with a specific internal diameter.
- the two previous steps of cutting and conditioning applied to 3D scaffolds can be inverted depending on different subsequent needs.
- the lyophilization step may occur before or after the sterilization step.
- the swollen matrix conditioned in deionized or ultrapure water or in an aqueous solution from deionized or ultrapure water (e.g. PBS, pH 7.4), in a suitable packaging, may be sterilized by moist heat process in autoclave.
- these 3D hydrogel sponge scaffolds resist to the high pressure and temperature of the sterilization treatment by moist-heat in autoclave, maintaining the mechanical and morphological properties and the suitability for culturing cells.
- the above-mentioned scaffolds, packaged in sealed pressure-resistant closed vial, can be submitted to a moist heat sterilization procedure, for example heating at 120°C under saturated steam pressure of 98 kPa over atmospheric pressure for 30 minutes, and the sterilized vial can be stored until use.
- the scaffold sterilized in PBS solution must be suitably pre-conditioned, with cell culture medium, under aseptic conditions, before culturing the cells.
- the sterilized scaffold is frozen at temperatures lower than -25°C and then lyophilized at a pressure lower than 50 ⁇ 10 -3 mBar until complete drying or by a unidirectional freezing procedure, dipping it at a constant rate (from 2 to 10 mm/min) into a cold bath maintained at a constant temperature lower than -100°C, typically at -196°C and then submitted to lyophilization.
- the swollen scaffolds conditioned in water may be lyophilized as disclosed above.
- the lyophilized scaffolds are subjected to a sterilization step, using one of the following well-known methods as, for example, ionizing radiation (gamma and beta), UV exposition, electron accelerator exposition, chemical and gas sterilization or dry heat sterilization.
- ionizing radiation gamma and beta
- UV exposition UV exposition
- electron accelerator exposition electron accelerator exposition
- chemical and gas sterilization dry heat sterilization.
- the lyophilized 3D scaffolds obtained according to any one of the sterilizing and leaching steps disclosed above can be stored in in dry form as lyophilized products, packaged in sealed closed vial.
- the lyophilized product, stored in sealed vial, can be reconstituted through an aseptic preparative procedure, with water (if the scaffold was conditioned in buffer or salt aqueous solution), buffer (if conditioned in water) or directly with the medium used for cell culturing (if conditioned in water).
- the lyophilized product appears as a highly trabecular dry white sponge or a non-transparent solid porous matrix.
- the scaffold in aqueous storage solution or solvent swells, becoming a transparent and resistant (tough and unerodible) hydrogel sponge, suitable for storage in the storing fluid and under sterile conditions for long time.
- a suitable amount of about 2 g of sodium chloride powder (purity ⁇ 99.5%, Sigma Aldrich, US) was milled in high oscillating frequency mill (Mixer Mill MM2, Retsch, D) in a 1.5 mL stainless steel grinding jar containing 3 stainless steel 5 mm-diameter balls at vibrational frequency of 8 Hz for 30 min.
- the ground NaCl powder was sieved between 250 and 125 ⁇ m on ASTM certified test sieves (Giuliani, IT) by an analytical sieve shaker (AS200 Retsch, D).
- Carbopol 980 powder (Carbopol 980NF, Lubrizol, US) was sieved between 250 and 125 ⁇ m on ASTM certified test sieves (Giuliani, IT).
- the compact units were subjected to thermal treatment positioned on a metal support in a metal meshed basket.
- the treatment was carried out in the forced-air oven of a gas chromatograph (HP 5890 series II, Perkin Elmer, US).
- the temperature program employed was as follows: 0.1 min at 25°C, reaching the final temperature of 150°C with a gradient equal to 30°C/min and maintenance of such temperature for 15 min, then the compacted units were cooled to room temperature by forced-air ventilation.
- the presence of sodium ion was measured potentiometrically (Compact Titrator G20 Mettlert Toledo, US) using an ion selective electrode (perfectION comb Na + ) on 20 mL of washing water, while the presence of Cl - was assayed by adding 0.5 mL 2M silver nitrate in 10 mL of washing water acidified by adding diluted (1:4) nitric acid. The absence of a visible precipitate indicated the absence of chloride ions.
- the leached scaffold was conditioned in 25 mL of PBS per gram of final weight of completely leached hydrogel sponge (i.e. 100 mL for 20 g) for at least 12-18 h, changing the conditioning solution every hour for the first initial 6 h and afterwards keeping the scaffolds in a fresh PBS volume for 12 h, until reaching the maximum volume contraction.
- Vacuum conditioning (optional step)
- some scaffolds can be submitted to vacuum conditioning in an evacuable chamber at residual pressure of 100 ⁇ 10 -3 mBar for 10 or 60 min depending on the weight of the conditioned hydrogelsponge.
- the conditioned hydrogel sponge was cut in 9 mm-diameter cylinders by a 9 mm (internal diameter) sharp edge metallic tube.
- the conditioned 3D-scaffolds were frozen at a temperature lower than -25°C, until complete water solidification, and lyophilized at a pressure lower than 50 ⁇ 10 -3 mBar until complete drying.
- the scaffolds were submitted to a secondary drying by increasing the temperature to 40°C and heating the dried scaffolds, under vacuum conditions, for at least 1 hour.
- the lyophilization of already sterilized scaffold can be performed in aseptic condition or the lyophilized scaffolds can be submitted to a following energy sterilization procedure (thermal, radiant) or by chemical agents (ethylene oxide, hydrogen peroxide, ClO 2 or another sterilizing agent).
- the thermal treatment causes an evident size increase of the compacted unit associated to a weight loss (Tab I-II) while the surface becomes rough ( Figs. 2 and 3 ).
- the density of the compacted unit decreases of approx. 68%, from 1.74 g/cm 3 to 0.56 g/cm 3 , for C2 and around 85%, from 1.63 to 0.23 g/cm 3 , for C8 due to the thermal treatment.
- the leaching in water increases, by swelling, the diameter and thickness of the thermally treated compacted units, more than 3 times for C2 and about 6 times for C8. As shown in Fig.
- Micrographs were acquired by FESEM (Field Emission Scanning Electron Microscope - ZEISS Supra VP40, Carl Zeiss STM, D). The samples were placed on a stub using double-sided conducting tape and coated with a thin Au layer (about 15-20 nm) by sputtering.
- the distribution and sizes of the pores of the lyophilized scaffold conditioned in PBS ( Figs. 7A to 12 ) is similar to that of the swollen scaffold ready for culturing the cells.
- the macropore size is up to 100-200 ⁇ m.
- micrographs of lyophilized scaffolds, after conditioning in water ( Fig. 10A, 10-B and 12 ), clearly show the mechanical tension due to the increased swelling of the hydrogel sponge in this medium with respect to PBS, and consequently the increase of the pore size.
- the transmittance was measured using a UV-Visible Spectrometer (HP8452, Hewlett Packard, D) Table 9: transmittance (%) values for pure polymer matrix (compacted units, thermally treated, swollen and conditioned) of Carbopol 980 NF, Carbopol 974P NF and Polycarbophil at 400, 600 and 800 nm. Wavelength (nm) Transmittance (%) Carbopol 974P NF Carbopol 980 NF Polycarbophil 400 45 43 50 600 60 65 65 800 65 75 70
- the low transmittance of C2 and C8 hydrogel-sponge scaffolds is due to their high porosity, which determines high light reflectivity.
- the pure polymer matrixes being non-porous, have higher transmittance ( Fig. 13 and Tab. 9).
- the spectral comparison of C2 and C8 visible spectra with the ones of pure polymer matrixes demonstrates that the visible profile is due to the cross-linked polyacrylic acid used and that the scaffold transmittance is influenced by the interface problem related to the high porosity.
- the scaffold transparency was evaluated by observing the letters printed on a paper sheet placed under a Petri capsule containing the PBS-swollen scaffold.
- the scaffold transparency is very useful to follow the cell proliferation during cell culture as shown in the micrographs of Figs. from 16 to 18.
- the soluble components of PBS-conditioned and sterilized scaffolds (Tab. 3) of cylindrical shape with 15-20 mm diameter were removed by using 800 mL of deionized water, under stirring, replaced every 15 min for at least 7 times until the scaffolds were swollen to their maximum size, and sodium and phosphate ions could be detected any more in the waste water.
- the presence of sodium ion is potentiometrically measured (Compact Titrator G20 Mettler Toledo, US) using an ion selective electrode (perfectION comb Na + ) on 20 mL of washing water.
- the absence of phosphate ions in the washing water is tested by adding several mL of ammoniacal solution of ammonium chloride and magnesium chloride: the absence of a visible white precipitate of magnesium ammonium phosphate (MgNH 4 PO 4 ) indicates the absence of residual phosphate ions in the washing solution.
- the purified scaffolds were frozen at a temperature lower than -18°C until complete water solidification, and lyophilized at pressure lower than 50 ⁇ 10 -3 mBar until complete drying.
- the dried products were submitted to a secondary drying by heating at 40°C for at least 1 hour, under vacuum. Weight, diameter and thickness of the lyophilized cylindrical scaffolds were measured and the densities were calculated.
- Table 10 density of scaffolds with different compositions.
- the scaffolds were conditioned in acetonitrile because it permeates through the matrix without swelling or shrinking it.
- the scaffold was placed in acetonitrile and the air bubbles were evacuated under vacuum, until the scaffolds sunk completely in the liquid.
- the conditioned scaffolds were collected and the excess liquid removed using filter paper and the weight was recorded (W w ); the procedure was carried out at room temperature (20 ⁇ 0.5°C).
- the recovered scaffolds were dried in forced-air oven at 80°C up to constant weight (w s ).
- V p W w ⁇ W s / ⁇ acetonitrile
- V s the scaffold volume of a 13 mm-diameter cylindrical tablet, obtained by compressing the dried scaffold in a 13 mm-diameter cylindrical die at the force of 8 tons for 15 minutes by hydraulic press eliminating the air using a vacuum pump connected to the die.
- the tested scaffold was completely immersed in PBS [31] with 1 mm of liquid exceeding the scaffold surface.
- the probe was moved up to contact with the flat surface of the scaffolds and the elongation was zeroed.
- the scaffolds were compressed increasing the force (test rate 1 mm/min) up to break. Stress-strain curves were recorded measuring the stress value, referred to the force divided by the area of probe in contact with the scaffold surface, and the strain, referred to the absolute deformation divided by the scaffold thickness.
- Two stress-strain curves for C2 and C8 scaffolds are shown in Figs. 20 and 21 respectively. The measurements were performed on 6 scaffolds for each composition. The following values have been measured for each scaffold composition:
- the molecular diffusion through the scaffolds at 37°C was evaluated in horizontal Franz diffusion cell apparatus, using metformin hydrochloride as small, very hydrophilic and soluble diffusing test molecule.
- the diffusion was studied in PBS-swollen scaffolds with 15 mm diameter and thickness ranging from 3 to 7 mm, which were placed so as to separate the two compartments, fitted into a PTFE ring of 14 mm internal diameter, measuring the resulting increased thickness (W H ) of the hydrogel scaffold.
- the cell was thermostated at 37°C.
- the receptor compartment was filled with 21.5 mL PBS solution preheated at 37°C, then the donor compartment was filled with 21.5 mL PBS, containing 500.0 ⁇ g/mL of metformin hydrochloride, preheated at 37°C.
- the diffusion coefficient D was calculated by the slope of ordinary least square regression line obtained plotting In C 1 t ⁇ C 2 t C 1 0 ⁇ C 2 0 against time t .
- Table 13 molecular diffusion (D) through some scaffolds at 37°C.
- Scaffold code D 37 °C of metformin hydrochloride (m 2 /s) (mean ⁇ SD) C2 1.06 ⁇ 10 -9 ⁇ 8.4 ⁇ 10 -11 C8 1.21 ⁇ 10 -9 ⁇ 9.6 ⁇ 10 -11 P2 1.14 ⁇ 10 -9 ⁇ 9.1 ⁇ 10 -11 K8 1.19 ⁇ 10 -9 ⁇ 9.5 ⁇ 10 -11
- a sample of water conditioned and lyophilized C2 scaffold was submitted to adsorption/desorption measurements (N 2 at 77 K) performed with an ASAP 2010 porosimeter (Micromeritics, IT). Pore size distribution was obtained by the well-known BJH method.
- the size distribution of the mesopores is shown in Fig. 24 .
- the BET surface area was 5.4 ⁇ 0.2 m 2 /g and BJH adsorption cumulative pore volume of pores between 1.7 and 300 nm diameter was 0.017 cm 3 /g.
- IR spectra of the different substances and mixtures were acquired through a Perkin Elmer FT-IR 2000 spectrometer (US), preparing the samples in KBr discs.
- the IR spectra can be used to characterize the freeze-dried scaffold previously washed in water.
- the IR spectra of these products are similar to the ones of the cross-linked polyacrylic components.
- Table 14 morphological characteristics of C2 and C8 hydrogel sponge scaffolds. Scaffold code Weight (g) Diameter (mm) Thickness (mm) C2 0.26 ⁇ 0.02 8.5 ⁇ 0.3 4.7 ⁇ 0.3 C8 0.36 ⁇ 0.02 8.3 ⁇ 0.3 6.6 ⁇ 0.2
- C2 and C8 hydrogel sponge scaffolds conditioned in PBS, in triplicate, were maintained in PBS solution until use. Then, they were transferred in 12 multiwell plate containing 1 mL of DMEM without phenol red and conditioned overnight to promote the PBS replacement in the gels. The day after, the gels were transferred into Petri dishes containing DMEM added with phenol red and monitored every hour, for the phenol red spread into gel core ( Fig. 28 ).
- phenol red was partially spread into the scaffold core ( Fig. 29A ). Afterwards, the scaffolds were incubated overnight and after 12 hours phenol red was completely spread into the gels ( Fig. 29B ). The diffusion of phenol red was monitored at 570 nm by TLC Scanner (Camag 3 controlled by WinCATS 1.4.2 software, CH).
- hydrogel sponge scaffolds were put into a 6 multiwell plate containing 2 mL of MTT, MTS and NRU reagents in duplicate, as shown in Figs. 30A and 30B for C2 and C8 scaffolds.
- Cell health can be monitored by numerous methods: plasma membrane integrity, DNA synthesis, DNA content, enzyme activity, presence of ATP, and cellular reducing conditions are known indicators of cell viability and cell death.
- plasma membrane integrity plasma membrane integrity
- DNA synthesis DNA content
- enzyme activity enzyme activity
- presence of ATP cellular reducing conditions
- cellular reducing conditions are known indicators of cell viability and cell death.
- the wellness of cells was checked by Alamar Blue ® assay.
- Alamar Blue ® cell viability reagent functions as a cell health indicator by using the reducing power of living cells to quantitatively measure the proliferation of various human and animal cell lines, bacteria, plant, and fungi allowing to establish the relative cytotoxicity of agents within various chemical classes.
- the assay is based on the use of resazurin, a non-toxic, cell-permeable substrate, that is blue and virtually non-fluorescent.
- Healthy living cells maintain a reducing state within their cytosol.
- This "reducing potential" of cells converts resazurin into resorufin, a red highly fluorescent (or absorbent) product.
- Viable cells continuously convert resazurin to resorufin, increasing the overall fluorescence and color of the media surrounding cells.
- Fluorescence of resorufin is detectable in spectrofluorimeter (at excitation/emission wavelengths of 570/585 nm, respectively) as well in spectrophotometer (at 570 nm).
- spectrofluorimeter at excitation/emission wavelengths of 570/585 nm, respectively
- spectrophotometer at 570 nm
- the scaffolds were transferred (using sterile plastic forceps with flattened tips) into another 24-well plate to perform Alamar Blue ® test. Each insert was gently washed with PBS and then 1 mL fresh medium containing 10% Alamar Blue ® reagent was added. After incubation, fluorescence was measured (excitation 530 nm, emission 590 nm). Wells containing culture medium without cells and hydrogel, 10% v/v Alamar Blue ® , and vitamin C (ascorbic acid 0.75 mg in 5 ( ⁇ L/well), that results in rapid full reduction of Alamar Blue ® , were used as positive controls. Wells with culture medium without cells containing 10% v/v Alamar Blue ® were assayed as negative controls.
- All the cells tested showed to be healthy when cultured in hydrogel sponge scaffolds (C2, C8, K2, K8, P2 and P8) for a longer time than in 2D culture (at least 20 days), depending on scaffold size and initial density of seeding, since metabolic rate is dependent on cell number present into the scaffold as function of the culture time.
- Results for HeLa and HECV cell lines, as models of human epithelial and endothelial cells, are shown for C2 and C8 scaffolds in Figs. 31A and 31B ; data are expressed as (AU Arbitrary Units) extrapolated by fluorescence of resorufin, where metabolic activity registered on 4 th day was reported as 100%.
- the test was performed on HeLa cells seeded into C2 ,C8, K2, K8, P2 and P8 hydrogel sponge scaffolds, after 10 days of culture (seeded at 7.5 ⁇ 10 4 cells/50 ⁇ L).
- Experimental conditions exposure of HeLa cells for 3 hours to 0.5 and 5 mM NiSO 4 , as positive control of irritation. Viability index, expressed as percentage versus the respective untreated culture, was assessed in terms of MTS assay.
- the hydrogel sponge scaffolds were fixed in paraformaldehyde (PAF) (4% in phosphate buffer saline, PBS 8 ⁇ NaCl and pH 7.4) for 24 h, at 4°C, and then gently washed 3 times with PBS at room temperature in soft agitation.
- PAF paraformaldehyde
- 4 g of paraformaldehyde powder were added to 50 mL H 2 Od, stirring and heating to 56°C until dissolution of the powder. Then, to make the solution (which is initially milky) clear, some drops of NaOH 1 N were added.
- 50 mL of PBS 8 % in phosphate buffer saline, PBS 16 ⁇ NaCl and pH 7.4 were added.
- the solution cooled down to room temperature, was filtered, aliquoted, and stored at -20°C.
- the scaffolds were embedded in agarose 3.5% in PBS (3.5 g of agarose powder are dissolved with gentle agitation in PBS, heating up to boiling).
- the agarose was cooled to 55/56°C and used immediately.
- the embedded hydrogel sponge scaffolds were maintained in the dark at 4°C and hydrated with PBS until the cutting operation.
- the cutting was performed in a PBS bath with an appropriate vibratome with a thickness of 40 ⁇ m and the sections were immediately mounted on histological slides.
- the following protocol can be used for counter-staining tissue sections or cultured cells on slides.
- PI propidium iodide
- the staining with propidium iodide (PI) was performed by working solution of PI (1 ⁇ g/mL PI and 10 ⁇ g/mL RNase A in PBS 8 ⁇ NaCl and pH 7.4), for 40 minutes at room temperature in the dark. After washing many times gently in PBS, the slides were mounted in PBS with cover slip. Glycerol, generally employed in the mounting media, was not used in order to avoid interactions with the hydrogel. The use of RNase A, removing the RNA, allows PI to bind only DNA. PI emits red fluorescence when excited by proper wavelength in epifluorescence microscope or in a CLSM that can excite the PI.
- PI stock solution (1 mg/mL - 1.5 mM PI - in deionized water) was stored at 4°C (or aliquoted and stored at - 20°C), protected from light.
- RNase A stock solution (1 mg/mL in bi-distilled water) was aliquoted and stored at -20°C.
- To prepare the PI working solution (1 ⁇ g/mL PI and 10 ⁇ g/mL RNase A in PBS), 2 ⁇ L of PI stock solution and 20 ⁇ L of RNase A stock solution were added to 2 mL of PBS (8 ⁇ NaCl and pH 7.4). Slides were observed through a Leica DMRB light microscope which was equipped for epifluorescence with a lamp (Mercury Short Arc Photo Optic Lamp HBO 100 W.
- Osram, D Osram, D and proper filter cubes, including A (blue fluorescence), 13 (green fluorescence) and N2.1 (red fluorescence).
- Micrographs were acquired with a Leica CCD camera DFC420C (Leica, D) and Leica Application Suite (LAS) software.
- images were obtained using a Leica TCS SL confocal microscope (Leica Microsytems) equipped with argon/He-Ne laser sources, a HCX PL APO CS 63.0 ⁇ 1.40 oil, and HC PL FLUOTAR 20.0 ⁇ 0.5 air objectives.
- the following protocol can be used for counter-staining tissue sections or cultured cells on slides.
- DAPI binds only DNA by intercalation and, only when bound, it emits blue fluorescence when excited by proper wavelength in epifluorescence microscope, or in a CLSM that can excite the DAPI.
- DAPI stock solution (5 mg/mL or 14.3 mM) (using DAPI Molecular Probes, Cat# D-1306) was prepared as follows: 10 mg DAPI added to 1 mL of dimethyl-sulfoxide then to 9 mL of ethyl alcohol absolute and mixed to complete dissolution, aliquoted, and stored at -20°C.
- DAPI working solution 100 ng/mL or 300 nM in PBS
- the scaffolds are colonized by all cultured cells from the seeding surface to the bottom, as shown for C2 ( Figs. 33A-33B ) and C8 (Figs. from 34 to 38) scaffolds. Ordered cellular structures, similar to spheroids, for HECV ( Fig. 34 ) and for HeLa ( Fig. 38 ) are evident.
Description
- This invention relates to the fields of material technology for cell culturing and tissue engineering.
- In particular, the present invention relates to a method for the production of an unerodible, transparent and sterilizable hydrogel scaffold for a three-dimensional cell culture which can be used to culture a variety of different cells and tissues in vitro for prolonged periods of time.
- In many chemical technological fields, efficacy and toxicity studies are required for pure substances and formulations. Health surveillance and regulatory agencies in many countries are urging for the development of alternative methods to replace experiments on animals in the aforementioned areas. Thus, development of more reliable cell cultures to mimic the in vivo biological environment, cross-talk among different cells/tissues/ organs need to be developed and performed worldwide.
- Cell culture is the process by which cells are grown under controlled conditions, generally outside their natural environment. Nowadays, the term "cell culture" refers to the culturing of cells derived from multi-cellular eukaryotes, especially animal cells, but the culturing can be extended to other growing cells, such as plant tissue culture, fungal and microbiological culture.
- Cells can be grown either in suspension or as adherent cultures. Some cells naturally live in suspension, without being attached to a surface, such as blood cellular components. There are also cell lines that have been modified to be able to survive in suspension, so they can be grown to a higher density than adherent conditions would allow. Adherent cells require a surface, such as tissue culture plastics or microcarriers, which may be coated with extracellular matrix components (such as collagen, laminine, polylysine) to improve adhesion properties and provide other signals needed for growth and differentiation. Plating density (number of cells per volume of culture medium) plays a critical role for culturing some cell types: cells generally continue to divide in culture until the available area or volume is filled.
- Traditional methods of cell culture have been studied on 2-dimensional (2D) surfaces such as Petri dishes, tissue culture flasks, and micro-well plates. It has been described that the cultured cells respond to environmental stimuli, and when in contact with a plastic support they normally form a monolayer, where the mutual interactions occur only along the cell edges [1, 2]. In 2D models only 50% of the cell surface is in contact with the culture medium. Moreover, the cells tend to flatten on the scaffold surface, with consequent morphological changes occurring relatively early during culture growth, that may induce alterations in cellular biochemical processes and trafficking. In fact, the two-dimensional growth apparently influences the gene and protein expression, with significant differences in cellular responses from those observed in vivo, possibly causing abnormally negative or positive assay outcomes.
- A "three-dimensional cell culture" or also named "3D cell culture" allows cells in vitro to grow in all directions, similar to in vivo condition.
- Three-dimensional cell cultures have greater stability and longer lifespans than cell cultures in 2D. Also, 3D aggregates can be cultured for longer, also more than two weeks, as compared to almost one week with 2D monolayer culture due to cell confluence. Therefore, they might be more appropriate for long-term studies and surviving cells and for demonstrating long-term effects of the drug. Thanks to the 3D environment, the cells are allowed to grow undisturbed compared to the 2D models, where regular dissociation by animal origin (porcine) trypsin, or more recent animal-free recombinant cell-dissociation enzymes, is necessary in order to provide them with sufficient nutrients for normal cell growth.
- Increasingly, 2D culture approaches have shown their limitations for new challenges in cell biology and biochemistry studies, as well as in drug discovery and pharmacological studies [3]. It has been proven that 2D culture cannot reproduce completely cell morphology and biochemical features in the original tissue. In order to overcome the 2D cultures shortcomings, research on structures suitable for cell culture three-dimensional growth has been active for a decade. A significant advantage of 3D cell cultures over the 2D methods is their well-represented geometry and chemistry; moreover, they provide a microenvironment more closely resembling the in vivo situation. Actually, 3D cultures, in which the whole cell surfaces can be in contact with the culture medium and with other cells, can mimic better the cross-talk among cells also from different tissues, to reassembly the complex in vivo interactions. These features come out by comparison with 2D cultures, in terms of cell proliferation and differentiation and response to environmental stimuli.
- While 2D cell culture monolayers facilitate examination of intracellular signaling cascades and cell behavior, this approach largely ignores the more complex structural organization present in the normal physiological setting. Cells behave differently in a 3D environment, in part because the extracellular matrix is a key regulator of normal homeostasis and tissue phenotype. Examination of cellular behavior and signaling using this 3D cell culture approach improves the relevance of cell-based assays.
- As 3D cell culture allows generating 3D aggregates in a non-turbulent environment, with minimal shear force and continually suspended "freefall" culture, it allows the generation of 3D tissue-like aggregates which display physiologically relevant phenotypes, such as lower proliferation rate, hypoxic regions and vasculature.
- The 3D cell culture systems let understand the complex cellular physiological mechanisms, and are therefore widely applied in differentiation studies, pharmaceutical assays, tumor models and cancer biology research [4], gene and protein expression studies, besides being applied in tissue engineering, in bioreactor and in vitro modeling of human organs.
- Lastly, through analysis of gene expression, microRNA and metabolic profiles, it has been shown that 3D generating aggregates display a genotype significantly more relevant to in vivo, as compared to 2D monolayers cultures [5] .
- In the 3D cell culture systems, the cells can grow as spheroids, or 3D cell colonies. 3D spheroids more closely resemble in vivo tissue in terms of cellular communication and the development of extracellular matrixes. These matrixes help the cells move within their spheroid similarly to the way cells would move in living tissue. The spheroids are thus improved models for cell migration, differentiation, survival, and growth and gene/ protein expression[6].
- By culturing stem cells or progenitor cells in a 3D culture, it is possible to assist to organoid formation.
- An organoid is a miniaturized and simplified version of an organ produced in vitro in three dimensions that shows realistic micro-anatomy. They are derived from one or a few cells from a tissue, embryonic stem cells or induced pluripotent stem cells, which can self-organize in three-dimensional culture owing to their self-renewal and differentiation capacities. Organoids have also been created using adult stem cells extracted from the target organ, and cultured in 3D media [7, 8].
- Hydrogels can be used to influence mesenchymal stem cell differentiation towards hard (bone) or soft tissue (neural-like, adipose) cell phenotypes in the absence of differentiation media, immobilized matrix proteins or bioactive motifs. The 3D nature of the gels offers a major opportunity to develop more realistic in vitro models for cancer research. Transwell or collagen overlay assays are standard methods used to measure macrophage and tumor cell co-migration. Hydrogels can be suitable to create a reliable, more in vivo-like culture system that opens up to new possibilities in cancer research, from mimicking ECM environment to designing multi-cellular, tumor-like systems, to developing culture systems that favor tumor stem cells. In these microenvironments also monocyte-derived cells, as macrophages, can be co-cultured with tumor cells into a 3D structure, to mimic the pathophysiological development of tumors in vivo, and tumor cell-macrophage interactions in the promotion of tumor invasion.
- Cell cultures on hydrogels are already finding applications in the following areas: cell-based assays, toxicity screening, cancer cell research, biofabrication, micro/millifluidics, regenerative medicine.
- There are a number of commercially available culturing tools for 3D cell culture, which can be classified in two types: scaffold techniques and scaffold-free techniques.
- Scaffold-free techniques employ another approach independent from the use of scaffolds.
- The scaffolds currently used may be classified in solid structures and hydrogel matrixes.
- The main requirements for 3D cell culture scaffolds are: high compatibility with most cell lines, suitable mechanical strength, optical transparency, high porosity and interconnectivity, sterilizability, manageability, hydrophilicity, easy diffusion of substances to be tested and gas, easy dissection into thin layers, absence of interference with conventional assays for cell growth evaluation, easy production and low cost [9-12]. However, the optimal 3D scaffold combining the most appropriate characteristics has not been developed yet.
- Solid scaffolds are normally made of either inorganic (calcium phosphate) or organic polymeric materials (polystyrene). Their main shortcomings are: they are not transparent (therefore limiting cell observation during culture growth), difficult to sterilize, not suitable to hold cells; moreover, cell detachment and recovery to perform viability tests or to move the culture to another support are labor intensive and allow only a partial recovery of the cells. This type of scaffolds may be applied in immunohistochemistry, electronic microscopy, fluorescence microscopy, confocal microscopy, cytofluorimetry, biochemical assays, protein and nucleic acid production and extraction, analysis of molecules synthesized by various cell lines.
- Hydrogels are three-dimensional, cross-linked polymeric networks which can swell in water forming soft elastic materials, and retain a significant fraction of water in their structure without dissolving.
- They can be employed for tissue engineering, since their structures are soft, easily hydrated and several hydrogels can be tuned to resemble specific tissues. These features support very well the transport/exchange of nutrients, and water-soluble factors, as removal of catabolites. With respect to polymeric scaffolds, the hydrogels are commonly quite transparent allowing to a sufficient extent the possibility of microscopy observation, during culture time, to check the healthy state of cells. However, hydrogels have to be maintained in a hydrated state, therefore they could possibly suffer from long term stability issues in vitro and some densely crosslinked gels can hinder cellular migration.
- The scaffolds based on polymeric hydrogels are more similar to the extracellular matrix (ECM) of living tissues and porous scaffolds based on hydrophilic polymer networks can mimic in vivo tissue architecture, therefore being more favorable for organotypic cell proliferation [13]. Yet, their weaknesses can be: inadequate mechanic strength or weak rheological consistency, difficult cell attachment, complex and expensive preparation costs.
- Porous materials are classified into several kinds by their size. According to IUPAC notation [14], microporous materials have pore diameters of less than 2 nm and macroporous materials have pore diameters of greater than 50 nm; the mesoporous category thus lies in the middle.
- Good mechanical properties allow easier handling of the scaffold during the process of cell culture; moreover, the flexibility of the scaffolds has demonstrated to play a crucial role in increasing gene expression for the cultured cells [14].
- Hydrogels are the most promising option for cell culture and have proven useful in a range of cell culture applications, revealing fundamental phenomena regulating cell behavior and providing tools for the expansion and directed differentiation of various cell types in ways not possible with conventional 2D cultures. For example, in 3D hydrogel mammary epithelial cell assemble into multicellular spherical structures resembling healthy acini; pluripotency markers of embryonic stem cells can be controlled over mechanic properties or chemical modifications; in peptide hydrogel cells show improved resistance to chemotherapeutics, neurons with genetic mutations related to Alzheimer's disease show the formation of the lesions typical of this pathology, as the amyloid plaques and the neurofibrillary tangles [15], [16].
- Three-dimensional scaffolds can be prepared by different techniques, such as gas-forming foam, three-dimensional printing, thermally-induced phase separation, electrospinning, freeze-drying, solvent casting, compression moulding, immersion precipitation, particulate leaching, supercritical CO2 technique, free-radical polymerization or copolymerization, double network polymerization, templating fabrication.
- Many hydrogels can encapsulate seeded cells after their fabrication or the viable cells can be encapsulated with the hydrogel precursor that generates the hydrogels by chain-growth or step-growth polymerization. It is important to use nontoxic initiators (it has been reported that free radicals in the photo-polymerization process can damage the cells) and cross linkers for a rapid gel formation to prevent cell settling during the encapsulation process [15].
- Moreover, in all processes using cross-linking agents the cell toxicity of the residual should be always evaluated.
- Conventional emulsion templating techniques require large amounts of organic solvent to generate the internal phase (more than 75%), which may be difficult to remove after curing, resulting in cell cytotoxicity.
- The porogenic template is a diverse and versatile route for the preparation of porous materials that has been applied over a wide range of length scales. Water is cheap and a number of porous scaffolds for tissue engineering and biological applications have been prepared by freeze-drying, in which ice was used as a porogenic template [17].
- However, freeze-drying techniques encounter difficulty in precisely tuning pore size since the hydrogel architectures formed using this method are extremely sensitive to the kinetics of the thermal quenching process; other drawbacks are the low structural stability and generally weak mechanical properties of the surface, because the matrix may collapse at the scaffold-air interface due to the interfacial tension caused by solvent elimination [18].
- Other processes to obtain synthetic polymer scaffolds use organic solvents that might remain as residues in the scaffold and being harmful for cultured cells.
- From a manufacturing point of view, the preparation of porous structures from the polymer melt or sintering of compacted powders are more convenient routes, as they allow the rapid and economic production of scaffolds of many shapes and sizes [19].
- Scaffolds should have high porosity and interconnected porous structure to provide adequate space for the cell seeding, growth and proliferation, in fact, an appropriate micro-architecture of the scaffolds can influence directly the behavior of the cultured cells.
- Previous studies reported that scaffolds with porosity higher than 80%, are ideal for uses in 3D cell culture. Some scaffolds show porosity up to 99% as the scaffold containing 1% gelatin described by Wu et al. [17] [20].
- However, most existing hydrogel scaffolds with highly interconnected porosity suffer from poor mechanical properties limiting their handling.
- As a matter of fact, the compression modulus of the porous structures was found to decrease with an increase in porosity according to power-law relationships. [21]
- Most scaffolds can be weak at high porosities (more than 90%) and they can collapse during preparation and in this case it is mandatory to find ways to strengthen them, for example through reinforcing fibers or solid supports. This can be detrimental to other useful properties like transparency, cytocompatibility or sterilizability.
- Conventional thermal processing techniques such as sintering and compression moulding of polymer and salt particle mixtures followed by salt leaching normally generate scaffolds with relatively low porosities and at porosities higher than 90% the structures are fragile [21].
- Furthermore, it is relatively infrequent that precision control is achieved over pore size and structure of the scaffold, because there are relatively few current technologies, as salt leaching, that allow such control [22].
- The capacity of the scaffolds to retain water is another essential parameter of the polymeric network for the permeation of nutrients and waste from the cells. In hydrogels three different types of water can exist, depending on the interactions: free water, water linked through hydrogen bonds and water more strongly linked through polar interactions as with carboxylate group [23]. Water within the hydrogel is mainly stored in pores and channels of the scaffolds and only in part is absorbed in the hydrogel wall. Generally, the elasticity of the hydrogel correlates with the swelling behavior of the hydrogels increasing with the amount of water absorbed.
- Natural biomaterials suitable for 3D cell culture in vitro include collagen (Purecol, Fibricol, Flexcell or collagen-containing mixtures such as Matrigel®), alginate, agarose, and fibrin. However, these hydrogels are known to exhibit fast release of loaded growth factors and degrade very quickly, often not allowing adequate time for cell attachment and growth. Synthetic materials, although non-toxic, could be non-suitable for culturing cells: in fact, neuronal cell are known to die in PEG-like hydrogels within 1 day of culture and do not exhibit greater viability or proliferation as compared to monolayer controls [24]; polyacrylamide is suitable for 2D cell culture only [15].
- Hybrid materials like hyaluronic acid can influence the cellular experiments because of their numerous cellular interactions, while polypeptides have prohibitive cost for large-scale culture systems and often they are not stable for a long period.
- Poly(acrylic acid) (PAA), a weak anionic polyelectrolyte, is considered a pH- and electrically-sensitive material. Hydrogel networks formed from PAA have the ability to absorb many times their weight in water and are the basis of a class of materials called super-absorbents. These polymers are used in many applications, including filters, ion exchange resins, and membranes for hemodialysis, ultrafiltration, and controlled release devices.
- Poly(acrylic acid) has a carboxylic acid functionality (or carboxyl group or -COOH), providing a useful substrate for subsequent surface modifications and bio-conjugations [25] to ameliorate the control of cultured cell behaviors: for example, collagen has been immobilized on PAA. which remarkably improved the attachment and proliferation of human dermal fibroblasts and myoblasts [26].
- Non cross-linked acrylic polymers [27] have also been disclosed as non-living material enveloped by stromal cells and connective tissue proteins to form a three-dimensional structure having interstitial spaces bridged by the stromal cells.
- A patent [28] discloses a polycarbophil conjugate with EGF (Epidermal growth factor) or bFGF (Basic fibroblast growth factor) as attachment and growth promoting agents for growing corneal endothelial cells, for artificial corneal transplants, but not as scaffold and not as thermally-treated polymer.
- Sheetz [29] discloses a non-porous scaffold for cell growth comprising a portion of substrate and fiber stretched over the substrate portion, wherein the substrate comprises a growth medium and a cross-linked polymer. Among the useful polymers, polyacrylic acid is only mentioned; but the procedure does not involve thermal treatment or leaching steps in the presence of porigen substances.
- Liu et al. [30] disclose a three dimensional solid construct which can be coated with a polyacrylic acid.
- Shin et al. [31] disclose a complex support for regenerating bone-cartilage, where a polyacrylic acid can be present in the bone regeneration layer.
- Zussman et al. [32] disclose a fiber-reinforced hydrogel containing acrylic polymers usable as scaffolds for cell culture.
- Scaffolds used as cell culture or bioreactors must be sterilized to exclude or reduce bacterial contamination, and this aspect represents a critical issue for most part of the scaffold.
- Rarely polymer scaffolds can be sterilized by thermal processes or ionizing radiation (gamma and beta-rays) which can be cause of damage to the polymeric skeleton of the scaffolds, or by a chemical process which can contaminate the cells with toxic residues or react with the polymers used in the scaffold. Furthermore, the largely employed ultraviolet irradiation is only an aid in the reduction of contamination only on the exposed surface because of its negligible penetration. Chemical disinfection (ethylene oxide, ethanol) can alter scaffold properties and leave toxic residues. Polymeric hydrogel can rarely resist to terminal sterilization by classical thermal methods, such as moist heat sterilization. For this reason the large majority of 3D scaffolds must be produced by expensive aseptic procedures [15].
- Sponges are porous structures whose properties are determined by interconnectivity, pore size, and porosity, which impact cell penetration and migration, matrix deposition and distribution, and nutrient and waste exchange. A hydrogel is a network of polymer chains that are hydrophilic, swollen polymer matrixes with a cross-linked structure and which retain a large amount of water. Sponges are defined by morphology, while hydrogels are defined by hydrophobicity. According to some authors, hydrogels are made of hydrophilic materials with water contact angles less than 60°, while sponges are porous structures made of materials with a water contact angle of 80° or above. Macroporous hydrogel sponges can be used as scaffolds for 3D culturing cells, tissue engineering and in the bioreactor technology [33],[30]. Also filling hydrogels into sponges have been reported to be a very efficient tool for 3D culture in scaffold [34].
- Bogdanowicz et al., [35] describe a model which allows for the study of the effects of both cell-cell contact and paracrine signaling on subpopulations of cells in co-culture; moreover, the model exerts spatial and temporal control over heterotypic cellular interactions through the development of a removable permeable hydrogel barrier, permitting the live tracking of populations throughout in vitro culture and allowing for the study of individual cell subpopulation response to co-culture.
- Caliari et al [15] describe the use of hydrogels to study cell viability, morphogenesis, aging, and disease, with a focus on commercially available hydrogels.
- Nasim Annabi et al. "Controlling the porosity and Microarchitecture of Hydrogels for Tissue Engineering", Tissue Engineering part B-Reviews, vol. 16, no. 4, August 2010, pages 371-383, disclose hydrogels for tissue engineering. In particular, by using sodium bicarbonate to fabricate an acrylic acid-acryl amide porous hydrogel by crosslinking acrylic acid and acrylic amide with N-N'-methylenebisacrylamide, a porous hydrogel having an interconnected structure with pore size ranging from 100 to 250 µm was obtained.
- Shengton Sun et al., "Hydrogels from amorphous calcium carbonate and polyacrylic acid: bio-inspired materials for "mineral plastics", Angewandte Chemie International Edition, vol. 55, no. 39, 22 July 2016, pages 11765-11769, disclose an amorphous CaCO3-based hydrogel consisting of very small particles of amorphous calcium carbonate physically cross-linked by poly(acrylic acid).
- Junmin Zhu, "Bioactive modification of poly(ethylene glycol) hydrogels for tissue engineering", Biomaterials, vol. 31, no. 17, June 2010, pages 4639-4656, is a review concerning the progress in material design and fabrication approaches leading to the development of bioactive hydrogels as tissue engineering scaffoldsFang Ren, "Synthesis of gold nanoparticle-hydrogel nanocomposites with controlled cytotoxicity and unique cell-adhesive properties", 9 September 2016, pages 1-132,https://depositonce.tu-berlin.de/bitstream/11303/5988/4/ren_fang.pdf, discloses the immobilization of gold nanoparticles on cyto-compatible hydrogels to synthesize novel nanocomposite hydrogels, which have been applied in cancer treatment and to control cell behavior on cell adhesion.
-
WO 2016/168196 A1 discloses water-insoluble but water-swellable and deformable crosslinked PEGylated microgel particles of proteins and protein-based macromolecules tha are pseudoplastic and flow in aqueous medium under shear. These microgel particles function as a matrix to support cell growth, viability and proliferation. -
US 2007/0098799 discloses mineralized hydrogels obtained by combining a first mixture including a calcium derivative, a second mixture including a phosphate derivative and a hydrogel to form a calcium phosphate dispersion containing the hydrogel. The hydrogel in the calcium phosphate dispersion is crosslinked to form a mineralized hydrogel, in which calcium phosphate minerals are substantially dispersed within the hydrogel. - The objective technical problem underlying the present invention is to provide a method for the production of a three-dimensional scaffold suitable for culturing cells for a long time, which, while being unerodable in aqueous mediums, has a high optical transparency allowing a microscopic observation of cell growth and morphology, and also has high molecular diffusion to permit the use in situ of agent for cell viability evaluation test or for standard immunostaining protocols and suitable mechanical properties to be easily handled. It should also be resistant to the energy sterilization process or to chemical agents.
- This problem has been solved, according to the invention, by the method for the preparation of a three-dimensional hydrogel scaffold for cell culturing as disclosed in appended
claim 1. - Preferred embodiments of this method are disclosed in dependent claims 2-15
- The thermal treatment carried out on the compact units obtained from the above-mentioned solid mixture generates a robust 3D matrix which can be submitted to the leaching treatment with deionized water to become highly porous.
- Compact units produced according to steps a) and b), but not subjected to the thermal treatment of step c) cannot undergo the leaching treatment of step d), because they disintegrate when contacted with water.
- In order to control porosity, pore shape and size, the at least one water-soluble salt and the at least one gas-forming agent can be used as powder with a size controlled by milling and sieving procedures.
- The present method does not use any organic solvent or cross-linking agent, and produces a scaffold with the above-mentioned properties suitable for culturing different kinds of the cells even for a long time (longer than 2D), allowing a good permeation of gases, nutrients and waste from the cells.
- The three-dimensional scaffold obtained with the method according to the present invention involves several advantages.
- The gas-forming agent improves the structure and increases the interconnectivity and porosity of the three-dimensional scaffold, thus guaranteeing and promoting cell and small molecules movement through the three-dimensional structure.
- The water-soluble salt improves micro-porosity and interconnectivity of the above-mentioned scaffold.
- Advantageously, the scaffold obtained with the method of the invention can be used in conventional cell culture vessels, such as cell culture dishes, cell culture plates, cell culture flasks, micro-well plates, cell culture bags, bioreactors and microfluidic devices.
- Due to its high molecular diffusion, said scaffold permits the use in situ of agents for cell viability evaluation test or for standard immune-staining protocols.
- Therefore, the scaffold with cultured cells may be employed in a variety of applications ranging from cytotoxical and pharmacological screening, assaying the biological activity of compounds in vitro, studying the growth, proliferation, and function of cells, and the production of biologically active molecules, as biological model of tissues, for growing tissue and for in vivo implantation o transplantation of tissue (bone, bone marrow, liver, mucosal epithelium, pancreas, brain, lung, vascular, hearth, gut, intestinal, membranous, retina, eyes, cartilaginous etc).
- The scaffold obtained with the method of the present invention may be used to grow other kinds of cells, such as plant tissue culture, mycological and microbiological culture (of microbes). For example, the 3D scaffold according to the invention can be used for culturing and studying microbiota that normally inhabits the skin, mouth, nose, digestive tract, and vagina.
- Moreover, the scaffold obtained with the method of the present invention resists to the high temperature and pressure of the sterilization treatment by moist-heat autoclave, maintaining the mechanical and morphological properties and the suitability for culturing cells.
-
-
Figure 1A shows a schematic view of a three layers compacted unit. -
Figure 1B shows a schematic view of a partially dry-coated unit, with only lower and lateral coating without upper coating layer. -
Figure 2 shows C2 before (left) and after (right) thermal treatment. -
Figure 3 shows C2 surface after thermal treatment. -
Figure 4 shows a comparison of a C2 scaffold (on the left) and a C2 unit that has been not submitted to thermal treatment (on the right) after leaching with water, showing an evident disaggregation caused by the leaching procedure. -
Figure 5A shows SEM micrograph of cross section of thermally-untreated C2 compacted unit. -
Figure 5B shows SEM micrograph of cross section of thermally-treated C2 compacted unit. -
Figures 6A, 6B and 6C show SEM micrographs of cross sections of thermally treated C2 compacted unit. -
Figure 7A shows SEM micrograph of cross section of thermally-untreated C5 compacted unit. -
Figure 7B shows SEM micrograph of cross section of thermally-treated C5 compacted unit. -
Figures 8A and 8B show SEM micrographs of cross sections of thermally treated C5 compacted unit. -
Figures 9A, 9B and 9C show SEM micrographs of cross sections of lyophilized C2 matrix after leaching, conditioning and sterilization in PBS. -
Figures 10A and 10B show SEM micrographs of cross sections of lyophilized C2 matrix after leaching and sterilization in water. -
Figure 11 shows SEM micrograph of cross section of lyophilized C5 matrix after leaching, conditioning and sterilization in PBS. -
Figure 12 shows SEM micrograph of cross section of lyophilized C5 matrix after leaching and sterilization in water. -
Figure 13 shows Quartz UV cuvette filled with cut cubes of C2 PBS-conditioned scaffold (left) andpure Carbopol 980 PBS-swollen matrix (right). -
Figure 14 represents a graph showing 300-800 nm spectra for pure Carbopol 980 (Cbp980), Carbopol 974 (Cbp974p), polycarbophyl (pol) thermally treated compacted units, and C2, C8 hydrogel sponge scaffolds, conditioned in PBS and sterilized. -
Figure 15 shows transparency of C2 (centre) and C8 (right) hydrogel sponge scaffolds with respect to PBS solution (left). -
Figure 16 shows HaCat keratinocytes organized in a cluster structure, being arranged inside the space of hydrogel sponge scaffold C2 showing the tendency to form compact spheroids, after 72 hours of seeding into C2 scaffold. (Contrast phase microscopy, magnification 10X). -
Figure 17A shows HECV cells after 72 hours in K8 resulting in a morphology similar to spheroids reassembling a tube. (Contrast phase microscopy, magnification 10X). -
Figure 17B shows HECV cells after 72 hours in C8 resulting in a morphology similar to spheroids reassembling a tube. (Contrast phase microscopy, magnification 10X). -
Figure 18 shows epithelial HeLa cells which appear dispersed in hydrogel sponge scaffold P8, not forming a compact cluster probably for their undifferentiated phenotype (Contrast phase microscopy, magnification 10X). -
Figure 19 shows a graph representing stress-strain curve of scaffolds. -
Figure 20 shows a graph representing stress-strain curve of scaffold C2. -
Figure 21 shows a graph representing stress-strain curve of scaffold C8. -
Figure 22 shows a graph representing an isothermal plot for scaffold C2. -
Figure 23 shows a graph representing BET surface plot of scaffold C2. -
Figure 24 shows a graph representing BJH dV/dD pore volume of scaffold C2. -
Figure 25 shows a graph representing IR spectrum of P11 in KBr -
Figure 26 shows a graph representing IR spectrum of K2 in KBr. -
Figure 27 shows a graph representing IR spectrum of C12 in KBr. -
Figure 28 shows the gels just placed into Petri dishes: on top C2 gels, on bottom C8 gels. -
Figure 29A A shows the phenol red spread into the gels after 4 hours of incubation (top panels: C2 gels, bottom panels: C8 gels): within 4 h exposure phenol red resulted into all the gels. -
Figure 29B shows the phenol red spread into the gels after 24 hours of incubation (top panels: C2 gels, bottom panels: C8 gels): within 24 h exposure phenol red resulted into all the gels. -
Figure 30A shows C2 and C8 gels, without cells, just placed into 6 multi-wells and exposed to MTT, MTS and NRU viability dyes. -
Figure 30B shows C2 and C8 gels, without cells, after 3 hour-exposure to MTT, MTS and NRU viability dyes. -
Figure 31A shows a bar graph representing 20 days long viability of HeLa cells cultured in C2 and C8 hydrogel sponge scaffolds and tested by Alamar Blue®. Data are the mean of three separate experiments ± SD, run in duplicate. -
Figure 31B shows a bar graph representing 20 days long viability of HECV cells cultured in C2 and C8 hydrogel sponge scaffolds and tested by Alamar Blue®. Data are the mean of three separate experiments ± SD, run in duplicate. -
Figure 32A shows a bar graph representing MTS response to nickel sulfate irritation test for HeLa cell line cultured in C8 scaffold after ten days; the viability indexes are expressed as mean of two genuine performed in duplicate ± SD. -
Figure 32B shows a bar graph representing MTS response to nickel sulfate irritation test for HeLa cell line cultured in C2 scaffold after ten days; the viability indexes are expressed as mean of two genuine performed in duplicate ± SD. -
Figures 33A and 33B show sections cut from C2 hydrogel sponge scaffold, embedded in agarose with PI-stained HECV cell line cultured-in for 20 days at fluorescence microscope; cells have prolongations (arrows). -
Figure 34 shows sections cut from C8 hydrogel sponge scaffold, embedded in agarose with DAPI-stained HECV cell line cultured-in for 20 days at fluorescence microscope. -
Figure 35A shows sections close to superior surface of the scaffold (ScS) which were cut from C8 hydrogel sponge scaffold, embedded in agarose with HeLa cell line cultured-in for 20 days; cells are visible in the whole thickness (arrows). -
Figure 35B shows sections close to the bottom of the scaffold which were cut from C8 hydrogel sponge scaffold, embedded in agarose with HeLa cell line cultured-in for 20 days at light microscope. Cells are visible in the whole thickness (arrows). -
Figure 36 shows a section cut from C8 hydrogel sponge scaffold, embedded in agarose with HeLa cell line cultured-in for 20 days at light microscope. Cells (arrows) are clustered. -
Figure 37 shows sections cut from C8 hydrogel sponge scaffold, embedded in agarose with IP-stained HeLa cell line cultured-in for 20 days at fluorescence microscope; the sequence of the sections ranging from the seeding surface to the bottom of the scaffold is reported. Cells (arrows) are distributed. -
Figure 38 shows a section cut from C8 hydrogel sponge scaffold, embedded in agarose with IP-stained HeLa cell line cultured-in for 20 days at fluorescence microscope. Cells (arrows) are clustered. - The present invention relates to a method for the preparation of a three-dimensional hydrogel scaffold for cell culturing, which comprises the steps of:
- a) preparing at least one first uniform solid mixture comprising at least one gas-forming agent, selected from the group consisting of sodium hydrogen carbonate, potassium hydrogen carbonate, sodium glycine carbonate, ammonium hydrogen carbonate, sodium bisulfite, sodium metabisulfite, calcium carbonate and sodium sulfite, at least one water-soluble salt and at least one non-water-soluble, water-swellable cross-linked poly(acrylic) polymer;
- b) preparing compressed or compact units starting from said at least one first solid mixture;
- c) subjecting the compressed or compact units thus obtained to heating at a temperature in the range of 120°C-160°C, for a time of 1-120 minutes, preferably 1-20 minutes;
- d) leaching the thermally treated units thus obtained in an aqueous medium;
- e) conditioning the leached units thus obtained in water or in an aqueous solution selected from the group comprising a buffer solution, preferably phosphate-buffered saline (PBS) and a cell culture medium;
- f) subjecting the conditioned units thus obtained to sterilization.
- The scaffold obtained by this method can be used to culture different cellular types in mixed co-culture models or segregated co-culture systems.
- In particular, the 3D scaffolds obtained by the method of the present invention are useful for culturing cells derived from multi-cellular eukaryotes, especially animal cells or genetically-modified cells or other types of cell culture such as plant tissue culture, fungal culture, and microbiological culture.
- When conditioned in an aqueous medium, the scaffold appears to be a highly transparent sponge, through which it is possible to observe and study the cell cultures growing in the pores of the structure.
- The expressions "initial composition" or "first uniform solid mixture" as used herein mean a mixture comprising a polymeric component, namely a cross-linked poly(acrylic) acid powder, which is hydrophilic but not soluble in water, and a fraction including a thermostable water-soluble salt and a gas-forming agent.
- In particular, said cross-linked poly(acrylic) acid may be a polymer of acrylic acid cross-linked with either allyl sucrose or allyl ethers of pentaerythritol like Carbomers (as defined by British Pharmacopeia (BP), European pharmacopoeia Ph. Eur., or US Pharmacopeia (USP) or Handbook of Pharmaceutical Excipients sixth edition, 2009 (UK ISBN 978 0 85369 792 3) and their salts, which is identified by CAS registry number [9003-01-4]. Alternative CAS registry numbers have been used for Carbomer 934 ([9007-16-3]), 940 ([9007-17-4]) and 941 ([9062-04-08]). The CAS registry number [9007-20-9] has also been used for Carbomer.
- The cross-linked poly(acrylic) acids may also be polymers of acrylic acid cross-linked with divinyl glycol like Polycarbophil [CAS number 9003-97-8] or Noveon AA-1 and its salts.
- The cross-linked polymers of acrylic acid can be used in an amount between 20-80% (w/w) of the initial mixture used to produce the compacted unit. Preferably, the cross-linked polymers of acrylic acid are used in an amount between or 22-60% or 30-50% (w/w) of the initial mixture.
- The above-mentioned thermostable water-soluble salt is preferably selected from the group comprising: sodium chloride (NaCl), potassium chloride (KCl), potassium sulfate (K2SO4), sodium sulfate (Na2SO4), potassium dihydrogen phosphate (KH2PO4), disodium hydrogen phosphate (Na2HPO4), magnesium sulfate (MgSO4), aluminum chloride (AlCl3), magnesium chloride (MgCl2), potassium acetate (KC2H3O2) or a mixture thereof. More preferably, the thermostable water-soluble salt is sodium chloride or potassium chloride.
- According to an aspect of the invention, said salts may be used in combination with non-ionic water soluble molecules (such as, for example, carbohydrates or polymers), provided that they are stable to the subsequent thermal treatment.
- Sodium chloride or any other thermostable water-soluble salt can be used in an amount between 0.5-79.5 % (w/w) of the initial composition preferably 10-50% (w/w), even more preferably 20-40% (w/w).
- According to an aspect of the invention, the gas forming agent may be thermolabile.
- The above-mentioned thermolabile gas-forming agent is able to generate gas upon the heating of said thermal treatment (up to temperature of about or less than 160°C) according to the method of the present invention. The thermolabile gas-forming agent may be sodium hydrogen carbonate or another thermolabile compound which is able to generate gas, such as, for example, potassium hydrogen carbonate, sodium glycine carbonate, ammonium hydrogen carbonate, sodium bisulfite or sodium metabisulfite.
- The gas-forming agent improves the structure and increases the porosity and interconnectivity, such as sodium hydrogen carbonate or any thermolabile or thermostable gas-forming agent.
- In another aspect, the gas-forming agent may be a thermostable compound, such as calcium carbonate or sulfites, in particular sodium sulfite. The decomposition of such thermostable gas-forming agent occurs in an acidic solution, because it does not decompose during the thermal treatment of the method according to the present invention (as instead the above-mentioned thermolabile gas-forming agent does). Therefore, in this particular embodiment, the step of gas forming occurs after the thermal treatment step and during the leaching step in a suitable acidic aqueous medium before the conditioning step (pH 0.1-3).
- Sodium hydrogen carbonate or other gas-forming agent could be used in a percentage between 0.5-79.5% (w/w) of the initial composition, preferably 10-50% (w/w), even more preferably 20-40% (w/w).
- The 3D scaffolds obtained with the method of the present invention have a porosity higher than 85%, preferably higher than 95% and a pore size comprised between 0.1 nm and 600 µm, as shown in the Examples.
- The Young's modulus, also known as the elastic modulus, of 3D hydrogel sponge scaffolds conditioned in PBS ranges from 5 to 200 kPa (15-120 or 20-110), while yield strength/weight of PBS-conditioned scaffolds ranges from 1 to 30 kPa/g or from 2 to 18 or 3 to 13 (see example 6).
- The apparent density of the lyophilized 3D scaffold obtained by freeze-drying from the hydrogel sponge conditioned in water ranges from (see example 4) 5 mg/ cm3 to 50 mg/cm3, preferably 10 mg/ cm3 to 45 mg/cm3, more preferably 12 mg/ cm3 to 40 mg/ cm3, even more preferably 13 to 30 mg/ cm3, being the most preferred the range between 14 mg/ cm3 and 25 mg/ cm3.
- According to an aspect of the method of the present invention, the compacted units can be multilayer units produced by step by step compaction of different layers with different composition, each containing at least one cross-linked polyacrylic acid. The layers can have different or equal composition and contain the same or different cross-linked polyacrylic acid. Some layers, for example the external top or bottom layers, can contain only a cross-linked polyacrylic acid as barrier layers. The compacted multilayer units are submitted to the same preparative steps of thermal treatment, leaching, medium/solvent conditioning, optional vacuum chamber conditioning, optional lyophilization, and sterilization. The different layers can be used to culture different cellular types in mixed co-culture models or segregated co-culture systems [35] (
Figure 1A ). - According to an aspect of the method of the present invention, the compacted units can also be partially dry-coated, so that the compacted units are made only of lower and lateral coating without upper coating layer. The coating layers are applied by pressure in a tableting machine by centering a pre-compacted cylindrical core in a cylindrical die containing the powder bed of the coating mixture. The coating layers can have different or equal composition and contain the same or a different cross-linked polyacrylic acid. Both the coating layer and the core of the coated unit must contain at least a cross-linked polyacrylic acid. The coating layers can contain only a cross-linked polyacrilic acid as barrier layer. The partially coated units are submitted to the same preparative steps of thermal treatment, water leaching, medium/solvent conditioning, optional steps of vacuum chamber conditioning or lyophilization and sterilization (
Figure 1B ). - The lyophilized scaffold obtained with the method of the present invention can also be partially film-coated by film forming agents like hydroxypropylcellulose (HPC), ethylcellulose (EC), hydroxyethylmethylcellulose (HEMC), hydroxypropylmethylcellulose (HPMC), methylcellulose (MC), polyvinylalcohol (PVA), polyvinylalcohol acetate phthalate, polymethacrylates (i.e. Eudragit)
- The at least one water-soluble salt (for example sodium chloride) and the at least one gas-forming agent (for example, sodium hydrogen carbonate), can be granulated together by one of the procedures well-known in the art, to obtain a porogenic template, generating pores with controlled or homogenous size by thermal treatment and subsequent leaching.
- For example, by means of a fluid-bed process it is possible to spray an aqueous sodium chloride solution against a fluid bed of sodium hydrogen carbonate powder to obtain a macroaggregate with a controlled size, for example through sieving, between 50 to 500 µm. This macroaggregate, after assaying its composition, can be used as template in the scaffold preparation to obtain a more regular porosity in the resulting hydrophilic sponge of 3D scaffold. The sodium chloride solution can contain up to 25% (w/w) of ethanol.
- By spray drying an aqueous solution containing the two above-mentioned components, namely the at least one water-soluble salt and the at least one gas-forming agent, at the same concentration (from 5 to 15 %) it is possible to obtain a mixed macro-aggregated powder with controlled size, usable as scaffold template. The aqueous solution of the two components for spray drying can contain up to 25% (w/w) of ethanol.
- By granulation and spheronization process followed by a sieving step, it is possible to obtain microspheres of a mixture of the at least one water-soluble salt and the at least one gas-forming agent with controlled sizes to use as porogenic template tableting with the other component (cross-linked polyacrylic acid).
- With the scaffold obtained by the method of the present invention, all culturing media or growing media known in the art may be used depending on the type of cells to be grown (including, but not limited to, HBSS = Hank's balanced salt solution; MEM: minimal essential medium; DMEM: Dulbecco's Modified Eagle Medium; RPMI: Roswell Park Memorial Institute medium) and they can contain all those factors used in the cell culture like fetal calf serum, L-glutamine, antibiotics (e.g. Pen-Strep, gentamycine), antifungals (e.g. amphotericin B) and supplementary growth factors.
- According to an aspect which is not part of the present invention, the hydrogel sponge or 3D scaffold can be filled with solution or gel (also obtainable in situ) based on artificial and natural biomaterials as hyaluronic acid, collagen (all types), Matrigel® matrix (a gelatinous protein mixture secreted by Engelbreth-Holm-Swarm mouse sarcoma cells and marketed by Corning Life Sciences and BD Biosciences), alginate, gelatin, agarose, chitosan, chitosan-glycerophosphate, bioactive peptides, polyethylene glycol (PEG) modified with either hydrolysable units or bioactive peptides, hydrolyzed or partially hydrolyzed egg shell membrane, fibrin, polylysine, polypropylene imine hexadecylamine, polyethylene imine, glycoproteins, glycosaminoglycans, (e.g., heparan sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate, dermatan sulfate, keratan sulfate).
- According to an aspect which is not part of the present invention, the surface of the hydrogel sponge or 3D scaffold can be physically or chemically modified to immobilize substances useful for cell growth, e.g.: collagen, fibronectin, vitronectin, laminin, heparin, plasma, Arg-Gly-Asp (integrin-binding sequence -RGD-) or heparin binding sequence (-FHRRIKA-) peptides, hyaluronic acid, chitosan, chitosan-glycerophosphate, bioactive peptides, polyethylene glycol (PEG) modified with either hydrolysable units or bioactive peptides, fibrin, and glycoproteins, glycosaminoglycans.
- According to an aspect which is not part of the invention, the three-dimensional scaffold can be coated with osteogenic proteins such as bone morphogenic protein (BMP) and bone sialoprotein (BSP). BSP, a small integrin-binding ligand N-linked glycoprotein (SIBLING), having osteogenic properties and playing an essential role in bone formation. BSP also mediates mineral deposition, binds type I collagen with high affinity, and binds αvβ3 and αvβ5 integrins which mediate cell signaling [37].
- The main mineral component of bone tissue is a nonstoichiometric carbonated multi-substituted apatite with calcium to phosphorus ratio (Ca:P) between 1.37 and 1.87
- Synthetic hydroxyapatite (Ca10(PO4)6(OH)2) is a popular bone replacement material because it has a similar crystal structure (Ca:P ratio fixed at 1.67) to native bone apatite. This resemblance can be exploited to 3D culture bone cells in the scaffolds.
- According to an aspect which is not part of the present invention, the scaffolds can be mineralized with other mineralizing components like tricalcium phosphate (Ca3(PO4)2), hydroxyapatite (Ca5(PO4)3OH), carbonated hydroxyapatite, wollastonite, magnesium silicate, alumina and zirconia. Synthetic hydroxyapatite (HA) or the above-mentioned other mineralizing components can be added to the powder in the first uniform solid mixture in the range between 0.5-70 % or 10-40 % or 20-30% to obtain the compact units which will be submitted to subsequent thermal treatment.
- Among the most popular methodologies to mineralize the scaffold there is precipitation of the above-mentioned mineralizing components in the scaffolds [38,39, 40, 41, 42].
- It is well known that for hydroxyapatite, the nucleation of mineral nanocrystals takes place in specific loci corresponding to non-collagenous acidic macromolecules, many of which are highly charged from carboxylate groups that can bind Ca2+ ions. Following the chemical binding of Ca2+, the supersaturation of physiological fluids in phosphate ions and other minor species (e.g. Na+ and K+) provokes the precipitation and nucleation of the mineral phase [43].
- In fact, it has been verified that carboxylic acid group (COOH) negatively charged, as those present in the scaffold described in the present invention, are the most potent inducers group of mineralization [44]
- According to an aspect which is not part of the invention, the mineralization may be carried out by hydro- and solvo-thermal methods [45 - 54], sol-gel method [55 - 58], or emulsion and microemulsion method [59-61].
- The scaffold may also be biomineralized.
- Biomineralization refers to the processes by which organisms form minerals; the control exerted by many organisms over mineral formation distinguishes these processes from abiotic mineralization.
- The term "biomineralization" is also used to refer to the process of mineralization of scaffolds influenced or favored by the presence of biologic materials, such as intestinal submucosa, collagen, body fluid or simulated body-fluid (SBF). In this case the process can be more precisely defined biomimetic nucleation/mineralization.
- SBF's as a rule contain the inorganic ion concentrations of human blood plasma and can be obtained by dissolving reagent grade salts (NaCl, NaHCO3, Na2SO4, KCl, K2HPO4·3H2O, MgCl2·6H2O, and CaCl2·2H2O) in distilled water obtaining a final ionic concentration also more times (e.g. 2x) higher than physiological concentrations. Its pH is adjusted to 7.4 (37 °C) with suitable buffer solution; for example, 0.05 mol L-1) of tris(hydroxymethyl)aminomethane (Tris) and hydrochloric acid.
- According to an aspect which is not part of the present invention, the scaffold can be conditioned or soaked in SFB [62-64].
- According to an aspect which is not part of the present invention, the skeleton of the scaffold is made of cross-linked polyacrylic acid having free carboxyl groups (-COOH), which can be grafted or linked by covalent or strong and weak ionic bonds or electric bonds with molecules useful for culturing cells, like for example with: peptides (natural or synthetic, as Ac-CGGNGEPRGDTYRAY-NH2 or Ac-CGGFHRRIKA-NH2), proteins, poly(ethylene terephthalate, poly(∈-caprolactone), carbohydrates (e.g. galactose) and carbohydrate derivatives, and with hyaluronic acid, collagen (all types), Matrigel®, alginate, gelatin, agarose, chitosan, chitosan-glycerophosphate, polyethylene glycol (PEG) with either hydrolysable units in bioactive peptides, bioactive peptides, hydrolyzed egg shell membrane, fibrin and growth factors including, but not limited to, bFGF (Basic fibroblast growth factor), EGF (Epidermal growth factor), VEGF (Endothelial growth factor).
- According to an aspect which is not part of the present invention, this scaffold can incorporate nanoparticles within the 3D hydrogel sponge network, either physically or covalently, to embrace various functionalities and properties.
- The-above mentioned nanoparticles may be silica, quantum dots, nanotubes, polymers, liposomes, micelles, or dendrimers. Moreover, they may contain different compounds such as, for example, graphene, gold, magnetic iron oxide, tricalcium phosphate (Ca3(PO4)2), hydroxyapatite (Ca5(PO4)3OH), carbonated hydroxyapatite, wollastonite, magnesium silicate, alumina and zirconia.
- On the scaffold, according to an aspect which is not part of the present invention, it is possible to grow primary cells, from normal and tumor tissues, immortalized cell lines, embryonic and induced pluripotent stem cells (e.g., ESCs and iPSCs), and mesenchymal stem cells (e.g., MSCs), from fetal and several adult tissues (for example, adipose, bone marrow, skin, liver, kidney, neural tissues).
- Such cells include, but are not limited to, endothelial cells, pericytes, macrophages, monocytes, plasma cells, mast cells, adipocytes, hematopoietic tissue and reticular cells, fibroblasts, glial cells, Kupffer cells, vascular and bile duct endothelial cells. Fibroblasts may be derived from organs, such as skin, liver, pancreas, bone marrow, skin, liver, pancreas, kidney, adrenal and neurologic tissue, etc. to name but a few.
- A non-limiting list of cells that can be cultured on this 3D scaffold or hydrogel sponge scaffold is reported here and in Table 1.
- Such cells include i.e. DU145 (prostate cancer), H295R (adrenocortical cancer), HeLa (cervical cancer), KBM-7 (chronic myelogenous leukemia), LNCaP (prostate cancer), MCF-7 (breast cancer), MDA-MB-468 (breast cancer), PC3 (prostate cancer), SaOS-2 (bone cancer), SH-SY5Y (neuroblastoma, cloned from a myeloma), T47D (breast cancer), THP-1 (acute myeloid leukemia), U87 (glioblastoma), National Cancer Institute's 60 cancer cell line panel (NCI60).
Table 1: list of cells which may be cultured on a 3D scaffold according to an aspect which is not part of the invention. Cell line Organism Origin tissue Morphology A172 Human Brain Glioblastoma A253 Human Submandibular duct Head and neck carcinoma A2780 Human Ovary Ovarian carcinoma A2780ADR Human Ovary Adriamycin-re sistant derivative of A2780 A2780cis Human Ovary Cisplatin-resistant derivative of A2780 A431 Human Skin epithelium Squamous cell carcinoma A549 Human Lung Lung carcinoma BCP-1 Human PBMC HIV+ primary effusion lymphoma BEAS-2B Human Lung Epithelial BOSC23 Human Kidney (embryonic) Epithelium BT-20 Human Breast epithelium Breast carcinoma BxPC3 Human Pancreatic adenocarcinoma Epithelial Caco-2 Human Colon Colorectal carcinoma Cal-27 Human Tongue Squamous cell carcinoma CML T1 Human CML acute phase T cell leukemia COR-L23 Human Lung Lung carcinoma COR-L23/5010 Human Lung Lung carcinoma COR-L23/CPR Human Lung Lung carcinoma COR-L23/R23- Human Lung Lung carcinoma COV-434 Human Ovary Ovarian granulosa cell carcinoma DAOY Human Brain Medulloblastoma DU145 Human Androgen insensitive prostate carcinoma DuCaP Human Metastatic prostate carcinoma Epithelial EM-2 Human CML blast crisis Ph+ CML line EM-3 Human CML blast crisis Ph+ CML line FM3 Human Lymph node metastasis Melanoma H1299 Human Lung Lung carcinoma HaCaT Human Skin Keratinocyte HCA2 Human Colon Adenocarcinoma HEK 293 Human Kidney (embryonic) Epithelium HEK 293T Human Kidney (embryonic) Epithelium HeLa Human Cervix epithelium Cervical carcinoma Hep G2 Human Liver Hepatoblastoma HL-60 Human Blood Myeloblast HT-1080 Human Fibrosarcoma HT-29 Human Colon epithelium Adenocarcinoma Jurkat Human White blood cells T cell leukemia JY Human Lymphoblastoid EBV-transformed B cell K562 Human Lymphoblastoid CML blast crisis KBM-7 Human Lymphoblastoid CML blast crisis KCL-22 Human Lymphoblastoid CML KG1 Human Lymphoblastoid AML Ku812 Human Lymphoblastoid Erythroleukemia KYO-1 Human Lymphoblastoid CML LNCaP Human Prostatic adenocarcinoma Epithelial Ma-Mel 1, 2, 3....48 Human Skin A range of melanoma cell lines MCF-7 Human Breast Invasive breast ductal carcinoma ER+, PR+ MCF-10A Human Breast epithelium MDA-MB-157 Human Pleural effusion metastasis Breast carcinoma MDA-MB-231 Human Pleural effusion metastasis Breast carcinoma MDA-MB-361 Human Melanoma (contaminated by M14) MDA-MB-468 Human Pleural effusion metastasis Breast carcinoma MG63 Human Bone Osteosarcoma MOR/0.2R Human Lung Lung carcinoma Mono-Mac-6 Human White blood cells Myeloid metaplasic AML MRC-5 Human Lung (fetal) Fibroblast NCI-H69 Human Lung Lung carcinoma NCI-H69/CPR Human Lung Lung carcinoma NCI-H69/LX10 Human Lung Lung carcinoma NCI-H69/LX20 Human Lung Lung carcinoma NCI-H69/LX4 Human Lung Lung carcinoma NALM-1 Human Peripheral blood Blast-crisis CML NK-92 Human Leukemia/lymphoma NTERA-2 Human Lung metastasis Embryonal carcinoma NW-145 Human Skin Melanoma OPCN / OPCT cell lines Human Prostate Range of prostate tumour lines PC-3 Human Bone metastasis Prostate carcinoma Peer Human T cell leukemia PNT1A Human Prostate SV40-transformed tumour line PNT2 Human Prostate SV40-transformed tumour line Raji Human B lymphoma Lymphoblast-like SaOS-2 Human Bone Osteosarcoma SH-SY5Y Human Bone marrow metastasis Neuroblastoma SiHa Human Cervix epithelium Cervical carcinoma SK-BR-3 Human Breast Breast carcinoma SK-OV-3 Human Ovary Ovarian carcinoma SK-N-SH Human Brain Epithelial T2 Human T cell leukemia/B cell line hybridoma T-47D Human Breast Breast ductal carcinoma T84 Human Lung metastasis Colorectal carcinoma T98G Human Glioblastoma-astrocytoma Epithelium THP-1 Human Monocyte Acute monocytic leukemia U2OS Human Osteosarcoma Epithelial U373 Human Glioblastoma-astrocytoma Epithelium U87 Human Glioblastoma-astrocytoma Epithelial-like U937 Human Leukemic monocytic lymphoma VCaP Human Vertebra metastasis Prostate carcinoma VG-1 Human Primary effusion lymphoma WM39 Human Skin Melanoma WT-49 Human Lymphoblastoid YAR Human Lymphoblastoid EBV-transformed B cell VERO African green monkey - Chlorocebus sabaeus Kidney epithelium CMT12 Dog Mammary gland Epithelium D17 Dog Lung metastasis Osteosarcoma DH82 Dog Histiocytosis Monocyte/macrophage MDCK II Dog Kidney Epithelium AHL-1 Hamster Lung BHK-21 Hamster Kidney Fibroblast CHO Hamster Ovary Epithelium C6/36 Insect - Asian tiger mosquito Larval tissue S2 Insect - Drosophila melanogaster Late stage (20-24 hours old) embryos Sf21 Insect (moth) - Spodoptera frugiperda Ovary Sf9 Insect (moth) - Spodoptera frugiperda Ovary High Five Insect (moth) - Trichoplusia ni Ovary Pt K2 Long-nosed potoroo - Potorous tridactylus Kidney Epithelial 3T3-L1 Mouse Embryo Fibroblast 4T1 Mouse Mammary gland A20 Mouse B lymphoma B lymphocyte ALC Mouse Bone marrow Stroma B16 Mouse Melanoma bEnd.3 Mouse Brain/cerebral cortex Endothelium C2C12 Mouse Myoblast C3H-10T1/2 Mouse Embryonic mesenchymal cell line CGR8 Mouse Embryonic stem cells CT26 Mouse Colon Colorectal carcinoma E14Tg2a Mouse Embryonic stem cells EL4 Mouse T cell leukemia EMT6/AR1 Mouse Mammary gland Epithelial-like EMT6/AR10 .0 Mouse Mammary gland Epithelial-like GL261 Mouse Brain Glioma Hepalclc7 Mouse Hepatoma Epithelial J558L Mouse Myeloma B lymphocyte cell L1210 Mouse Lymphocytic leukemia Ascitic fluid L243 Mouse Hybridoma Secretes L243 mAb (against HLA-DR) MA2.1 Mouse Hybridoma Secretes MA2.1 mAb (against HLA-A2 and HLA-B17) MC-38 Mouse Colon Adenocarcinoma MTD-1A Mouse Epithelium MyEnd Mouse Endothelium Neuro-2a Mouse Nerve/neuroblastoma Neuronal stem cells NIH-3T3 Mouse Embryo Fibroblast Neuro2a Mouse Nerve/neuroblastoma Neuronal stem cells P3X63Ag8 Mouse Myeloma RenCa Mouse Kidney Renal carcinoma RIN-5F Mouse Pancreas RMA-S Mouse T cell tumour YAC-1 Mouse Lymphoma COS-7 Old World monkey - Cercopithecus aethiops (Chlorocebus) Kidney Fibroblast 9L Rat Brain Glioblastoma B35 Rat Neuroblastoma C6 Rat Brain astrocyte Glioma PC12 Rat Adrenal medulla Pheochromocytoma RBL-1 Rat Leukemia Basophil cell OK Virginia opossum - Didelphis virginiana Kidney AB9 Zebrafish Fin Fibroblast - According to an aspect which is not part of the present invention, the cells were seeded on top of the dried scaffold placed in a culture medium and the culture medium was adjusted within 15-30 minutes. The seeding stage could require a centrifugation step, immediately after overlayering the cells, for 2 to 10 min, not over 1000 g at temperature ranging from 4°C to 37°C to achieve a uniform cell distribution in the scaffold. The different cell cultures were incubated for a different time (up to 60 days) in humidified atmosphere of 5% CO2 and 95% air at 37°C, with a variable medium change frequency depending on cell type, ranging from 1 to 4 days.
- According to said aspect which is not part of the present invention, some cellular lines can be cultured into the scaffold under different dynamic conditions by a proper mechanical stimulation which promotes an efficient progenitor cell expansion, or nutrients and catabolites exchange. The scaffold with the cells can be subjected to periodic manual compressive force in a suitable compressive apparatus or device.
- To recover the cells, different enzymes can be used, including, but not limited to, trypsin, chymotrypsin, collagenase, elastase, and/or hyaluronidase, DNase, pronase, dispase etc. The cells can be recovered from the scaffold by the application of a mild centrifugation force.
- Scaffold mechanical disruption can also be accomplished by a number of methods including, but not limited to, the use of grinders, blenders, sieves, homogenizers, pressure cells or insonators.
- The presence or the number or the growth of cells inside the scaffold could be monitored by impedance based assay or by other electrical known measurement or method based on eco-Doppler effect or other acoustic methods.
- According to the present invention, the three-dimensional scaffold is obtained by compression of the cross-linked polyacrilyc acid powder uniformly mixed with at least one water-soluble salt and at least one gas-forming agent. The resulting compact unit is submitted to a thermal treatment and the soluble fraction of the resulting matrix is leached therefrom by repeated washing with suitable amounts of deionized water up to complete swelling of the matrix and disappearance of the soluble fraction.
- According to the present invention, the expression "water-soluble fraction" of said unit means the fraction consisting of the at least one water-soluble gas-forming agent and the at least one water-soluble salt, prior to the thermal treatment of the method according to the present invention.
- After said thermal treatment, where the at least one gas-forming agent is thermolabile, the expression "water-soluble fraction" of the thermally treated unit means the fraction consisting of the at least one water-soluble salt and the residue resulting from the decomposition of the at least one thermolabile gas-forming agent during the thermal treatment.
- Optionally, the scaffold can be frozen and subjected to lyophilization. After conditioning in a suitable volume of water or an aqueous medium, the scaffolds are sterilized by moist heat in autoclave.
- The above-mentioned method according to the present invention is explained in great detail below.
- Since the porosity and pore size are independently controlled by the concentration of the salts, in the initial composition of the mixed powder, and by the particle size range of the salts of the water-soluble fraction, the particles of the salts can be milled and sieved or only sieved or granulated, alone or together, to yield various particle sizes in the range from 50 to 500 µm.
- The thermostable salt and the gas-forming agent can be used as powder aggregates in microbeads or microspheres of different size and shape, as pure components or in combination between them.
- Also, the cross-linked polyacrylic acid can be sieved to yield various particle sizes ranging from 50 to 500 µm.
- The powder of each component, before or after sieving, can be dried in oven at 100°C for 30 minutes and the dried powder is stored, before use, in a desiccator containing silica gel.
- The mixing of the components, each optionally sieved, is conducted in a suitable stainless-steel container using a Turbula® mixer until the mixture of the components is completely uniform, generally in the following manner:
- 1. a core formed of the 33.3% (w/w) of the final amount of each formulation component is added and mixed at 62 rpm for a variable mixing time depending on the masses at stake (generally 5-60 min);
- 2. after the set mixing time, another 33.3% (w/w) of the final amount of each formulation component is added and mixed at 62 rpm, for the set mixing time;
- 3. after the mixing time of the previous step, the remaining amount of each formulation component is added and mixed at 62 rpm for the same mixing time.
- Using a suitable mixing jar amounts of mixed powders from 100 mg to 100 kg can be prepared.
- Using a different mixing apparatus larger amounts of mixed powders could be prepared
- The uniform mixed powder can be directly submitted to a direct compression procedure or can be granulated.
- Granulation can be performed in an apparatus for granulation commonly described (Handbook of chemical engineering), through the following preparative steps:
- 1) spraying pure water (or 25% ethanol aqueous solution) on the uniform mixed powder during the mixing;
- 2) sieving of the wet mass;
- 3) drying of the sieved mass at a temperature lower than 70°C.
- Alternatively, the granulating fluid can be a saturated solution or brine of the salt used, like NaCl, which can be sprayed on the uniform mixed powder containing the remaining part of the salt used in the formulation.
- The granulation can involve only the uniform powder mixture of water soluble salts and the gas forming agents following the above-mentioned procedure and the granulate so obtained, after assaying the concentration of each component of the mixture and optionally sieving, is mixed with the polymeric fraction in a suitable ratio.
- The granulation, involving only the water-soluble salts and the gas forming agent, can be performed in spray-dryer or in a fluid bed apparatus.
- In spray driers it is possible to spray a solution containing the components of the water-soluble fraction. The solution containing the components of the water-soluble fraction can contain up to 25% (w/w) of ethanol.
- The granulate so obtained, after assaying the concentration of each component of the mixture and optionally sieving, is mixed with the polymeric fraction in a suitable ratio.
- The expression "polymeric fraction" means at least one cross-linked polyacrylic acid according to the present invention.
- In fluid bed a solution containing the water-soluble salts of the water-soluble fraction (e.g. sodium chloride) is sprayed against a fluid bed of the gas-forming agent (e.g. sodium hydrogen carbonate). The solution containing the salt of the water-soluble fraction can contain up to 25% (w/w) of ethanol. The granulate so obtained, after assaying the concentration of each component of the mixture and optionally sieving, is mixed with the polymeric fraction in a suitable ratio.
- The powder or the granulate are compacted in a compact unit machine or using a hydraulic press. The shape of the compact unit depends on punch/die shape.
- The form of the compressed powder can be any regular three-dimensional geometric shape, and the weight of powder used can be any between 5 mg and 100 kg.
- The compression of the uniform powder can be conducted by working with a pressure per gram of powder between 2 kPa/g - 2500 GPa/g or 150 kPa/g - 25 GPa/g or 16 MPa/g -12 GPa/g.
- The machine may be a suitably modified model for carrying out multilayer or dry coating tableting.
- The treatment is carried out in a precise forced-air oven as the oven of a gas chromatograph and consists of heating to a predetermined treatment temperature and maintaining such temperature for a predetermined time. The treatment temperature ranges from 120 to 160°C (in particular 125-155°C) for a time in the range of 1-120 minutes, as a function of solid mixture weight, in particular 1-20 minutes. The heating rate of the compressed units can vary from 1°C/minute to 50°C/minute.
- The temperature program employed is as follows: 0.1 min at 25°C, then heating up to the treatment temperature with a gradient equal to 30°C/min and maintenance of such temperature for the established time, then forced or natural cooling of the compact units to room temperature.
- The cooling step after heating can occur naturally or in forced manner, for example controlling the cooling through the ventilation of dry air or inert gas (N2, Ar, He) at room temperature or dry air or inert gas cooled to a temperature lower than room temperature.
- After heating, a conditioning time at environmental conditions, which can even last 24 hours, can be necessary. Generally, such waiting time does not affect the quality of the production, but it is in any case preferable to wait a standard time of 5 minutes before the next steps.
-
- The thermally treated compact unit is repeatedly washed in ultra-pure water up to full hydrogel matrix swelling and complete elimination of the water-soluble fraction, evaluated by detecting the water-soluble fraction components, as salt ions, in the washing water.
- As the leaching step occurs after the thermal treatment, the water-soluble fraction contains at least one water-soluble salt and the water-soluble residue of at least one thermolabile gas-forming agent.
- For example, the presence of chloride ion is measured potentiometrically using a chloride ion selective electrode (ISE) in conjunction with a double-junction reference electrode and a pH meter with an expanded millivolt scale or an ISE meter capable of being calibrated directly in terms of chloride concentration.
- Standards and samples are mixed 50:1 with an ionic strength adjustment solution (ISA). Calibration is performed by analyzing a series of standards and plotting mV vs. chloride concentration on semi-log graph or by calibrating the ion meter directly in terms of chloride concentration. The presence of chloride is assayed also by formation of a precipitate with silver nitrate in the washing water acidified by adding diluted nitric acid. The absence of a visible precipitate or opalescence indicates the absence of chloride ions.
- Generally, the matrixes are washed with deionized water (leaching liquid) with a volume equal to 2.7 L per g of the compact unit and the washing is repeated replacing for 5-10 times the volume of leaching liquid with fresh water. For each washing the porous hydrogel sponge is kept in water under stirring for a variable time ranging from 15 to 120 min depending on the scaffold weight.
- The final point of leaching is determined after the complete matrix swelling when the hydrogel sponge reaches the maximum size and the residual salt ions are no more detectable in washing/leaching water.
- For example, the presence of sodium ion is measured by sodium ion selective electrodes.
- If necessary, the sodium ion in washing water can be determined potentiometrically using a sodium ion selective electrode (ISE) in conjunction with a double-junction reference electrode, or a chloride combination ISE, and a pH meter with an expanded millivolt scale or an ISE meter capable of being calibrated directly in terms of sodium concentration.
- Standards and samples are mixed 50:1 with an ionic strength adjustment solution (ISA). Calibration is performed by analyzing a series of standards and plotting mV vs. sodium concentration on semi-log graph or by calibrating the ion meter directly in terms of sodium concentration.
- To evaluate the complete elimination of water-soluble fraction, during the leaching phase, it is possible to compare the weight of the scaffold dried by lyophilization with respect to the nominal amount of polymer. In fact, for a perfect washing out the weight difference should be the lowest.
- According to an aspect of the invention, after the above-mentioned leaching step, the scaffold is stored in a vacuum chamber to increase interconnectivity due to escape of the residual gas produced by the at least one gas-forming agent, which is still trapped in the matrix.
- The vacuum conditioning occurs in an evacuable chamber at residual pressure of 100× 10-3 mBar for 10 or 60 min depending on the weight of the conditioned hydrogel sponge.
- After vacuum conditioning, a further leaching step may be carried out in order to eliminate the water-soluble residue of the water-soluble fraction, after the escaping of the residual gas.
- The leached 3D scaffolds can be conditioned at different pH in different buffers.
- For example, they can be conditioned at pH 7.4 in PBS or phosphate buffer saline solution, replacing completely the water or other liquid in the swollen hydrogel sponge obtained after the washing procedure, with this buffer solution. To this aim the swollen hydrogel sponge is conditioned in a suitable volume of PBS (or other buffer), replacing the conditioning buffer with fresh buffer every hour until the hydrogel sponge is completely conditioned in the new solvent/buffer up to constant weight and/or dimensions.
- In particular, before sterilization, the matrixes are conditioned in 5 mL of PBS for gram of final weight of completely leached swollen scaffold or hydrogel sponge (i.e. 100 mL per 20 g) for at least 12-20 h, changing the conditioning solution every 1 hour for the initial 6 h and afterwards maintaining the scaffolds in a fresh PBS volume up to 12-20 h, or until maximum diameter contraction or volume contraction.
- The replacement of water in the water-swollen hydrogel with PBS solution or other conditioning medium can be obtained by reconstituting the freeze-dried hydrogel sponge or scaffold directly with PBS solution or other conditioning medium.
- Conditioning can be carried out also with other solutions or media used in cell culturing, e.g. DMEM or Dulbecco's Modified Eagle Medium, or EMEM (Eagle's Minimal Essential Medium), RPMI (Roswell Park Memorial Institute medium) or other medium used in the field.
- Therefore, the scaffold of the invention may be conditioned in water, a buffer solution or cell culturing media.
- The porous swollen hydrogel sponge or 3D scaffold can be used as such or cut in a suitable irregular or regular shape: for example, it is possible to obtain a cylinder shape by a cylindrical cut mold or sharp edge tube with a specific internal diameter.
- The two previous steps of cutting and conditioning applied to 3D scaffolds can be inverted depending on different subsequent needs.
- The lyophilization step may occur before or after the sterilization step.
- The swollen matrix conditioned in deionized or ultrapure water or in an aqueous solution from deionized or ultrapure water (e.g. PBS, pH 7.4), in a suitable packaging, may be sterilized by moist heat process in autoclave. In fact, these 3D hydrogel sponge scaffolds resist to the high pressure and temperature of the sterilization treatment by moist-heat in autoclave, maintaining the mechanical and morphological properties and the suitability for culturing cells.
- The above-mentioned scaffolds, packaged in sealed pressure-resistant closed vial, can be submitted to a moist heat sterilization procedure, for example heating at 120°C under saturated steam pressure of 98 kPa over atmospheric pressure for 30 minutes, and the sterilized vial can be stored until use.
- The scaffold sterilized in PBS solution must be suitably pre-conditioned, with cell culture medium, under aseptic conditions, before culturing the cells.
- Then, the sterilized scaffold is frozen at temperatures lower than -25°C and then lyophilized at a pressure lower than 50 × 10-3 mBar until complete drying or by a unidirectional freezing procedure, dipping it at a constant rate (from 2 to 10 mm/min) into a cold bath maintained at a constant temperature lower than -100°C, typically at -196°C and then submitted to lyophilization.
- The swollen scaffolds conditioned in water may be lyophilized as disclosed above.
- The lyophilized scaffolds are subjected to a sterilization step, using one of the following well-known methods as, for example, ionizing radiation (gamma and beta), UV exposition, electron accelerator exposition, chemical and gas sterilization or dry heat sterilization. The sterile conditions are necessary to avoid contamination of the cultured cells, not to preserve the scaffold.
- The lyophilized 3D scaffolds obtained according to any one of the sterilizing and leaching steps disclosed above can be stored in in dry form as lyophilized products, packaged in sealed closed vial.
- The lyophilized product, stored in sealed vial, can be reconstituted through an aseptic preparative procedure, with water (if the scaffold was conditioned in buffer or salt aqueous solution), buffer (if conditioned in water) or directly with the medium used for cell culturing (if conditioned in water).
- The lyophilized product appears as a highly trabecular dry white sponge or a non-transparent solid porous matrix. The scaffold in aqueous storage solution or solvent swells, becoming a transparent and resistant (tough and unerodible) hydrogel sponge, suitable for storage in the storing fluid and under sterile conditions for long time.
- The materials used in the present invention are summarized in the following Table 2
Table 2: materials. SUBSTANCE PRODUCER Carbopol 980 NF POLYMER Lubrizol Carbopol 974P NF POLYMER Lubrizol Polycarbophil Noveon AA-1 Lubrizol Sodium chloride Sigma-Aldrich (>99.5%) Sodium hydrogen carbonate Merck Disodium hydrogen phosphate dihydrate Sigma-Aldrich Potassium dihydrogen phosphate anhydrous Sigma-Aldrich Table 2A: PBS pH 7.4 composition mM g/L Sodium chloride 137 8.006 Potassium chloride 2.7 0.201 Disodium hydrogen phosphate dihydrate 8 1.424 Potassium dihydrogen phosphate or Monobasic potassium phosphate 1.5 0.204 - A suitable amount of about 2 g of sodium chloride powder (purity ≥ 99.5%, Sigma Aldrich, US) was milled in high oscillating frequency mill (Mixer Mill MM2, Retsch, D) in a 1.5 mL stainless steel grinding jar containing 3 stainless steel 5 mm-diameter balls at vibrational frequency of 8 Hz for 30 min. The ground NaCl powder was sieved between 250 and 125 µm on ASTM certified test sieves (Giuliani, IT) by an analytical sieve shaker (AS200 Retsch, D).
-
Carbopol 980 powder (Carbopol 980NF, Lubrizol, US) was sieved between 250 and 125 µm on ASTM certified test sieves (Giuliani, IT). - Sodium hydrogen carbonate (purity ≥ 99.5%, Merck, D) was used as received having a powder granulometry under 250 µm.
Table 3: initial compositions of some mixed powders used for the compacting unit preparation. code Carbopol 980 Sodium hydrogen carbonate Sodium chloride C2 30 30 40 C5 40 30 30 C8 50 30 20 C9 60 30 10 C12 20 30 50 C41 40 20 40 C61 40 40 20 code Carbopol 974P Sodium hydrogen carbonate Sodium chloride K2 30 30 40 K8 50 30 20 K61 40 40 20 K5 40 30 30 code Polycarbophil Sodium hydrogen carbonate Sodium chloride P2 30 30 40 P11 40 10 50 P41 40 20 40 P5 40 30 30 - All powders were mixed in Turbula® mixer at 62 rpm using a stainless-steel jar of suitable volume taking up 60% to 70% of its capacity.
Table 4: preparation of 10 g of C2 powder. % (w/w) added Mixing Steps Carbopol 980 Sodium hydrogen carbonate Sodium chloride Mixing time (min) I 10 10 13.3 20 II 10 10 13.3 40 III 10 10 13.4 60 Table 5: preparation of 10 g of C5 powder. % (w/w) added Mixing Steps Carbopol 980 Sodium hydrogen carbonate Sodium chloride Mixing time (min) I 13.3 10 10 20 II 13.3 10 10 40 III 13.4 10 10 60 Table 6: preparation of 10 g of C8 powder. % (w/w) added Mixing Steps Carbopol 980 Sodium hydrogen carbonate Sodium chloride Mixing time (min) I 20 20 20 20 II 20 10 - 40 III 10 - - 60 - 300 ± 1 mg of powder were compacted in a 13 mm×1.4 mm (diameter × thickness) evacuable stainless steel die (Perkin-Elmer, US) using a hydraulic press (Specac, UK) applying a force of 1 tons for 15 seconds.
- The compact units were subjected to thermal treatment positioned on a metal support in a metal meshed basket. The treatment was carried out in the forced-air oven of a gas chromatograph (HP 5890 series II, Perkin Elmer, US). The temperature program employed was as follows: 0.1 min at 25°C, reaching the final temperature of 150°C with a gradient equal to 30°C/min and maintenance of such temperature for 15 min, then the compacted units were cooled to room temperature by forced-air ventilation.
- The 300 mg compacted units were swollen in 800 mL deionized water (HPLC grade) in a 1 L beaker under stirring; the water was changed every 15 min for at least 7 times until the compacted units were swollen to their maximum size, and until chloride and sodium ions could not be detected any more in the waste water that had pH = 7.
- The presence of sodium ion was measured potentiometrically (Compact Titrator G20 Mettlert Toledo, US) using an ion selective electrode (perfectION comb Na+) on 20 mL of washing water, while the presence of Cl-was assayed by adding 0.5 mL 2M silver nitrate in 10 mL of washing water acidified by adding diluted (1:4) nitric acid. The absence of a visible precipitate indicated the absence of chloride ions.
- Before sterilization the leached scaffold was conditioned in 25 mL of PBS per gram of final weight of completely leached hydrogel sponge (i.e. 100 mL for 20 g) for at least 12-18 h, changing the conditioning solution every hour for the first initial 6 h and afterwards keeping the scaffolds in a fresh PBS volume for 12 h, until reaching the maximum volume contraction.
- To increase interconnectivity some scaffolds can be submitted to vacuum conditioning in an evacuable chamber at residual pressure of 100×10-3 mBar for 10 or 60 min depending on the weight of the conditioned hydrogelsponge.
- The conditioned hydrogel sponge was cut in 9 mm-diameter cylinders by a 9 mm (internal diameter) sharp edge metallic tube.
- Five 9 mm-diameter cylinders of hydrogel sponge, conditioned in PBS and suspended in 5 mL of PBS, were placed in 10 mL borosilicate glass vial sealed by aluminum crimp cap with PTFE/SIL liner. The crimped vials were sterilized in autoclave at 120°C and saturated steam pressure of 98 kPa over atmospheric pressure for 30 min (Sterilplus Vacum De Lama, IT).
- The conditioned 3D-scaffolds were frozen at a temperature lower than -25°C, until complete water solidification, and lyophilized at a pressure lower than 50 × 10-3 mBar until complete drying. As conclusion of the freeze-drying process, the scaffolds were submitted to a secondary drying by increasing the temperature to 40°C and heating the dried scaffolds, under vacuum conditions, for at least 1 hour. The lyophilization of already sterilized scaffold can be performed in aseptic condition or the lyophilized scaffolds can be submitted to a following energy sterilization procedure (thermal, radiant) or by chemical agents (ethylene oxide, hydrogen peroxide, ClO2 or another sterilizing agent).
- The thermal treatment causes an evident size increase of the compacted unit associated to a weight loss (Tab I-II) while the surface becomes rough (
Figs. 2 and3 ). The density of the compacted unit decreases of approx. 68%, from 1.74 g/cm3 to 0.56 g/cm3, for C2 and around 85%, from 1.63 to 0.23 g/cm3, for C8 due to the thermal treatment. The leaching in water increases, by swelling, the diameter and thickness of the thermally treated compacted units, more than 3 times for C2 and about 6 times for C8. As shown inFig. 4 , the compacted units not submitted to the thermal treatment (NT), on the right in the photo, disintegrated during the leaching step because the porous matrix was not formed. The sterilization does not cause scaffold weight and size variation with respect to the PBS-conditioned compacted units (p>0.05).Table 7: morphological and weight change during the preparation of C2 scaffold starting from a 13 × 1.3 mm (diameter × thickness) cylindrical compact unit before cutting. weight (mg) weight change (%) after thermal treatment diameter (%) after treatment change thermal thickness change (%) after thermal treatment SI(%) after leaching diameter (mm) after PBS conditionin g thickness (mm) after PBS conditioning weight (g) after PBS conditioning 300.3 ±0.1 -12.2±0.4 21.6±1.5 85.5±1.9 5486±569 44.6±1.5 4.7±0.2 8.1±0.4 number of compacted units treated =6 Table 8: morphological and weight change during the preparation of C8 scaffold starting from a 13 × 1.4 mm (diameter × thickness) cylindrical compact unit before cutting. weight (mg) weight change (%) after thermal treatment diameter change (%) after thermal treatment thickness change (%) after thermal treatment SI(%) after leaching diameter (mm) after PBS conditionin g thickness (mm) after PBS conditionin g weight (g) after PBS conditionin g 300.2 ±0.1 -12.7±0.9 54.5±2.2 177.0±10 .1 9878±286 64.6±0.7 7.6±0.3 14.4±1.3 number of compact units treated =6 - Micrographs were acquired by FESEM (Field Emission Scanning Electron Microscope - ZEISS Supra VP40, Carl Zeiss STM, D). The samples were placed on a stub using double-sided conducting tape and coated with a thin Au layer (about 15-20 nm) by sputtering.
- In the first experiment, the SEM micrograph cross sections of the compacted unit of C2 and C5 as such and thermally treated before the leaching procedure were acquired. The comparison of the SEM cross-section of the compacted units as such (left) or thermally treated (right), shown in
Figs. 5A, 5B , and7A and 7B for C2 and C5 scaffolds respectively, highlighted that the controlled heating generates a continuous and porous matrix (zoomed inFigs. 6A-6C andFig. 8A and 8B for thermally treated C2 and C5 scaffolds, respectively) that allows the swelling of the compacted units in aqueous medium, transforming them into hydrogel sponge scaffolds able, after leaching procedure and suitable conditioning, to support the 3D cell culture. Noteworthy is the behavior of the thermally untreated compacted units when submitted to leaching or conditioning in aqueous medium: they underwent disintegration because did not acquire the heating-induced macroporous architecture, with relevant mechanical and chemical-physical properties, necessary for forming the resistant hydrogel structure useful for vital cellular growth: in fact, inFig. 4 -right the erosion occurred in the untreated matrix during the leaching procedure is evident. - In the second experiment, the SEM micrographs of cross sections of the lyophilized C2 and C5 scaffolds obtained following the previously described procedure, involving the steps of leaching in water, conditioning and sterilization in water or PBS, were acquired.
- In the SEM observations, the highly interconnected porous nature of the scaffolds is evident. The distribution and sizes of the pores of the lyophilized scaffold conditioned in PBS (
Figs. 7A to 12 ) is similar to that of the swollen scaffold ready for culturing the cells. The macropore size is up to 100-200 µm. - The micrographs of lyophilized scaffolds, after conditioning in water (
Fig. 10A, 10-B and12 ), clearly show the mechanical tension due to the increased swelling of the hydrogel sponge in this medium with respect to PBS, and consequently the increase of the pore size. - It has been necessary to measure the transmittance in the UV-visible spectra also of an unporous matrix obtained by submitting to thermal treatment and PBS conditioning the compacted units composed of the pure cross-linked polyacrilic acid used to prepare the 3D-scaffolds. The water-swollen pure matrixes were cut into cubic portions using a quartz cuvette; for every test, the cuvette was filled with 4 cubes and further PBS was added; the measurements were performed in the visible range (300-800 nm) and the empty cuvette was used as blank. The transmittance was measured using a UV-Visible Spectrometer (HP8452, Hewlett Packard, D)
Table 9: transmittance (%) values for pure polymer matrix (compacted units, thermally treated, swollen and conditioned) of Carbopol 980 NF, Carbopol 974P NF and Polycarbophil at 400, 600 and 800 nm.Wavelength (nm) Transmittance (%) Carbopol 974P NF Carbopol 980 NF Polycarbophil 400 45 43 50 600 60 65 65 800 65 75 70 - As shown in
Fig. 14 the low transmittance of C2 and C8 hydrogel-sponge scaffolds is due to their high porosity, which determines high light reflectivity. The pure polymer matrixes, being non-porous, have higher transmittance (Fig. 13 and Tab. 9). The spectral comparison of C2 and C8 visible spectra with the ones of pure polymer matrixes demonstrates that the visible profile is due to the cross-linked polyacrylic acid used and that the scaffold transmittance is influenced by the interface problem related to the high porosity. - In another experiment, the scaffold transparency was evaluated by observing the letters printed on a paper sheet placed under a Petri capsule containing the PBS-swollen scaffold. The sharpness of the typographical sign, read through the scaffolds completely immersed in PBS, with respect to a reference read through a PBS solution (
Fig. 15 ), proves the good optical properties of the scaffold. - The scaffold transparency is very useful to follow the cell proliferation during cell culture as shown in the micrographs of Figs. from 16 to 18.
- The soluble components of PBS-conditioned and sterilized scaffolds (Tab. 3) of cylindrical shape with 15-20 mm diameter were removed by using 800 mL of deionized water, under stirring, replaced every 15 min for at least 7 times until the scaffolds were swollen to their maximum size, and sodium and phosphate ions could be detected any more in the waste water.
- The presence of sodium ion is potentiometrically measured (Compact Titrator G20 Mettler Toledo, US) using an ion selective electrode (perfectION comb Na+) on 20 mL of washing water. The absence of phosphate ions in the washing water is tested by adding several mL of ammoniacal solution of ammonium chloride and magnesium chloride: the absence of a visible white precipitate of magnesium ammonium phosphate (MgNH4PO4) indicates the absence of residual phosphate ions in the washing solution.
- The purified scaffolds were frozen at a temperature lower than -18°C until complete water solidification, and lyophilized at pressure lower than 50 × 10-3 mBar until complete drying. The dried products were submitted to a secondary drying by heating at 40°C for at least 1 hour, under vacuum. Weight, diameter and thickness of the lyophilized cylindrical scaffolds were measured and the densities were calculated. The density of scaffolds with different compositions is reported in Table 10 4/A (five scaffolds were used for each density measurement); the density was expressed as mean value ± standard deviation (n=5).
Table 10: density of scaffolds with different compositions. Scaffold code Density (mg/cm3) mean ± SD C2 17.6±0.6 C5 20.9±0.6 C9 17.4±0.7 C12 13.7±0.2 C41 17.5±1.1 C61 17.9±0.9 K61 15.4±1.1 P41 15.2±1.2 - Two methods were utilized for measurement of the scaffold porosity [14-18]. The swollen scaffolds, used for porosity measurement, after conditioning and sterilization in PBS, were washed with water up to complete elimination of the soluble fraction and lyophilized following the procedure described in example 4.
- For a cylindrical shape lyophilized scaffold, the weight, radius and thickness (or height) were measured and the apparent density was calculated (ρ1 ), then the scaffolds were cut into smaller pieces, weighed and put into a 13 mm-diameter die and compacted at a compression force of 8 tons for 15 minutes in a hydraulic press under vacuum. Finally, the weight and volume of the produced tablet were measured and its density was calculated (ρ2 ). The scaffold porosity (ε) was calculated using the following equation:
- The scaffolds were conditioned in acetonitrile because it permeates through the matrix without swelling or shrinking it. The scaffold was placed in acetonitrile and the air bubbles were evacuated under vacuum, until the scaffolds sunk completely in the liquid. The conditioned scaffolds were collected and the excess liquid removed using filter paper and the weight was recorded (Ww); the procedure was carried out at room temperature (20 ± 0.5°C). The recovered scaffolds were dried in forced-air oven at 80°C up to constant weight (ws). The following equation was used to calculate the scaffold porosity (ε):
- The values of porosity calculated following the two methods are reported in Tab. 11 for some scaffolds of different compositions.
Table 11: values of porosity calculated following the above-mentioned two methods. Scaffold code Porosity method 1, mean ± SD (%) Porosity method 2, mean ± SD (%)C2 97.9±0.1 97.6±0.3 C5 98.8±0.1 97.9±0.3 C8 98.7±0.1 98.0±0.2 C9 98.9±0.1 97.8±0.1 C12 99.1±0.1 98.1±0.3 K61 98.2±0.1 97.7±0.3 P2 97.4±0.1 97.2±0.3 - The mechanical properties of the hydrated scaffolds were evaluated by compression tests on LRX dynamometer (Lloyd Instruments, UK), at a speed of 1 mm/min and a temperature of 25±2 °C. Twenty mm-diameter cylindrical scaffolds, conditioned and sterilized in PBS, were submitted to a compression test using a LRX dynamometer equipped with a 20 N load cell and cylindrical (r=5.82 mm) test probe. For the test sterilized and PBS conditioned hydrogel sponge scaffolds were weighed (wc) after removing excess liquid on external surface using filter paper. For the test, sterilized and PBS-conditioned hydrogel sponge scaffolds were weighted (wc) after removing excess liquid on the external surface using filter paper. The tested scaffold was completely immersed in PBS [31] with 1 mm of liquid exceeding the scaffold surface. The probe was moved up to contact with the flat surface of the scaffolds and the elongation was zeroed. The scaffolds were compressed increasing the force (
test rate 1 mm/min) up to break. Stress-strain curves were recorded measuring the stress value, referred to the force divided by the area of probe in contact with the scaffold surface, and the strain, referred to the absolute deformation divided by the scaffold thickness. Two stress-strain curves for C2 and C8 scaffolds are shown inFigs. 20 and 21 respectively. The measurements were performed on 6 scaffolds for each composition. The following values have been measured for each scaffold composition: - YM = Young's Modulus (kPa) measured as the slope of the linear part of the stress-strain curve before the plastic deformation at YS (
Fig. 19 ). - YS = yield strength (
Fig. 19 ), i.e. the stress causing the minimum irreversible deformation in the material, measured as the stress value (kPa); - Yield strength/weight = yield strength referred to wc, weight of conditioned scaffold.
- The YM, YS and Yield strength/weight for some scaffolds are reported in Table 12.
Tab.12: mechanical parameters of different scaffold compositions, reported as Scaffold code PBS conditione d weight (mg) PBS conditione d Thickness (mm) Young's modulus (kPa) Yield strength(kPa) Yield strength/weig ht (kPa/g) C12 1221.2 ± 82.5 3.71 ± 0.09 39.0 ± 2.3 7.4 ± 0.7 6.46 ± 0.67 C2 1456.9 ±1 43.5 5.11 ± 0.32 38.8 ± 5.2 9.8 ± 1.0 6.71 ± 0.63 C5 1780.2 ± 148.6 4.83 ± 0.12 52.4 ± 1.9 11.7 ± 1.3 6.57 ± 0.20 C8 1801.3 ± 79.4 6.18 ± 0.20 53.3 ± 5.9 10.3 ± 0.6 5.70 ± 0.34 C9 2149.1 ± 130.9 6.76 ± 0.20 68 ± 2.0 12.4 ± 0.7 5.79 ± 0.49 K5 1587.7 ± 22.5 5.15±0.1 28.3 ± 1.2 6.32 ± 0.2 3.98 ± 0.09 P5 1599.3 ± 51.4 5.37 ±0.1 38.69 ±2.1 7.9 ± 0.3 4.97 ± 0.3 mean ± SD (n=6). - The molecular diffusion through the scaffolds at 37°C was evaluated in horizontal Franz diffusion cell apparatus, using metformin hydrochloride as small, very hydrophilic and soluble diffusing test molecule. The diffusion was studied in PBS-swollen scaffolds with 15 mm diameter and thickness ranging from 3 to 7 mm, which were placed so as to separate the two compartments, fitted into a PTFE ring of 14 mm internal diameter, measuring the resulting increased thickness (WH) of the hydrogel scaffold. The cell was thermostated at 37°C. The receptor compartment was filled with 21.5 mL PBS solution preheated at 37°C, then the donor compartment was filled with 21.5 mL PBS, containing 500.0 µg/mL of metformin hydrochloride, preheated at 37°C. Solution aliquots of 500.0 µL were withdrawn from both compartments at predetermined time periods (at 45 min and 3, 6, 21, 24, 27, 30 h) and metformin hydrochloride concentration was assayed by UV (HP8452 spectrophotometer, Perkin Elmer, US) at λ = 233 nm, against a metformin hydrochloride standard solution (5.0 µg/mL). At any sampling time t, the metformin hydrochloride concentration values in the two chambers were used to calculate the diffusion coefficient D, from the following equation:
-
- C 1(t) = concentration of metformin hydrochloride in donor compartment after time t;
- C 2(t) = concentration of metformin hydrochloride in receptor compartment after time t;
- AH= effective cross-sectional area of diffusion in the hydrogel scaffold;
- WH= thickness of the hydrogel scaffold;
- V 1= volume of donor compartment;
- V 2= volume of receptor compartment.
-
- The measured D of some scaffolds are reported in Table 13.
Table 13: molecular diffusion (D) through some scaffolds at 37°C. Scaffold code D (37 °C) of metformin hydrochloride (m2/s) (mean ± SD) C2 1.06×10-9±8.4×10-11 C8 1.21×10-9±9.6×10-11 P2 1.14×10-9±9.1×10-11 K8 1.19×10-9±9.5×10-11 - A sample of water conditioned and lyophilized C2 scaffold was submitted to adsorption/desorption measurements (N2 at 77 K) performed with an ASAP 2010 porosimeter (Micromeritics, IT). Pore size distribution was obtained by the well-known BJH method.
- The analysis (
Figs. 22, 23 ) of BET curve indicated the microporous and confirmed the macroporous (see SEM observations of Example 2) nature of the scaffolds. The size distribution of the mesopores is shown inFig. 24 . The BET surface area was 5.4 ± 0.2 m2/g and BJH adsorption cumulative pore volume of pores between 1.7 and 300 nm diameter was 0.017 cm3/g. - The IR spectra of the different substances and mixtures were acquired through a Perkin Elmer FT-
IR 2000 spectrometer (US), preparing the samples in KBr discs. - The IR spectra can be used to characterize the freeze-dried scaffold previously washed in water.
- The IR spectra of these products are similar to the ones of the cross-linked polyacrylic components.
- Noteworthy is the presence of C=O stretching band near 1760 cm-1 (
Fig. 25 ) for unionized carboxylic acid, typical of the scaffolds with low bicarbonate content; for higher bicarbonate content (Figs. 26 and 27 ) this band is less evident: a band for asymmetrical stretching of COO- near 1650-1550 cm-1 appears and the band near 1400 cm-1 for the symmetrical stretching of COO- becomes more intense with respect to the band near 1450 cm-1. In the presence of only unionized carboxylic group or higher [COOH]/[COO-] ratio, the band near 1450 cm-1 becomes more intense with respect to the one near 1400 cm-1. The band near 1450 cm-1 probably arises from the scissoring vibration of the CH2 group adjacent to the carbonyl and OH bending. -
Table 14: morphological characteristics of C2 and C8 hydrogel sponge scaffolds. Scaffold code Weight (g) Diameter (mm) Thickness (mm) C2 0.26±0.02 8.5±0.3 4.7±0.3 C8 0.36±0.02 8.3±0.3 6.6±0.2 - C2 and C8 hydrogel sponge scaffolds, conditioned in PBS, in triplicate, were maintained in PBS solution until use. Then, they were transferred in 12 multiwell plate containing 1 mL of DMEM without phenol red and conditioned overnight to promote the PBS replacement in the gels. The day after, the gels were transferred into Petri dishes containing DMEM added with phenol red and monitored every hour, for the phenol red spread into gel core (
Fig. 28 ). - At the fourth hour, the phenol red was partially spread into the scaffold core (
Fig. 29A ). Afterwards, the scaffolds were incubated overnight and after 12 hours phenol red was completely spread into the gels (Fig. 29B ). The diffusion of phenol red was monitored at 570 nm by TLC Scanner (Camag 3 controlled by WinCATS 1.4.2 software, CH). - Where:
- MTT is 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- MTS is (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
- NR is 3-amino-7-dimethylamino-2-methylphenazine hydrochloride
- C2, C8, K2, K8, P2 and P8 hydrogel sponge scaffolds, conditioned in PBS, were maintained in DMEM medium until the assays. To avoid any interference between phenol red present in DMEM and the viability dyes, gels were removed from the plates and were submitted to centrifugation at 720 × g.
- The hydrogel sponge scaffolds were put into a 6 multiwell plate containing 2 mL of MTT, MTS and NRU reagents in duplicate, as shown in
Figs. 30A and 30B for C2 and C8 scaffolds. - After a three hour-incubation time, the dyes resulted spread into all gels.
- Cell health can be monitored by numerous methods: plasma membrane integrity, DNA synthesis, DNA content, enzyme activity, presence of ATP, and cellular reducing conditions are known indicators of cell viability and cell death. In this example the wellness of cells was checked by Alamar Blue® assay.
- Alamar Blue® cell viability reagent functions as a cell health indicator by using the reducing power of living cells to quantitatively measure the proliferation of various human and animal cell lines, bacteria, plant, and fungi allowing to establish the relative cytotoxicity of agents within various chemical classes. The assay is based on the use of resazurin, a non-toxic, cell-permeable substrate, that is blue and virtually non-fluorescent.
- Healthy living cells maintain a reducing state within their cytosol. This "reducing potential" of cells converts resazurin into resorufin, a red highly fluorescent (or absorbent) product. Viable cells continuously convert resazurin to resorufin, increasing the overall fluorescence and color of the media surrounding cells.
- Fluorescence of resorufin is detectable in spectrofluorimeter (at excitation/emission wavelengths of 570/585 nm, respectively) as well in spectrophotometer (at 570 nm). In preliminary experiments to assess the optimal time to measure fluorescence following addition of Alamar Blue® in wells, consecutive measurements (1-2-3 hours) by withdrawing 10 µL of experimental medium have been performed. The obtained results suggested that a 3 h incubation time is optimal compared to shorter incubation times
- Applied procedures: the different cells studied were seeded into C2, C8, K2, K8, P2 and P8 hydrogel sponge scaffolds conditioned in DMEM, previously reconstituted into single wells of a 24 well plates, at 100 - 200 × 103 cellular density in 500 µL DMEM medium supplemented with 10% FBS, 2mM glutamine, and were cultured at 37°C in a humidified atmosphere containing 5% CO2.
- At each check point time, the scaffolds were transferred (using sterile plastic forceps with flattened tips) into another 24-well plate to perform Alamar Blue® test. Each insert was gently washed with PBS and then 1 mL fresh medium containing 10% Alamar Blue® reagent was added. After incubation, fluorescence was measured (excitation 530 nm, emission 590 nm). Wells containing culture medium without cells and hydrogel, 10% v/v Alamar Blue®, and vitamin C (ascorbic acid 0.75 mg in 5 (µL/well), that results in rapid full reduction of Alamar Blue®, were used as positive controls. Wells with culture medium without cells containing 10% v/v Alamar Blue® were assayed as negative controls.
- All the cells tested (A549, Caco-2, Cal-27, HaCaT, HeLa) showed to be healthy when cultured in hydrogel sponge scaffolds (C2, C8, K2, K8, P2 and P8) for a longer time than in 2D culture (at least 20 days), depending on scaffold size and initial density of seeding, since metabolic rate is dependent on cell number present into the scaffold as function of the culture time.
- Results for HeLa and HECV cell lines, as models of human epithelial and endothelial cells, are shown for C2 and C8 scaffolds in
Figs. 31A and 31B ; data are expressed as (AU= Arbitrary Units) extrapolated by fluorescence of resorufin, where metabolic activity registered on 4th day was reported as 100%. - Example 13 Hydrogel sponge scaffold suitability for test with positive irritation compound (NiSO 4 )
- The test was performed on HeLa cells seeded into C2 ,C8, K2, K8, P2 and P8 hydrogel sponge scaffolds, after 10 days of culture (seeded at 7.5 × 104 cells/50 µL). Experimental conditions: exposure of HeLa cells for 3 hours to 0.5 and 5 mM NiSO4, as positive control of irritation. Viability index, expressed as percentage versus the respective untreated culture, was assessed in terms of MTS assay.
- The results evidence the suitability of the hydrogel sponge scaffold for irritation test with nickel sulfate. The test gave similar response for the two kind of scaffolds (
Figs. 32A-32B ). - The hydrogel sponge scaffolds were fixed in paraformaldehyde (PAF) (4% in phosphate buffer saline,
PBS 8‰ NaCl and pH 7.4) for 24 h, at 4°C, and then gently washed 3 times with PBS at room temperature in soft agitation. To prepare PAF, 4 g of paraformaldehyde powder were added to 50 mL H2Od, stirring and heating to 56°C until dissolution of the powder. Then, to make the solution (which is initially milky) clear, some drops of NaOH 1 N were added. Finally, 50 mL of PBS (8 % in phosphate buffer saline,PBS 16‰ NaCl and pH 7.4) were added. The solution, cooled down to room temperature, was filtered, aliquoted, and stored at -20°C. The scaffolds were embedded in agarose 3.5% in PBS (3.5 g of agarose powder are dissolved with gentle agitation in PBS, heating up to boiling). The agarose was cooled to 55/56°C and used immediately. The embedded hydrogel sponge scaffolds were maintained in the dark at 4°C and hydrated with PBS until the cutting operation. The cutting was performed in a PBS bath with an appropriate vibratome with a thickness of 40 µm and the sections were immediately mounted on histological slides. - The staining with propidium iodide (PI) was performed by working solution of PI (1 µg/mL PI and 10 µg/mL RNase A in
PBS 8‰ NaCl and pH 7.4), for 40 minutes at room temperature in the dark. After washing many times gently in PBS, the slides were mounted in PBS with cover slip. Glycerol, generally employed in the mounting media, was not used in order to avoid interactions with the hydrogel. The use of RNase A, removing the RNA, allows PI to bind only DNA. PI emits red fluorescence when excited by proper wavelength in epifluorescence microscope or in a CLSM that can excite the PI. - PI stock solution (1 mg/mL - 1.5 mM PI - in deionized water) was stored at 4°C (or aliquoted and stored at - 20°C), protected from light. RNase A stock solution (1 mg/mL in bi-distilled water) was aliquoted and stored at -20°C. To prepare the PI working solution (1 µg/mL PI and 10 µg/mL RNase A in PBS), 2 µL of PI stock solution and 20 µL of RNase A stock solution were added to 2 mL of PBS (8‰ NaCl and pH 7.4). Slides were observed through a Leica DMRB light microscope which was equipped for epifluorescence with a lamp (Mercury Short Arc Photo
Optic Lamp HBO 100 W. Osram, D) and proper filter cubes, including A (blue fluorescence), 13 (green fluorescence) and N2.1 (red fluorescence). Micrographs were acquired with a Leica CCD camera DFC420C (Leica, D) and Leica Application Suite (LAS) software. Alternatively, images were obtained using a Leica TCS SL confocal microscope (Leica Microsytems) equipped with argon/He-Ne laser sources, a HCX PL APO CS 63.0×1.40 oil, and HC PL FLUOTAR 20.0×0.5 air objectives. - The following protocol can be used for counter-staining tissue sections or cultured cells on slides.
- The staining with DAPI was performed using a working solution of DAPI (100 ng/mL or 300 nM in
PBS 8‰ NaCl and pH 7.4) and with an incubation of the sections in dark for 10 minutes at room temperature. Without washing, the sections were mounted with cover slip and PBS as reported above. DAPI binds only DNA by intercalation and, only when bound, it emits blue fluorescence when excited by proper wavelength in epifluorescence microscope, or in a CLSM that can excite the DAPI. - DAPI stock solution (5 mg/mL or 14.3 mM) (using DAPI Molecular Probes, Cat# D-1306) was prepared as follows: 10 mg DAPI added to 1 mL of dimethyl-sulfoxide then to 9 mL of ethyl alcohol absolute and mixed to complete dissolution, aliquoted, and stored at -20°C. DAPI working solution (100 ng/mL or 300 nM in PBS) was obtained diluting 2 µL of DAPI stock solution in 100 mL of PBS, and stored at 4 °C in dark bottle. Observations were performed with an epifluorescence microscope as reported above.
- The scaffolds are colonized by all cultured cells from the seeding surface to the bottom, as shown for C2 (
Figs. 33A-33B ) and C8 (Figs. from 34 to 38) scaffolds. Ordered cellular structures, similar to spheroids, for HECV (Fig. 34 ) and for HeLa (Fig. 38 ) are evident. -
- 1. Lee J, Cuddihy MJ, Kotov NA: Three-dimensional cell culture matrices: State of the art. Tissue Engineering Part B-Reviews 2008, 14(1):61-86.
- 2. Andrei G: Three-dimensional culture models for human viral diseases and antiviral drug development. Antiviral Research 2006, 71(2-3):96-107.
- 3. Ravi M, Paramesh V, Kaviya SR, Anuradha E, Solomon FDP: 3D Cell Culture Systems: Advantages and Applications. Journal Of .
- 4. Xu X, Farach-Carson MC, Jia X: Three-dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnology Advances 2014, 32(7): 1256-1268.
- 5. Smith SJ, Wilson M, Ward JH, Rahman CV, Peet AC, Macarthur DC, Rose FRAJ, Grundy RG, Rahman R: Recapitulation of Tumor Heterogeneity and Molecular Signatures in a 3D Brain Cancer Model with Decreased Sensitivity to Histone Deacetylase Inhibition. Plos One 2012, 7(12).
- 6. Picollet-D'hahan N, Dolega ME, Liguori L, Marquette C, Le Gac S, Gidro X, Martin DK: A 3D Toolbox to Enhance Physiological Relevance of Human Tissue Models. Trends in Biotechnology 2016, 34(9):757-769.
- 7. Chuah JKC, Zink D: Stem cell-derived kidney cells and organoids: Recent breakthroughs and emerging applications. Biotechnology Advances 2017, 35(2): 150-167.
- 8. Prestwich GD: Evaluating drug efficacy and toxicology in three dimensions: Using synthetic extracellular matrices in drug discovery. Accounts of Chemical Research 2008, 41(1): 139-148.
- 9. Yang J, Shi GX, Bei JZ, Wang SG, Cao YL, Shang QX, Yang GG, Wang WJ: Fabrication and surface modification of macroporous poly(L-lactic acid) and poly(L-lactic-co-glycolic acid) (70/30) cell scaffolds for human skin fibroblast cell culture. Journal of Biomedical Materials Research 2002, 62(3):438-446.
- 10. Klein F, Richter B, Striebel T, Franz CM, von Freymann G, Wegener M, Bastmeyer M: Two-Component Polymer Scaffolds for Controlled Three-Dimensional Cell Culture. Advanced Materials 2011, 23(11): 1341-1345.
- 11. Nie L, Chen D, Suo JP, Zou P, Feng SB, Yang Q, Yang SH, Ye SN: Physicochemical characterization and biocompatibility in vitro of biphasic calcium phosphate/polyvinyl alcohol scaffolds prepared by freeze-drying method for bone tissue engineering applications. Colloids and Surfaces B-Biointerfaces 2012, 100:169-176.
- 12. Bokhari M, Carnachan RJ, Przyborski SA, Cameron NR: Emulsion-templated porous polymers as scaffolds for three dimensional cell culture: effect of synthesis parameters on scaffold formation and homogeneity. J Mater Chem 2007, 17(38):4088-4094.
- 13. Ruedinger F, Lavrentieva A, Blume C, Pepelanova I, Scheper T: Hydrogels for 3D mammalian cell culture: a starting guide for laboratory practice. Applied Microbiology and .
- 14. Rouquerol J, Avnir D, Fairbridge CW, Everett DH, Haynes JH, Pernicone N, Ramsay JDF, Sing KSW, Unger KK: Recommendations For The Characterization Of Porous Solids. Pure and Applied Chemistry 1994, 66(8):1739-1758.
- 15. Caliari SR, Burdick JA: A practical guide to hydrogels for cell culture. Nat Methods 2016, 13(5):405-414.
- 16. Zhang D, Pekkanen-Mattila M, Shahsavani MO, Falk A, Teixeira AI, Herland A: A 3D Alzheimer's disease culture model and the induction of P21-activated kinase mediated sensing in iPSC derived neurons. Biomaterials 2014, 35(5):1420-1428.
- 17. Wu X, Liu Y, Li X, Wen P, Zhang Y, Long Y, Wang X, Guo Y, Xing F, Gao J: Preparation of aligned porous gelatin scaffolds by unidirectional freeze-drying method. Acta Biomaterialia 2010, 6(3):1167-1177.
- 18. Annabi N, Nichol JW, Zhong X, Ji CD, Koshy S, Khademhosseini A, Dehghani F: Controlling the Porosity and Microarchitecture of Hydrogels for Tissue Engineering. Tissue Engineering Part B-Reviews 2010, 16(4):371-383.
- 19. Nam YS, Yoon JJ, Park TG: A novel fabrication method of macroporous biodegradable polymer scaffolds using gas foaming salt as a porogen additive. Journal .
- 20. Nieto-Suarez M, Lopez-Quintela MA, Lazzari M: Preparation and characterization of cross-linked chitosan/gelatin scaffolds by ice segregation induced self-assembly. Carbohydr Polym 2016, 141:175-183.
- 21. Botchwey EA, Pollack SR, Levine EM, Laurencin CT: Bone tissue engineering in a rotating bioreactor using a microcarrier matrix system. Journal of Biomedical Materials Research 2001, 55(2):242-253.
- 22. Teng WQ, Long TJ, Zhang QR, Yao K, Shen TT, Ratner BD: A tough, precision-porous hydrogel scaffold: Ophthalmologic applications. Biomaterials 2014, 35(32):8916-8926.
- 23. Ostrowska-Czubenko J, Gierszewska-Druzynska M: Effect of ionic crosslinking on the water state in hydrogel chitosan membranes. Carbohydr Polym 2009, 77(3):590-598.
- 24. Hopkins AM, De Laporte L, Tortelli F, Spedden E, Staii C, Atherton TJ, Hubbell JA, Kaplan DL: Silk Hydrogels as Soft Substrates for Neural Tissue Engineering. .
- 25. Hayward AS, Sano N, Przyborski SA, Cameron NR: Acrylic-Acid-Functionalized PolyHIPE Scaffolds for Use in 3D Cell Culture. .
- 26. Son JS, Park K, Oh S, Kim J-J, Han DK: Preparation and characterization of porous heparin-immobilized PLGA scaffolds using novel solid hydrogen peroxide for cartilage regeneration. Tissue Eng Regen Med 2008, 5(3):528-534.
- 27.
Purchio, A. F.; Zimber, M.; Dunkelman, N.; Naughton, G. K.; Naughton, B. A. Three-dimensional cartilage cultures using transforming growth factor-β. US5902741A, 1999 . - 28.
Liu, G. M. Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artificial corneal transplants. WO2005037144A2, 2005 . - 29.
Sheetz, M. P.; Hone, J. C.; Tanase, M.; Wind, S. J. Active cell growth substrates and apparatus for applying perturbation to a cell in vitro. WO2007103135A2, 2007 . - 30.
Liu, Q. Three dimensional cell culture construct and apparatus for its making. US20080194010A1, 2008 . - 31.
Shin, J. U.; Shin, J. W.; Park, S. H. Complex support body comprising biodegradable polymers, ceramics, and precursor cells for treating bone-cartilage diseases. KR2012111380A, 2012 - 32.
Zussman, E.; Chaganti, S. R.; Venugopal, J. R.; Ramakrishna, S.; Regev, O. Fiber-reinforced hydrogel composites and methods of forming fiber-reinforced hydrogel composites. WO2013172788A1, 2013 . - 33.
Yue, Z.; Wen, F.; Yu, H. Forming porous scaffold from cellulose derivatives. US8283028B2, 2012 . - 34. Zhang J, Yang Z, Li C, Dou Y, Li Y, Thote T, Wang D-a, Ge Z: Cells Behave Distinctly Within Sponges and Hydrogels Due to Differences of Internal Structure. Tissue .
- 35. Bogdanowicz DR, Lu HH: Multifunction Co-culture Model for Evaluating Cell-Cell Interactions. In: Biomimetics and Stem Cells: Methods and Protocols. Edited by Vunjak-Novakovic G, Turksen K. New York, NY: Springer New York: 29-36.
- 36. D.P. Mohanty, S. Mohapatra, S. Misra, P.S. Sahub Milk derived bioactive peptides and their impact on human health - A review, Saudi J Biol Sci. 2016 Sep; 23(5): 577-583.
- 37. Kruger, T. E.; Miller, A. H.; Wang, J. X., Collagen Scaffolds in Bone Sialoprotein-Mediated Bone Regeneration. Sci. World J. 2013.
- 38. Ferraz, M.P., F.J. Monteiro, and C.M. Manuel, Hydroxyapatite nanoparticles: A review of preparation methodologies. J Appl Biomater Biomech, 2004. 2(2): p. 74-80.
- 39. Cunniffe, G.M., et al., The synthesis and characterization of nanophase hydroxyapatite using a novel dispersant-aided precipitation method. Journal of Biomedical Materials Research Part A, 2010. 95A(4): p. 1142-1149.
- 40. Wang, P.P., et al., Effects of synthesis conditions on the morphology of hydroxyapatite nanoparticles produced by wet chemical process. Powder Technology, 2010. 203(2): p. 315-321.
- 41.Bouyer, E., F. Gitzhofer, and M.I. Boulos, Morphological study of hydroxyapatite nanocrystal Suspension. Journal of Materials Science-Materials in Medicine,2000. 11(8): p. 523-531.
- 42. Kothapalli, C., et al., Influence of temperature and concentration on the sintering behavior and mechanical properties of hydroxyapatite. Acta Materialia, 2004. 52(19): p. 5655-5663.
- 43.Tampieri, A.; Sprio, S.; Sandri, M.; Valentini, F., Mimicking natural bio-mineralization processes: A new tool for osteochondral scaffold development. Trends in Biotechnology 2011, 29 (10), 526-535.
- 44. Kretlow, J. D.; Mikos, A. G., Review: Mineralization of synthetic polymer scaffolds for bone tissue engineering. Tissue Engineering 2007, 13 (5), 927-938.
- 45. Niu, J.L., Hydrothermal synthesis of nano-crystalline hydroxyapatite. Bioceramics, Vol 19, .
- 46.Yoshimura, M. and K. Byrappa, Hydrothermal processing of materials: past, present and future. Journal of Materials Science, 2008. 43(7): p. 2085-2103.
- 47. Manafi, S.A., et al., Synthesis of nano-hydroxyapatite under a sonochemical/hydrothermal condition. Biomedical Materials, 2008. 3(2).
- 48. Chaudhry, A.A., et al., Instant nano-hydroxyapatite: a continuous and rapid hydrothermal synthesis. Chemical Communications, 2006(21): p. 2286-2288.
- 49. Manafi, S.A., et al., Synthesis of nano-hydroxyapatite under a sonochemical/hydrothermal condition. Biomedical Materials, 2008. 3(2).
- 50. Guo, X.Y. and P. Xiao, Effects of solvents on properties of nanocrystalline hydroxyapatite produced from hydrothermal process. Journal of the European Ceramic Society, 2006. 26(15): p. 3383-3391.
- 51. Wang, Y.J., et al., Investigations on the formation mechanism of hydroxyapatite synthesized by the solvothermal method. Nanotechnology, 2006. 17(17): p.4405-4412.
- 52. Zhang, S.Y., et al., Kinetic studies on the synthesis of hydroxyapatite nanowires by solvothermal methods. Australian Journal of Chemistry, 2007. 60(2): p. 99-104.
- 53. Ma, M.G. and J.F. Zhu, Solvothermal Synthesis and Characterization of Hierarchically Nanostructured Hydroxyapatite Hollow Spheres. European Journal of Inorganic Chemistry, 2009(36): p. 5522-5526.
- 54. Yang, C., et al., Solvothermal synthesis and characterization of Ln (Eu(3+),Tb(3+)) doped hydroxyapatite. Journal of Colloid and Interface Science, 2008. 328(1): p. 203-210.
- 55. Liu, D.M., T. Troczynski, and W.J. Tseng, Water-based sol-gel synthesis of hydroxyapatite: process development. Biomaterials, 2001. 22(13): p. 1721-1730.
- 56. Bezzi, G., et al., A novel sol-gel technique for hydroxyapatite preparation.Materials Chemistry and Physics, 2003. 78(3): p. 816-824.
- 57. Weng, W.J., et al., The effect of citric acid addition on the formation of sol-gel derived hydroxyapatite. Materials Chemistry and Physics, 2002. 74(1): p. 92-97.
- 58. Agrawal, K., et al., Synthesis of HA by various sol-gel techniques and their comparison: a review. National Conference on Advancements and Futuristic Trends in Mechanical and Materials Engineering, 2011.
- 59. Zhang, H. And Cooper, A. I., Synthesis and applications of emulsion-templated porous materials. Soft Matter, 2005. 1: p. 107-113
- 60. Lim, G. K., et al., Processing of hydroxyapatite via microemulsion and emulsion routes. Biometerials, 1997. 18: p. 1433 - 1439.
- 61. Yang, J. H., et al., Synthesis of spherical hydroxyapatite granules with interconnected pore channels using camphene emulsion. J Biomedical Materials Research Part B, 2011. 99B(1): p. 150-157.
- 62.Yang et al. Biomineralization of Natural Collagenous Nanofibrous Membranes and Their Potential Use in Bone Tissue Engineering J Biomed Nanotechnol. 2015. 11(3): p. 447-456.
- 63.Pawelec et al. Biomineralization of Recombinant Peptide Scaffolds: Interplay among Chemistry, Architecture, and Mechanics ACS Biomater. Sci. Eng., 2017. 3(6): p 1100-1108
- 64. Xu et al. Biomimetic mineralization J. Mater. Chem., 2007. 17: p. 415-449
Claims (15)
- A method for the preparation of a three-dimensional hydrogel scaffold for cell culturing, which comprises the steps of:a) preparing at least one first uniform solid mixture comprising at least one gas-forming agent, selected from the group consisting of sodium hydrogen carbonate, potassium hydrogen carbonate, sodium glycine carbonate, ammonium hydrogen carbonate, sodium bisulfite, sodium metabisulfite, calcium carbonate and sodium sulfite, at least one water-soluble salt and at least one non-water-soluble, water-swellable cross-linked poly(acrylic) polymer;b) preparing compressed or compact units starting from said at least one first solid mixture;c) subjecting the compressed or compact units thus obtained to heating at a temperature in the range of 120°C-160°C, for a time of 1-120 minutes, preferably 1-20 minutes;d) leaching the thermally treated units thus obtained in an aqueous medium;e) conditioning the leached units thus obtained in water or in an aqueous solution selected from the group comprising a buffer solution, preferably phosphate-buffered saline (PBS) and a cell culture medium;f) subjecting the conditioned units thus obtained to sterilization.
- The method according to claim 1, wherein the sterilized units obtained in said step f) are subjected to lyophilization.
- The method according to claim 1 or 2, wherein said compressed or compact units are prepared by direct compression of said solid mixture, in which said at least one gas-forming agent, said at least one water-soluble salt and said at least one non-water-soluble, water-swellable cross-linked poly(acrylic) polymer are all in powder form.
- The method according to claim 1 or 2, wherein said compressed or compact units are prepared by compressing said solid mixture, preferably at a pressure comprised between 2 kPa/g and 2500 GPa/g, more preferably 150 kPa/g to 25 GPa/g, for a period ranging from 0.1 seconds to 30 minutes, in which said at least one non-water-soluble, water-swellable cross-linked poly(acrylic) polymer is in powder form and said at least one gas-forming agent and said at least one water-soluble salt have previously been granulated or spheronized.
- The method according to any one of claims 1 to 4, which comprises- preparing a second uniform solid mixture comprising at least one non-water-soluble, water-swellable cross-linked poly(acrylic) polymer, which can be the same as said first uniform solid mixture or different therefrom;- forming a layer of said second uniform solid mixture, depositing a layer of said first solid mixture over said layer of second uniform solid mixture and optionally depositing one more layer of said second uniform solid mixture onto said layer of first solid mixture;wherein said compressed or compact units of step b) are prepared by compressing all of said layers.
- The method according to any one of claims 1 to 4, which comprises- preparing a second uniform solid mixture comprising at least one non-water-soluble, water-swellable cross-linked poly(acrylic) polymer, which can be the same as said first uniform solid mixture or different therefrom;- preparing a compressed or compact core from said first uniform solid mixture;- forming a layer of said second uniform solid mixture inside a mold, having a bottom and a peripheral wall, depositing said compressed or compact core onto said layer, the compressed or compact core being less wide than the mold, so that a gap is formed between the core and the peripheral wall,- filling said gap with said second uniform solid mixture, until the upper surface of said second uniform solid mixture is flush with the upper surface of said compressed or compact core;wherein said compressed or compact units of step b) are prepared by compressing said second uniform solid mixture and said compressed or compact core contained in said mold.
- The method according to any one of claims 1 to 6, wherein the compressed or compact units obtained in step b) are partially coated with a film made of a polymeric material selected from the group consisting of hydroxypropylcellulose (HPC), ethylcellulose (EC), hydroxyethylmethylcellulose (HEMC), hydroxypropylmethylcellulose (HPMC), methylcellulose (MC), polyvinylalcohol (PVA), polyvinylalcohol acetate phthalate, polymethacrylates (i.e. Eudragit) and mixtures thereof.
- The method according to any one of claims 1 to 7, wherein after said step d) of leaching, the leached units are kept at a pressure comprised between 80×10-3 mBar and 120×10-3 mBar for a period comprised between 10-60 minutes, preferably 10-30 minute.
- The method according to any one of claims 1 to 8, wherein said sterilization is a moist heat sterilization in autoclave, which is preferably carried out at a temperature comprised between 100°C and 130°C, in the presence of steam pressure comprised between 90 kPa and 150 kPa over atmospheric pressure for a time comprised between 10- 90 minutes, where said step e) of conditioning the leached units is carried out in water or in a buffer solution, preferably phosphate-buffered saline.
- The method according to any one of claims 1 to 8, wherein said at least one gas-forming agent is selected from the group consisting of sodium hydrogen carbonate, potassium hydrogen carbonate, sodium glycine carbonate, ammonium hydrogen carbonate, sodium bisulfite, and sodium metabisulfite, and said aqueous medium is deionized water.
- The method according to any one of claims 1 to 8, wherein said gas-forming agent is selected from the group consisting of calcium carbonate and sodium sulfite, and said aqueous medium is an acidic aqueous solution having a pH ranging from 0.1-3.
- The method according to any one of claims 1 to 11, wherein said water-soluble salt is an alkali metal or an alkaline-earth metal salt, preferably selected from the group consisting of sodium chloride (NaCl), potassium chloride (KCl), potassium sulfate (K2SO4), sodium sulfate (Na2SO4), potassium dihydrogen phosphate (KH2PO4), disodium hydrogen phosphate (Na2HPO4), magnesium sulfate (MgSO4), aluminum chloride (AlCl3), magnesium chloride (MgCl2), and potassium acetate (KC2H3O2).
- The method according to any one of claims 1 to 12, wherein said at least one non-water-soluble, water-swellable cross-linked poly(acrylic) polymer constitutes 20-80%, preferably 22-60%, even more preferably 30-50% by weight of the total weight of said solid mixture, and is selected from the group consisting of Carbomer, Polycarbophil and salts thereof.
- The method according to any one of claims 1 to 13, wherein said at least one gas-forming agent constitutes 0.5%-79.5% by weight of the total weight of said solid mixture preferably 10-50%, even more preferably 20-40%, and wherein said water-soluble salt constitutes 0.5%-79.5% by weight of the total weight of said solid mixture preferably 10-50%, even more preferably 20-40%.
- The method according to any one of claims 1 to 14, wherein said at least one first uniform solid mixture comprises a mineralizing compound selected from the group consisting of synthetic hydroxyapatite (Ca10(PO4)6(OH)2, tricalcium phosphate (Ca3(PO4)2), hydroxyapatite (Ca5(PO4)3OH), carbonated hydroxyapatite, wollastonite, magnesium silicate, alumina and zirconia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102017000087978A IT201700087978A1 (en) | 2017-07-31 | 2017-07-31 | Three-dimensional hydrogel scaffold for cell cultures and its production method |
PCT/EP2018/066096 WO2019025070A1 (en) | 2017-07-31 | 2018-06-18 | A three-dimensional hydrogel scaffold for cell culturing and a method for the production thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3662054A1 EP3662054A1 (en) | 2020-06-10 |
EP3662054B1 true EP3662054B1 (en) | 2022-08-03 |
Family
ID=60570143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18730009.0A Active EP3662054B1 (en) | 2017-07-31 | 2018-06-18 | A three-dimensional hydrogel scaffold for cell culturing and a method for the production thereof |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3662054B1 (en) |
IT (1) | IT201700087978A1 (en) |
WO (1) | WO2019025070A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102375692B1 (en) * | 2020-02-27 | 2022-03-17 | 연세대학교 산학협력단 | Culture apparatus that provides a haman-like environment including cell cultrue unit and culture system |
CN111705034A (en) * | 2020-06-30 | 2020-09-25 | 山东省医药生物技术研究中心(山东省病毒研究所) | Method for efficiently promoting chondrocyte proliferation |
CN112940337B (en) * | 2020-12-30 | 2023-03-24 | 中国科学技术大学 | Anti-swelling composite hydrogel and preparation method and application thereof |
CN112921000B (en) * | 2021-03-24 | 2023-01-24 | 华中农业大学 | Method for constructing glioma in-vitro 3D culture and analysis system and application |
CN113249327B (en) * | 2021-05-06 | 2022-10-14 | 东华大学 | Three-dimensional cell culture scaffold for tumor cell culture and preparation method thereof |
IL309563A (en) * | 2021-06-21 | 2024-02-01 | Bio Change Ltd | Microparticle tissue scaffold compositions, apparatuses, methods of preparation, and uses thereof |
CN113493741B (en) * | 2021-09-10 | 2021-12-03 | 广东乾晖生物科技有限公司 | Three-dimensional co-culture device, culture system and culture method for organoid |
CN114805917B (en) * | 2022-03-30 | 2023-06-16 | 浙江大学 | Preparation method of three-level porous material based on fibrin fiber bridging |
CN114870094B (en) * | 2022-06-02 | 2023-07-04 | 中国科学院大学宁波华美医院 | Injectable bone repair hydrogel manufacturing method based on poloxamer |
CN115531614B (en) * | 2022-09-22 | 2023-03-17 | 新乡医学院 | RGD coupled cross-linked PVA scaffold for promoting endothelial differentiation and preparation method thereof |
CN117511851B (en) * | 2024-01-03 | 2024-03-26 | 中国肉类食品综合研究中心 | Application of hydrogel scaffold in preparation of cell culture meat |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5902741A (en) | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
CA2542041C (en) | 2003-10-10 | 2014-12-09 | Cellular Bioengineering, Inc. | Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants |
US20070098799A1 (en) * | 2005-10-28 | 2007-05-03 | Zimmer, Inc. | Mineralized Hydrogels and Methods of Making and Using Hydrogels |
WO2007103135A2 (en) | 2006-03-02 | 2007-09-13 | The Trustees Of Columbia University In The City Of New York | Active cell growth substrates and uses thereof |
CN101245313A (en) | 2007-02-13 | 2008-08-20 | 刘青 | Three dimensional cell culture construct and apparatus for its making |
JP5420565B2 (en) | 2007-12-18 | 2014-02-19 | エージェンシー フォー サイエンス, テクノロジー アンド リサーチ | Method for forming porous scaffolds from cellulose derivatives |
KR101375828B1 (en) | 2011-03-31 | 2014-03-17 | 인제대학교 산학협력단 | Complex Scaffold For Bone-Cartilage Regeneration, Method For Preparing Thereof And Composition for Treating Bone Cartilage Disease Comprising The Same |
US9950093B2 (en) | 2012-05-15 | 2018-04-24 | National University Of Singapore | Fiber-reinforced hydrogel composites and methods of forming fiber-reinforced hydrogel composites |
US20160303281A1 (en) * | 2015-04-17 | 2016-10-20 | Rochal Industries, Llc | Composition and kits for pseudoplastic microgel matrices |
JP6618299B2 (en) * | 2015-08-24 | 2019-12-11 | 日本酢ビ・ポバール株式会社 | Method for producing hydrogel |
-
2017
- 2017-07-31 IT IT102017000087978A patent/IT201700087978A1/en unknown
-
2018
- 2018-06-18 EP EP18730009.0A patent/EP3662054B1/en active Active
- 2018-06-18 WO PCT/EP2018/066096 patent/WO2019025070A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019025070A1 (en) | 2019-02-07 |
EP3662054A1 (en) | 2020-06-10 |
IT201700087978A1 (en) | 2019-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3662054B1 (en) | A three-dimensional hydrogel scaffold for cell culturing and a method for the production thereof | |
Distler et al. | 3D printed oxidized alginate-gelatin bioink provides guidance for C2C12 muscle precursor cell orientation and differentiation via shear stress during bioprinting | |
Ahlfeld et al. | Development of a clay based bioink for 3D cell printing for skeletal application | |
Maji et al. | Preparation and evaluation of gelatin-chitosan-nanobioglass 3D porous scaffold for bone tissue engineering | |
Marrella et al. | Enhanced mechanical performances and bioactivity of cell laden-graphene oxide/alginate hydrogels open new scenario for articular tissue engineering applications | |
Ribeiro et al. | Development of silk fibroin/nanohydroxyapatite composite hydrogels for bone tissue engineering | |
Chang et al. | Fabrication and properties of chitin/hydroxyapatite hybrid hydrogels as scaffold nano-materials | |
Salerno et al. | Bio-safe fabrication of PLA scaffolds for bone tissue engineering by combining phase separation, porogen leaching and scCO2 drying | |
Roohani-Esfahani et al. | Effect of self-assembled nanofibrous silk/polycaprolactone layer on the osteoconductivity and mechanical properties of biphasic calcium phosphate scaffolds | |
Ji et al. | A gelatin composite scaffold strengthened by drug-loaded halloysite nanotubes | |
EP2234655B1 (en) | Forming porous scaffold from cellulose derivatives | |
Zhao et al. | Construction of highly biocompatible hydroxyethyl cellulose/soy protein isolate composite sponges for tissue engineering | |
Buchtová et al. | Nanocomposite hydrogels for cartilage tissue engineering: mesoporous silica nanofibers interlinked with siloxane derived polysaccharide | |
EP3528858B1 (en) | Printed hyaluronic acid scaffolds | |
Dicker et al. | Core–shell patterning of synthetic hydrogels via interfacial bioorthogonal chemistry for spatial control of stem cell behavior | |
Parthiban et al. | BoneMA—synthesis and characterization of a methacrylated bone-derived hydrogel for bioprinting of in-vitro vascularized tissue constructs | |
Heid et al. | Bioprinting with bioactive alginate dialdehyde-gelatin (ADA-GEL) composite bioinks: Time-dependent in-situ crosslinking via addition of calcium-silicate particles tunes in vitro stability of 3D bioprinted constructs | |
Zhu et al. | Fabrication and characterization of bioactive silk fibroin/wollastonite composite scaffolds | |
Ferreira et al. | Peptide-based microcapsules obtained by self-assembly and microfluidics as controlled environments for cell culture | |
Fan et al. | Effect of hyaluronan molecular weight on structure and biocompatibility of silk fibroin/hyaluronan scaffolds | |
Shpichka et al. | Fabrication and handling of 3D scaffolds based on polymers and decellularized tissues | |
Alagoz et al. | PHBV wet-spun scaffold coated with ELR-REDV improves vascularization for bone tissue engineering | |
Lam et al. | Effectiveness of bio-dispersant in homogenizing hydroxyapatite for proliferation and differentiation of osteoblast | |
Morozova et al. | Design, characterization and applications of nanocolloidal hydrogels | |
Zhou et al. | Catechol functionalized ink system and thrombin-free fibrin gel for fabricating cellular constructs with mechanical support and inner micro channels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200225 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210224 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602018038750 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C12N0005070000 Ipc: C12N0005000000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C08J 3/24 20060101ALI20220117BHEP Ipc: C08J 3/075 20060101ALI20220117BHEP Ipc: C12N 5/00 20060101AFI20220117BHEP |
|
INTG | Intention to grant announced |
Effective date: 20220222 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1508769 Country of ref document: AT Kind code of ref document: T Effective date: 20220815 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602018038750 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20220803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221205 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221103 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1508769 Country of ref document: AT Kind code of ref document: T Effective date: 20220803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221203 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602018038750 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230519 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |
|
26N | No opposition filed |
Effective date: 20230504 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230523 Year of fee payment: 6 Ref country code: FR Payment date: 20230523 Year of fee payment: 6 Ref country code: DE Payment date: 20230523 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230523 Year of fee payment: 6 Ref country code: CH Payment date: 20230702 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220803 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20230630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230618 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230618 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230618 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230618 |